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 1.1 Alzheimer’s disease, mild cognitive impairment and neuropathological changes  
 
The diagnosis ‘possible and probable’ AD is based on clinical criteria (see Appendix for 
description of the NINCDS-ADRDA criteria1) supported by neuropsychological tests, 
neuroimaging and follow up. A person is demented when he suffers from dysfunction in at least 
two cognitive domains as well as in daily activities, under the condition that the patient has a 
clear conscience. AD is defined as ‘early onset’ AD (EAD), when the symptoms start before the 
age of 65 years.2 This definition is arbitrary, and based on historic decisions regarding the 
pension age only. Alois Alzheimer in 1907 described the first AD patient, being a 51-year old 
woman, and considered AD as a presenile type of dementia, while there existed already another 
poorly defined senile type of dementia in elderly persons. Almost sixty years later, it was found 
that this senile type of dementia exhibited the same neuropathological findings as in presenile 
AD.3 The arbitrary distinction between the two types of AD still exists, but more and more 
evidence is gathered that distinguishes subtypes of AD based on other findings than age.4,5,83 
Still, EAD is considered to be a rare condition, although the frequency of EAD in a presenile 
dementia population is rather high.6 Some autosomal dominant cases are associated with 
mutations in the amyloid precursor protein (APP) and presenilin (PSEN) genes.7 However, in the 
majority of sporadic EAD no mutation was found.8 The presence of one or more ε4-alleles of the 
Apolipoprotein E (Apo E) genotype is a risk factor for sporadic AD and is associated with an 
earlier age-at-onset. 84-86 Yet, Apo E gene polymorphism is not used in the diagnostic process of 
AD, as it has low specificity and sensitivity and little predictive value in an individual patient. 88 
A definite diagnosis AD can only be obtained at autopsy, which holds true for most other types of 
dementia too. The clinicopathological correlation differs between centers and is around 70-80% 
overall.9 On microscopic examination AD is characterized by a combination of abnormalities: 
diffuse and neuritic plaques (NP), containing extracellular non-fibrillar amyloid β (Aβ), 
predominantly Aβ42, and fibrillar Aβ42 respectively; intraneuronal neurofibrillary tangles (NFT) 
composed of abnormally phosphorylated tau (Ptau); and loss of synaptic proteins and neurons.10 
Aβ42 is formed by proteolytic processing of APP (see also Appendix). The pattern of distribution 
of NP and NFT throughout the brain differs with development of disease; in early preclinical 
stages NFT are found in the entorhinal cortex (EC) and hippocampus, and with progression of 
disease they spread via the medial temporal neocortex to other cortical areas. On the other hand, 
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 NP deposition starts in the neocortical frontal/temporal areas and they spread in later stages to the 
hippocampal areas. The staging system developed by Braak and Braak describe the extent of 
tangle related abnormalities in AD, which correlates well with severity of dementia11. NP 
correlate less with cognitive dysfunction in AD patients.12  
 
Plaques and, to a lesser extent, tangles are also found in brains of elderly non-demented controls 
and patients with mild cognitive impairment (MCI).13,14 MCI is a clinical entity15, describing 
patients with subjective and/or objective cognitive complaints and mild functional disabilities, 
but no dementia. A variety of definitions exist for the concept MCI in literature. In our studies we 
included patients with ‘amnestic MCI’, conceptualized according to the criteria of Petersen et 
al.16 According to these criteria patients have MCI when they have subjective and objective 
problems with short term memory compared to persons with the same age, with no interference 
in daily activities thus no dementia (see also Appendix). These amnestic MCI patients have a 
high chance of developing AD in the future, especially when they are over 70 years of age.15 A 
few autopsy studies investigated whether NFT and NP are related to memory function in MCI 
patients13,14, NFT in the medial temporal lobe seem to have a relation with memory function in 
amnestic MCI. However, all these studies must be interpreted with caution as there might be a 
selection bias. The results might depend on the definition used for the concept MCI. In the next 
chapter (1.2) an overview is presented of studies describing the most promising biochemical 
markers in cerebrospinal fluid (CSF) for the (early) diagnosis AD which are supposed to reflect 
the neuropathological changes in AD. Chapter 2 describes the aim of the present thesis in detail. 
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 Introduction 
Alzheimer’s disease (AD) is considered to be the most common type of dementia. 1 Due to the 
aging of the population, the number of persons affected by AD is expected to increase 3-fold by 
2050. 2 The diagnosis AD is made by exclusion and based on clinical criteria3, supported by 
neuropsychological tests, neuroimaging and extended follow-up. In the early stage, it is difficult 
to differentiate AD from other types of dementia, as the clinical symptoms are subtle and the 
diagnostic methods may be normal. Furthermore, clinical overlap exists between the different 
types of dementias, while volume changes of the hippocampus and medial temporal lobe on 
magnetic resonance imaging (MRI) are not specific for AD. 4 With the advent of novel 
therapeutic strategies5, it became important to diagnose AD as early as possible, as 
pharmacological treatment needs to be started before extensive and irreversible brain damage has 
occurred. Over the last decade, many studies have been set out to find an appropriate biomarker 
for the diagnosis of AD. 6 This chapter starts with an overview as regards the most promising 
cerebrospinal fluid (CSF) biomarkers for the early and differential diagnosis of AD. Next, the 
relation of the biomarkers with atrophy on MRI will be discussed. Finally, limitations and topics 
for future research will be presented. 
 
Neuropathology 
The basis for the research on biochemical markers are the neuropathological changes present in 
the various types of dementias. 7 Neuropathological hallmarks of AD -accumulation of 
extracellularly senile plaques (SP) and neurofibrillary tangles (NFT), synaptic reductions and 
neuron loss- gradually accumulate in time, and start long before the clinical picture of AD 
becomes overt. 8 SP are divided into two types: diffuse and neuritic plaques (NP). NP are 
composed of the highly insoluble fibrillar protein amyloid β 42 (Aβ42). Aβ depositions tend do 
accumulate with age. NFT are intraneuronal accumulations of abnormally (hyper)phosphorylated 
tau protein. NFT can be found already in non-demented subjects in the hippocampus and EC, the 
regions affected earliest in AD. NP initially are found in the neocortex, but in later stages they 
also affect the EC and the hippocampus. 9,10 Patients with frontotemporal dementia (FTD) show 
heterogeneity in underlying pathology11, with tau deposits in some of them. Creutzfeldt Jakob 
disease (CJD) is characterized by spongiform changes, neuronal loss, gliosis and immunostaining 
of the protease-resistant prion protein. 12 Dementia with Lewy Bodies (DLB) is part of the α-
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 synucleïnopathies, in which α-synucleïn accumulates in the intraneuronal Lewy Bodies. 13 
Vascular dementia (VAD) is characterized by ischemic lesions, lacunes and extensive white 
matter changes. 14 Between the different types of clinically diagnosed dementias significant 
neuropathological overlap exists. 15 Lewy bodies are present in AD, whereas in DLB, FTD and 
VAD plaques and tangles can be found. White matter changes are found in all types of dementia, 
especially in AD. 16 
 
CSF amyloid β 42 and tau in AD versus controls 
According to criteria established in 1998, a good biomarker has to have a sensitivity of at least 
85% for AD and a specificity of ≥ 75% to differentiate AD from other types of dementia. 7 The 
most promising CSF markers to differentiate AD from non-demented elderly are Aβ42 and tau. 
Below, each biomarker will be discussed separately. Next, the most valid studies will be 
summarized for the combination of CSF Aβ42 and tau. 
 
Aβ42 
In numerous studies it has been shown that Aβ42 is decreased in CSF of AD patients compared 
to non-demented controls. 6,17 The decrease of Aβ42 concentration in CSF is thought to be the 
result of several mechanisms:  
1. Deposition of insoluble Aβ42 in the SP of the brain, which might be in part the result of 
disturbance of the clearance of Aβ42 
2. Decrease of production of Aβ42 by less (active) neurons, inevitably a result of 
neurodegeneration 
3. Altered binding to Aβ42-specific proteins (e.g. Apo E), resulting in masking of the epitope, to 
which the antibodies of the assays are directed.  
 
The concentration of CSF Aβ42 in AD is about 50% of that recorded in controls. 17 The most 
commonly used assay is the commercial ELISA of Innogenetics (Table 1). The median values of 
Aβ42, as measured in two large case-control studies, are:  
AD: 487 (394-622) pg/mL, controls: 849 (682-1063) pg/mL.18  
AD: 394 (326-504) pg/mL, controls: 1076 (941-1231) pg/mL.19  
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 Reference value for CSF Aβ42 obtained from a control population is set above 500 pg/mL. 20 
Sensitivity ranged from 69-100%, while specificity ranged from 56-85% in a subset of studies. 
19,21-25 Considerable variability in absolute levels of Aβ42 exists among centers, even when using 
the same commercial assay. Cross-sectional studies show little evidence of a relationship between 
CSF Aβ42 and age, except for one study showing a U-shaped natural course in normal aging, 
with an increase of CSF Aβ42 until 29 and over 60 years old. 26 No18,23 or only a weak22 cross-
sectional relation has been found between CSF Aβ42 and disease duration or mini-mental state 
examination (MMSE). Only one study investigated and found an association between the number 
of SP and the CSF Aβ42 concentration.27 
 
Tau 
Many studies have demonstrated that tau is increased in CSF of AD patients; concentrations are 
about three times higher in AD than in non-demented controls. However, there is a large variation 
in the range of CSF tau concentration in AD. Median and mean concentrations of CSF are: 
AD: 425 (274-713) pg/mL and 587 (365) pg/mL. 6,18 
Controls:195 (121-294) pg/mL and 224 (156) pg/mL.  
The increase of tau in CSF is supposed to be the result of release from dying neurons containing a 
large number of NFT. One study demonstrated that CSF tau concentration was related to the 
number of NFT in the brain.28 
 
Again, the most common used assay for tau is the ELISA from Innogenetics (Table1). Mean 
sensitivity ranged from 55 to 81% at a mean specificity value of 90% comparing AD with 
controls17. Important is that CSF tau increases with age19,29, which stresses the need to compare 
only groups from the same age category. 30 Furthermore, CSF tau tends to be increased in several 
other neurological disorders, such as acute stroke31, and trauma32, indicating that the marker is 
not very specific. Reference values for tau in healthy individuals are defined as:  
< 300 pg/mL (21-50 years)  
< 450 pg/mL (51-70 years)  
< 500 pg/mL (71-93 years). 19  
No correlation was found between CSF tau and MMSE or disease duration. 
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 Combination of CSF Aβ42 and tau 
Diagnostic accuracy, especially the specificity, increases when using the combination of CSF 
Aβ42 and tau comparing AD with controls, including patients with depression or memory 
problems due to alcohol abuse. 17 In Table 1 an overview is given of class IA and 1A case-control 
studies, with neuropathological (IA) or clinical diagnosis (1A) as gold standard, and patient and 
control groups included with a minimum of thirty individuals. 33 
 
Isoprostanes 
Oxidative stress is thought to play an important role in the cascade resulting in cell death in AD. 
36 A few studies have demonstrated that isoprostanes are increased in CSF of AD patients, even 
already at an early stage of disease. 37,38 Further studies are needed how these proteins can be 
used in the diagnostic work up for AD, especially to clarify the specificity of these markers. 
 
CSF markers in AD versus other dementias 
Combination of CSF Aβ42 and tau 
How good is the diagnostic accuracy when using the combination of Aβ42 and tau in AD 
compared to other types of dementias? Although this topic is much more relevant for clinical 
practice, only a few studies investigated these two markers in large groups of patients. Most 
studies found a lower specificity as compared to the studies mentioned in Table 1. There is 
substantial overlap in CSF Aβ42 and tau concentrations between different types of dementias. A 
decreased concentration of CSF Aβ42 can be found in DLB, FTD, and VAD. 18,20,30,39 A high 
CSF tau is also not specific for AD: CSF tau is found to be increased in a subset of FTD and 
VAD patients. 18,30 In most cases of DLB CSF tau concentration is normal. 39 In CJD, CSF Aβ42 
is decreased and CSF tau is found to be very high, even higher than in AD. 40 The specificity of 
the combined CSF Aβ42/tau analysis varies from 85% comparing AD with FTD to 67% in AD 
versus DLB and 48% in AD versus VAD (Table 2).  
 
Phosphorylated tau 
Several investigators have developed assays to detect phosphorylated tau (Ptau) in CSF. As NFT 
are abundant of abnormally phosphorylated tau, it is to be expected that Ptau is increased in CSF 
from AD patients. Several immunoassays have been developed that are specific for the 
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 Table 1 Diagnostic accuracy of CSF Aβ42 and tau combined in AD versus controls 
 
Study Population Gold standard Criteria Result Cut off Method 
Galasko, 199822 82 probable AD  
60 controls 
 
Clinical diagnosis (1A) NINCDS-ADRDA Sensitivity 77% 
Specificity 93% 
Aβ42: 1032 pg/mL 
Tau: 503 pg/mL 
Aβ42 and tau: In house 
methods 
Multi-center study 
Kanai, 199834 93 probable AD 
41 controls 
 
 
Clinical diagnosis (1A) NINCDS-ADRDA Sensitivity 40% 
Specificity 90% 
 
Aβ42: 256 fmol/mL 
Tau: 474 pg/mL 
Aβ42: In house method 
Tau: Innogenetics 
Hulstaert, 199918 150 probable AD 
100 controls = 42 HC + 58 
OND 
 
Clinical diagnosis (1A) NINCDS-ADRDA Sensitivity 85% 
Specificity 86% 
Aβ42: 643 pg/mL 
Tau: 252 pg/mL 
Aβ42 and tau: Innogenetics 
Multi-center study 
Tapiola, 200023 80 probable AD  
41 definite AD 
39 OND 
 
Clinical (1A) and 
neuropathological 
diagnosis (IA) 
 
NINCDS-ADRDA 
CERAD 
Sensitivity 46-53%*  
Specificity 95% 
 
 
Aβ42 : 340 pg/mL 
Tau : 380 pg/mL 
Aβ42: In house method 
Tau: Innogenetics 
Andreasen, 200135 105 probable AD 
100 controls of  Hulstaert 
et al. 1999 
 
Clinical diagnosis (1A) NINCDS-ADRDA 
 
Sensitivity 94% 
Specificity 89% 
 
Aβ42: 643 pg/mL 
Tau: 252 pg/mL 
Aβ42 and tau: Innogenetics 
Riemenschneider, 200220  74 probable AD 
40 controls 
Clinical diagnosis (1A) NINCDS-ADRDA Sensitivity 92% 
Specificity 95% 
Aβ42: 738 pg/mL 
Tau: 255 pg/mL 
Aβ42 and tau: 
Innogenetics 
Kapaki, 200324 49 probable AD 
49 controls 
Clinical diagnosis (1A) 
3 year follow-up 
 
NINCDS-ADRDA  Sensitivity 96%
Specificity 86%  
Aβ42: 490 pg/mL 
Tau : 317 pg/mL 
Aβ42 and tau: Innogenetics 
Sunderland, 20036 131 probable AD 
 72  controls 
Clinical diagnosis (1A) DSM-IV 
NINCDS-ADRDA 
 
Sensitivity 92% 
Specificity 89% 
Aβ42 : 444 pg/mL 
Tau: 195 pg/mL 
Aβ42: In house method 
Tau: Innogenetics 
 
* Definite and probable AD vs OND. Probable AD = AD according to the clinical NINCDS-ADRDA criteria; definite AD = AD confirmed at neuropathological examination; OND = other neurological 
diseases. 1A = clinical diagnosis is gold standard, prospective collected materials, including groups of patients and controls with a minimum of 30 individuals; IA neuropathological diagnosis is gold 
standard, rest conform class 1A. 
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 Table 2 Diagnostic accuracy of CSF Aβ42 and tau combined in AD versus other types of dementia 
Study        Population Gold standard Criteria Result Cut off
Galasko, 199822 82 probable AD  
74 NAD 
 
Clinical diagnosis (1A) NINCDS-ADRDA Sensitivity 77% 
Specificity 65% 
Aβ42: 1032 pg/mL 
Tau: 503 pg/mL 
Hulstaert, 199918 150 probable AD 
79 NAD 
 
Clinical diagnosis (1A) NINCDS-ADRDA Sensitivity 85% 
Specificity 58% 
Aβ42: 643 pg/mL 
Tau: 252 pg/mL 
Tapiola, 200023 80 probable AD  
41 definite AD 
27 NAD 
 
Clinical (1A) and 
neuropathological 
diagnosis (IA) 
 
NINCDS-ADRDA 
CERAD 
Sensitivity 50%  
Specificity 85% 
 
 
Aβ42 : 340 pg/mL 
Tau : 380 pg/mL 
Andreasen, 200135 105 probable AD 
23 VAD 
9 DLB 
Clinical diagnosis (1A) NINCDS-ADRDA  
VAD: NINDS-AIREN 
DLB: McKeith  
 
Sensitivity 94% 
Specificity VAD 48% 
Specificity DLB 67% 
 
Aβ42: 643 pg/mL 
Tau: 252 pg/mL 
Riemenschneider, 200220  74 probable AD 
34 FTLD 
Clinical diagnosis (1A) NINCDS-ADRDA 
FTLD: Neary  
Sensitivity 85% 
Specificity 85% 
Aβ42: 528 pg/mL 
Tau: 432 pg/mL 
Kapaki, 200324 49 probable AD 
15 NAD 
6 VAD 
 
Clinical diagnosis (1A) 
 
 
NINCDS-ADRDA 
VAD: NINDS-AIREN 
AD vs NAD/VAD: 
Sensitivity: 71-90% 
Specificity: 83-100%  
 
  
AD vs NAD: 
Aβ42 : 435 pg/ml 
Tau : 437 pg/ml 
 
Schoonenboom, 200430 47 probable EAD 
28 FTLD 
 
Clinical diagnosis (1A) NINCDS-ADRDA 
FTLD: Neary  
Sensitivity 72% 
Specificity 89% 
Aβ42 : 413 pg/mL 
Tau: 377 pg/mL 
 
Probable AD = AD according to the clinical NINCDS-ADRDA criteria; definite AD = AD confirmed at neuropathological examination; EAD = early onset AD, disease starting before 65 years old; 
VAD = vascular dementia; DLB = diffuse lewy body disease; FTLD = frontotemporal lobar degeneration; NAD = non-Alzheimer-dementia. 1A = clinical diagnosis is gold standard, prospective 
collected materials, including groups of patients and controls with a minimum of 30 individuals; IA neuropathological diagnosis is gold standard, rest conform class 1A.
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 phosphorylated epitopes threonine 181 (Ptau-181)41, serine 199 (Ptau-199)42, and threonine 
231 (Ptau-231). 43 Good results have been obtained comparing AD with other types of 
dementia; in the majority of patients Ptau is found to be normal in DLB44, VAD45, FTD30, and 
CJD. 46 One study demonstrated an increase in diagnostic accuracy of Ptau-231 and Ptau-181 
compared to Ptau-199 in differentiating AD from other types of dementia. 47 The same authors 
found a decline of CSF Ptau-231 during the course of AD in 17 patients. 48 These data need to 
be confirmed in another independent study, preferably with post-mortem confirmation of 
diagnoses. A greater diagnostic accuracy of Ptau compared to total tau is obtained in most 
studies. 30,49 In one study it has been shown that the combination of CSF Aβ42 with Ptau-181 
differentiated best (early onset) AD (EAD) from FTD with a high specificity (93%) and a low 
negative predictive value (negative likelihood ratio: 0.03). 30 As there still exists overlap 
between the different types of dementia, either clinically or biochemically, a combination of 
the three markers seems best for routine clinical practice, with at least two of the three 
biomarkers positive as indicator for AD. 50  
 
14-3-3 protein 
The 14-3-3 protein gives, like tau, a reflection of (fast progressive) neuron loss. It can be 
detected in CSF by the semi-quantitative method Western Blot analysis. When used in the 
proper context, with a high clinical suspicion and in combination with EEG, MRI scan and 
routine CSF analysis, the measurement of 14-3-3 protein in CSF supports the diagnose CJD 
with high diagnostic accuracy. 51 False-positive results can be obtained in acute stroke, brain 
tumor, encephalitis, or even (fast progressive) AD. Sensitivity and specificity values of CSF 
14-3-3 and tau have been reported to be the same in one study (cut off level for tau = 1300 
pg/mL). 52 Recently it has been shown that the combination of 14-3-3 protein and Aβ42 gives 
the highest diagnostic accuracy for CJD (sensitivity 100%, specificity 98%, positive 
predictive value 93%, negative predictive value 100%).40 
 
Gold standard 
The majority of above-mentioned studies have been obtained in groups of patients where the 
diagnosis has been obtained clinically. Accuracy of the clinical diagnosis in specialized 
settings is estimated around 85%.53 By use of clinical criteria there is risk of circular 
reasoning -ie, the diagnostic performance of CSF markers cannot be higher than the accuracy 
of the clinical criteria. 17 The NINCDS/ADRDA criteria for AD have a high sensitivity but a 
moderately high specificity. Illustrative is the specificity of only 23% of the 
 
   
NINCDS/ADRDA criteria for the differentiation of AD from FTD in one retrospective 
neuropathological study. 54 Furthermore, 40-80% of the clinically diagnosed VAD patients 
have concomitant AD pathology. 55 Only two studies were published in which (in part) the 
neuropathological diagnosis was used as gold standard. 23,56 For the differentiation of AD 
from controls similar sensitivity and specificity was obtained for CSF tau and Aβ42 as 
compared to clinical studies (Table 123). However, specificity of FTD and DLB as compared 
to AD was not optimal, 69%.56  
Most published studies were done in specialized tertiary referral settings with selected patient 
groups.  Only a few studies were done with consecutively recruited patients from a memory 
clinic; sensitivity was high, but specificity was lower in this setting with ‘unselected’ patients. 
35,57 More studies are needed in large primary and secondary referral centers to get insight 
how to use CSF Aβ42, tau and Ptau in an elderly population in clinical practice. Population-
based studies are under way to establish CSF markers as potential biomarkers for routine 
diagnostic use. 
 
Mild cognitive impairment 
Mild cognitive impairment (MCI) is considered to be a transitional state between normal 
aging and dementia. Around 10-15% of the MCI patients progress to Alzheimer type 
dementia each year.58 Several studies have shown that a subgroup of MCI patients has low 
CSF Aβ42 levels and/or high CSF tau levels at baseline, that are indicative for AD.17 
Furthermore, there is evidence that these markers can be used as predictors for the conversion 
of MCI to AD.50,59 It is not clear yet which marker is changing first in the disease process, as 
contradictory findings are reported by various studies describing either an increased CSF 
tau50,60 or a decreased CSF Aβ42 at baseline.61,62 In two independent studies a relation 
between CSF tau with memory impairment was found, while this was not the case for CSF 
Aβ42.63,64 Good results have been obtained for CSF Ptau as indicator of AD-related changes 
in the MCI stage.4,59,65 In one study it has been demonstrated that high CSF levels of Ptau at 
baseline, but not CSF tau levels, correlated with cognitive decline and conversion of MCI to 
AD.66 A very recent study, following 78 MCI patients, shows the best prediction for the 
development of AD using the combination of CSF Aβ42 with Ptau.67 Most of the studies 
mentioned have been conducted retrospectively in research settings, and limited data are 
available about the frequency of a biomarker profile typical for AD in a prospective setting 
that reflects clinical practice. But overall, the use of biomarkers in combination with other 
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diagnostic tools is very promising in recognizing MCI patients who will develop AD in the 
future.  
 
Neuroimaging and CSF biomarker studies 
Cross-sectional studies 
Hippocampal size reduction, atrophy of the medial temporal lobe (MTL) and the entorhinal 
cortex are sensitive markers for AD. Moreover, atrophy of the hippocampus is found to be a 
good predictor in MCI for the development of AD. However, these markers are not disease-
specific and cannot be used as primary evidence for AD.4 By combining CSF and MRI 
markers one could get a better diagnostic accuracy. In addition, by investigating the relation 
between the two markers a better understanding of the agreement between the two disease 
markers could be obtained: do they reflect the same pathological substrate at the same time? 
Only a few studies investigated the cross-sectional relation between CSF biomarkers and 
atrophy on MRI in small groups of patients. One study showed a correlation between CSF 
Aβ42 and the volume of the temporal lobes. 68 We were unable to find a relationship between 
medial temporal lobe atrophy (MTA), and CSF Aβ42, tau and Ptau in 62 mild-moderate AD 
patients and 32 controls when considered as separate groups.69 Moreover, both disease 
markers contributed independently to the diagnose AD. In MCI patients, we found a relation 
between CSF Aβ42 and MTA, while CSF tau did not relate to MTA. 63 These data 
corresponded to a larger study reporting lower baseline CSF Aβ42 levels with lower brain 
volume and larger ventricular volume in the spectrum of normal aging, MCI and AD. 70 In 
contrast, higher CSF tau and Ptau were found with an increase in ventricular widening during 
follow up. In this light, CSF Aβ42 can be more considered as a stage marker, indicating the 
presence of disease at a certain time, while CSF tau is more a state marker, indicating the 
intensity of the neuronal damage and degeneration.17,70 However, these data give only 
information about one time-point in disease, and until yet it was not possible to show 
progressive changes in CSF Aβ42 or (P)-tau concentrations, except for one study.71 On the 
other hand, atrophy rates on MRI are good indicators of disease progression in MCI and AD. 
The question is therefore: can one or both disease markers be used as markers of progression? 
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Longitudinal studies 
The few studies investigating the change in CSF biomarkers were done in AD patients. Little 
is known about the change of CSF Aβ42, tau and Ptau in MCI, while one would expect that in 
this early stage of disease the biomarkers are more prone to change than in later stages. One 
study investigated whether there was a longitudinal relationship between the change in 
biomarkers with the change in hippocampal volume on MRI in a small group of aged 
individuals with and without memory problems.4 In a 2 time-point longitudinal design, the 
MCI group, N=8, showed an inverse relationship between hippocampal volume reductions 
and elevations in CSF Ptau, while CSF Aβ42 levels showed a positive relation with 
hippocampal volume reductions. However, there are several limitations of this study: a very 
small group was investigated; it is not known whether these MCI patients will develop AD; 
and the change in biomarkers could also be due to the intra-assay variability, as very small 
changes are detected. The authors did not find a significant change in CSF Aβ42, tau and Ptau 
between two time points, only if they corrected for dilution of Ptau due to ventricular 
enlargement; this ‘Ptau-231 load’ was increased in MCI at follow-up.65 These findings need 
to be replicated in larger groups of patients, while additional studies are warranted for a better 
understanding of CSF flow and clearance dynamics of biomarkers. 
 
Additive value of CSF markers over other diagnostic tools 
In a recent review the position of CSF markers in the clinical assessment of patients with MCI 
and early AD has been discussed.17 The authors suggest that only after intensive screening of 
the patients by history, neurological examination, routine laboratory tests (blood and CSF), 
and neuroimaging (CT, MRI or SPECT) there is place for CSF markers for the (early) 
diagnosis of AD. The clinical diagnosis of AD should be based on cumulative information of 
all the different diagnostic tools, as in other areas of medicine. For the differential diagnosis 
of AD, we state that the biomarkers are especially important for the early onset dementias, as 
there is clinical and radiological overlap, especially between EAD and FTD. In the older age 
group, the prevalence of AD is much higher, and the usefulness of biomarkers to distinguish 
AD from other types of dementia becomes less relevant. However, since the currently 
available medications to enhance cognition are approved for mild to moderate AD, every hint 
to the correct diagnosis should be taken into account irrespective of age. The additive value of 
CSF markers to other diagnostic tools has not yet been investigated systematically, and is an 
aim for future studies. 
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Limitations in research on CSF markers 
For the differentiation of AD from normal aging, depression or other types of dementia 
overlap is seen in CSF Aβ42, tau and Ptau concentrations between the groups. One 
explanation is that the control or demented groups could have neuropathological findings 
indicative for AD, resulting in an AD biomarker profile. Other explanations are the use of 
different processing and storage conditions of CSF71, the use of different reagent antibodies, 
differences in the definition of cut off values, and intra- and inter-assay variability of the 
assays used.17 Standardization of the (pre-) analytical methods will increase the reliability of 
the results and it will improve collaboration with other neurological/biochemical research 
centers or memory clinics. Although it is not difficult to obtain CSF by lumbar puncture, this 
method is considered to be somewhat invasive for an outpatient clinic, especially in the US. 
Therefore, a sensitive serum or plasma marker for AD would be very valuable for the use in 
clinical practice.  
  
Conclusion 
For the differentiation of AD from normal aging, depression, or alcoholic dementia the 
combination of CSF Aβ42 with tau gives a high sensitivity and specificity of ≥ 85%, with 
minimal overlap in individual cases. In the pre-clinical (MCI) stage of disease CSF Aβ42, tau 
and Ptau could be used as predictors for the development of AD. For the differentiation of AD 
from other types of dementia the combination of CSF Aβ42, tau and Ptau gives a good 
sensitivity and a reasonable specificity, especially for the differentiation of AD from FTD and 
less for AD versus DLB or VAD. For clinical practice a high positive predictive value, and a 
low negative predictive value are important. With at least two markers positive, the diagnosis 
AD is very likely, while two markers negative can practically rule out the diagnosis AD. The 
CSF biomarkers must be only used in combination with other diagnostic tools, including 
clinical investigation, imaging and neuropsychological work up. 
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Guide lines for the use of CSF Aβ42, tau and Ptau in clinical practice 
1. When there is doubt about the diagnosis AD, with non-conclusive MRI and 
neuropsychological findings. 
2. In patients with early onset dementias (disease onset before 65 years old), as the 
differential diagnosis here is wider and more complicated; especially the 
differentiation of EAD from FTD is relevant. 
3. In patients suspected for AD, and for whom treatment is being considered. 
4. In patients suspected for CJD, in combination with CSF 14-3-3 protein, MRI scan and 
EEG. 
 
Topics for future research 
- Investigate the additional value of the biomarkers CSF Aβ42, tau and Ptau to other 
diagnostic methods, i.e. MRI parameters, and/or neuropsychological examinations. 
- Investigate the diagnostic value of the biomarkers in primary and secondary referral settings, 
preferably with neuropathological or prolonged clinical follow-up. 
- Investigate which markers could be used for tracking the progression of the disease, 
especially in the MCI stage of disease. Promising markers are: C-and N-terminally truncated 
Aβ peptides, oxidative stress markers or inflammatory markers.  
- Develop new tests for a sensitive marker, which can be determined in blood or urine. 
- Standardize (pre-analytical) laboratory methods between research centers. 
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CHAPTER 2 
 
 
 
AIM OF THE THESIS  
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In chapter 1.2 an overview was given of studies on CSF markers published in the past 10 
years. The number of centers investigating biomarkers in AD is increasing, and one would 
expect that CSF Aβ42, tau and Ptau will soon be accepted as established diagnostic markers 
in clinical practice. However, several issues still need thorough attention before this can be 
done. First, CSF data with neuropathological confirmation of clinically diagnosed AD patients 
as well as patients with other types of dementia are merely lacking. One must also bear in 
mind that the exact etiology of AD is still not known. Plaques and tangles are classical in AD, 
but what triggers the development of senile plaques containing insoluble Aβ42? Are Aβ 
peptides indeed the first manifestation of AD –described in the amyloid beta cascade 
hypothesis17- or do they need neurofibrillary tangles at a very early stage of disease to become 
neuropathogenic, leading to neuron loss and thus clinical symptoms? Recent insights show 
that various truncated forms and oligomers of Aβ play an important role in disease 
development18, as well as inflammation and oxidative stress.19 The emerging knowledge from 
basic science is a must for research on biomarkers, especially for how and when to use them 
properly in clinical practice. 
 
General aim of the thesis 
The aim of studies described in the current thesis was to investigate whether the CSF markers 
Aβ42, tau and Ptau can be used for an early and differential diagnosis of AD in clinical 
practice.  
 
Reliability of the assays 
First we had to define whether the assays we (and most centers in Europe) used were reliable 
with regard to (pre-) analytical factors involved. Among centers there is a large variation of 
CSF concentrations of Aβ42 and tau, even when using the same assays in clinically well 
defined control groups and patients. The manufacturers of the commercial available assays 
reported that repeated freeze/thaw cycles and tube type may influence concentrations of CSF 
Aβ42.20 Little is known about the stability of the samples when stored for a longer period. 
We, therefore, addressed the following questions. 
 
Are CSF samples stable as far as Aβ42 and tau are concerned? 
We conducted an independent study to investigate the effects of storage temperature, repeated 
freeze/thaw cycles and centrifugation on CSF concentrations of Aβ42 and tau (chapter 3.2). 
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This study should shed some light to the influence of pre-analytical factors and their 
physicochemical mechanisms on CSF concentrations of both markers. Final aim was to 
formulate standardized conditions, which are crucial for the implementation of the CSF 
markers as a diagnostic tool in clinical practice.  
 
Are CSF concentrations of Aβ42 comparable when measured by two different ELISAs? 
CSF concentrations of Aβ42 also varied between assays, from decreased levels in AD to no 
change (two studies) or even increased (one study) levels as compared to controls.21,22 This 
might be due to the use of different antibodies directed against distinct epitopes of the Aβ 
peptide. To address this, we compared CSF concentrations of Aβ42 as measured by two 
different Aβ42 assays in the same CSF samples (chapter 3.3).  
 
In addition to N-terminally truncated Aβ42 peptides various C-terminally truncated Aβ 
peptides can be found in brain tissue and CSF.23 
 
Is there a relation between various C-terminally truncated Aβ peptides in CSF? 
We wondered whether there was a relation between the three C-terminally truncated Aβ 
species, Aβ38, 40 and 42, measured by ELISA in CSF from AD patients and controls 
(chapter 4). By studying the relation between Aβ42 to other Aβ peptides, we hoped to get a 
better understanding of the specific decrease of concentration of Aβ42 in CSF from AD 
patients, for which the exact mechanism is not known.  
 
CSF Aβ42, tau and Ptau in early and differential diagnosis  
After these more fundamentally orientated studies, we conducted three case-control studies in 
order to approach the main question: can these CSF biomarkers be used for early and 
differential diagnosis in clinical practice?  To this end several subquestions were formulated, 
i.e.: 
 
What is the diagnostic value of CSF Aβ42, tau and Ptau in early onset AD versus 
frontotemporal dementia?  
This study (chapter 5.1) is particularly relevant as these two types of presenile dementia 
syndromes show clinical, neuropsychological and radiological overlap. Most previous studies 
compared older AD patients with younger patients with frontotemporal lobar degeneration 
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(FTD), or older FTD patients with age-matched AD patients, but in this older age group FTD 
is less prevalent.24,25 The combination of CSF Aβ42, tau and Ptau had not yet been studied in 
these two types of presenile dementia (see also chapter 5.2). 
 
Are CSF Aβ42 and tau independent predictors of AD? 
Patients with mild cognitive impairment (MCI) have an increased risk of developing AD, and 
several studies have shown that CSF Aβ42 is decreased while CSF tau is increased in 
MCI.26,27 We investigated whether MCI patients at different risk for AD according to their 
biomarker profile differed from each other with respect to other clinical markers or risk 
factors (chapter 6). Furthermore, the relation between CSF Aβ42 and tau with other clinical 
markers –medial temporal lobe atrophy (MTA) on MRI scan and memory disturbance- was 
investigated. To date, cognitive and intellectual impairment with the support of MRI markers 
are the clinical indicators of AD.28 CSF biomarkers might well add to this panel of disease 
markers.  
 
What is the relation between CSF markers and medial temporal lobe atrophy? 
The final study as reported in this thesis focused on the relation between CSF Aβ42, tau and 
Ptau with MTA in a cohort of AD patients and controls (chapter 7). The aim of this study was 
two-fold: first, to get insight whether both CSF and MRI markers reflect the same 
neuropathological substrate simultaneously. Second aim was to investigate whether both 
disease markers contribute equally to the diagnosis AD. The comparison with other diagnostic 
methods becomes more and more important, because neuropathological ante-mortem data as 
gold standard are missing and none of the disease markers can be 100 percent accurate. 
 
With the abovementioned cross-sectional studies we might well get more insight in whether, 
how, and when to use the currently most specific biomarkers for AD in clinical practice. Of 
course much more research is needed, and fortunately enough the topic of biomarkers is an 
expanding area, especially considering the development of novel biomarkers for diagnosis as 
well as for tracking progression of the disease. 
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3.1 Description of ELISA’s for Aβ 1-42, Aβ N-42, Aβ38, Aβ40, total tau and tau 
phosphorylated at threonine 181  
 
- INNOTESTTM β-amyloid [1-42] (Innogenetics, Ghent, Belgium) 
The monoclonal antibody (mAb) 21 F12 binds the COOH terminus of the Aβ42 peptide 
(amino acids 36-40) and is used as capture antibody. Biotinylated mAb 3D6, which binds the 
NH2 terminus (amino acids 1-6) , is used as detector antibody. Synthetic Aβ (1-42) peptides 
from Bachem were used as calibrators. 
 
- Sandwich ELISA for Aβ N-42 (P. Mehta, Staten Island, NY, US) 
Monoclonal antibody 6E10 (Signet Labs) is used as capture antibody, and is specific to an 
epitope covering N-terminal amino acid residues 1-17. The polyclonal antibody R165 is used 
as detector antibody. R165 is made by immunizing rabbits with conjugated 33-42 Aβ peptides 
(Ana Spec). Aβ (1-42) peptides from Bachem were used as calibrators. 
 
- Sandwich ELISA for Aβ38 (P. Mehta, Staten Island, NY, US) 
Monoclonal antibody 6E10 (Signet Labs) is used as capture antibody. Antisera to Aβ38 
peptide were produced in rabbits by immunization of peptide “hCys-aminohexoanoyl-Ala-Ile-
Ile-Gly-Leu-Met-Val-Gly-GlyOH”. The antibody lacked reactivity against Aβ40 or Aβ42 
peptides as examined by sandwich ELISA and Western blot analysis. This antibody is used as 
detector antibody. Aβ (1-42) peptides from Bachem were used as calibrators. 
 
- Sandwich ELISA for Aβ40 (P. Mehta, Staten Island, NY, US) 
Monoclonal antibody 6E10 (Signet Labs) is used as capture antibody. The polyclonal 
antibody R208 is used as detector antibody. R208 is made by immunizing rabbits with 
conjugated 33-40 Aβ peptides (Ana Spec). Aβ (1-42) peptides from Bachem were used as 
calibrators. 
 
- INNOTESTTM hTAU-Ag (Innogenetics, Ghent, Belgium) 
Monoclonal antibody AT120 is used as capture antibody, while two mAbs are used as 
detection antibodies: HT7 and BT2, recognizing different epitopes on the tau protein. 
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- INNOTESTTM Phosphotau (181P (Innogenetics, Ghent, Belgium) 
Monoclonal antibody HT7 is used as capture antibody, and biotinylated mAb AT270 is used 
as detector antibody, which is specific for the phosphotau-Thr181 epitope. 
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CHAPTER 3.2 
 
 
 
Effects of processing and storage conditions on CSF amyloid β (1-42) and tau 
concentrations in cerebrospinal fluid: implications for use in clinical practice 
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Abstract  
Background: Reported concentrations of Aβ42 and tau in cerebrospinal fluid (CSF) differ 
among reports. We investigated the effects of storage temperature, repeated freeze/thaw 
cycles, and centrifugation on the CSF Aβ42 and tau concentrations. 
Methods: Stability of samples stored at -80°C was determined by use of an accelerated 
stability testing protocol according to the Arrhenius equation. CSF Aβ42 and tau 
concentrations were measured in CSF samples stored at 4°C, 18°C, 37°C and -80°C. Relative 
CSF concentrations (%) of the biomarkers after 1 freeze/thaw cycle were compared with those 
after 2, 3, 4, 5, and 6 freeze/thaw cycles. In addition, relative Aβ42 and tau concentrations in 
samples not centrifuged were compared to samples centrifuged after 1, 4, 48, and 72 hours.  
Results: Aβ42 and tau concentrations were stable in CSF when stored for a long period at  
-80°C. CSF Aβ42 decreased by 20% during the first two days at 4°C, 18°C, and 37°C 
compared with -80°C. CSF tau decreased after storage for 12 days at 37°C. After 3 
freeze/thaw cycles CSF Aβ42 decreased with 20%. CSF tau was stable up to 6 freeze/thaw 
cycles. Centrifugation did not influence the biomarker concentrations. 
Conclusions: Repeated freeze/thaw cycles and storage at 4°C, 18°C, and 37°C influence the 
quantitative result of the Aβ42 test. Preferably, samples should be stored immediately at -
80°C after collection. 
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Introduction 
In the last decade many studies have set out to find an appropriate biochemical marker for the 
diagnosis of Alzheimer’s disease (AD). Several authors have shown that the sensitivity and 
specificity of amyloid β (1-42) (Aβ42) and total tau (tau) in cerebrospinal fluid (CSF) are 
high when comparing AD patients with controls. 1,2 However, upon comparing AD with other 
types of dementia3, overlap in each biomarker occurs, hampering clinical utility. Ideally, the 
diagnostic value of biomarkers needs to be validated in neuropathologically confirmed cases, 
but most studies use the clinical criteria as the gold standard, with risk of circular reasoning. 
Furthermore, the use of the markers in clinical practice still needs to be established, as most 
studies have been carried out in research settings with selected patient samples. 4 A recent 
meta-analysis5 demonstrated considerable variability in absolute levels of both markers 
among centres, even when using the same commercial assay.  This variability could be 
attributed to differences in patient groups or to a difference in processing and storage methods 
among centres. Few published studies have investigated which factors produce a major 
influence on the quantitative outcome of the INNOTESTTM β-amyloid (1-42) ELISA. 6,7 An 
important confounding factor is the tendency of both Aβ42 and tau to adhere to glass or hard 
plastic tubes4, reducing the concentration. Furthermore, repeated freeze/thaw cycles seem to 
play a role in the decrease of CSF Aβ42, although different methods are used to investigate 
this phenomenon. One study6 showed a large decrease of CSF Aβ42 between the first and 
second freeze/thaw cycle, while no difference was found between Aβ42 concentrations in 
fresh CSF and CSF that had been frozen and thawed once. 7 No studies have been published 
regarding the stability of both Aβ42 and tau in CSF when stored frozen at -20°C or -80°C for 
many years. Knowing sample stability at freezing temperature is especially important for 
longitudinal studies in which samples are stored for long periods and analyzed simultaneously 
with samples stored for short periods to minimize inter-assay variability. 
  
In this study we sought to answer the following questions: What are the stabilities of Aβ42 
and tau in CSF samples stored at -80°C for several years? What are the stabilities of Aβ42 and 
tau in samples stored at 4°C, 18°C (room temperature), and 37°C up to three weeks, in order 
to investigate the effect of mailing? What is the effect of repeated freeze/thaw cycles on the 
concentration of Aβ42 and tau in CSF? What is the effect of centrifugation on CSF Aβ42 and 
tau concentrations? Awareness of pre-analytical factors that may influence the concentration 
of the markers could improve collaboration with other neurological research centers or 
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memory clinics and provide more reliable results. Our final aim is to formulate standardized 
conditions, which will be crucial when the use of Aβ42 and tau become standard practice for 
the (early) diagnosis of AD.  
 
Materials and Methods 
Participants 
Twenty-three individuals provided CSF for the entire study: 3 AD patients, 5 patients with 
mild cognitive impairment (MCI), 5 patients with frontotemporal dementia (FTD), 1 patient 
with mixed-type dementia (MD), and 9 controls with no dementia. All individuals gave 
informed consent to participate in the study. Four patients entered the accelerated stability 
testing protocol. For the analysis of tau in this experiment, one sample was excluded because 
the results were higher than the values for the highest calibrator. Two of the four individuals 
used in the accelerated stability testing protocol also participated in the freeze/thaw 
experiment. Thirteen other individuals provided CSF for the freeze/thaw experiments: 5 for 
the comparison of unfrozen CSF versus CSF frozen and thawed once, plus 8 for the 
comparison of samples frozen and thawed once with samples subjected to several freeze/thaw 
cycles. Six individuals provided CSF for the centrifugation experiment, including one who 
provided a haemolytic CSF specimen, which was not centrifuged and was compared with the 
baseline centrifuged specimen. 
 
Lumbar puncture 
CSF was obtained by lumbar puncture in the L3/L4 or L4/L5 intervertebral space, using a 25-
gauge needle, and was collected in 12 mL polypropylene tubes. A small amount of CSF was 
used for routine analysis, including total cells, total protein, and erytrocytes. Within two hours 
after collection CSF samples were centrifuged at 2100g for 10 minutes at 4°C. Samples were 
kept at room temperature until centrifugation. After centrifugation, CSF was pipetted into 
polypropylene tubes in 0.11-, 0.2- or 0.5-mL aliquots, depending on the experiment for which 
the CSF was to be used. 
 
Accelerated stability testing protocol 
For studying the stability at -80°C we used an accelerated stability testing protocol based on 
the principle of the Arrhenius equation8, describing a linear relationship between the 
logarithm of the reaction rate constant (e.g. the degradation rate) and the inverse of the 
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absolute temperature. Three temperatures 4°C, 18°C and 37°C were used for calculation of 
the rate constant.  
The principle and calculations of this protocol applying the Arrhenius method are provided in 
the APPENDIX at the end of this article. 
 
Participants 
Two patients and two controls participated in the accelerated stability testing protocol. 
One patient was a 73-year-old male with MD, and the other a 54-year-old female with 
probable AD according to the clinical criteria. 9 The controls were two non-demented spouses 
of patients, a male and a female of 77 and 58 years old.  
 
Samples 
After centrifugation, CSF samples were divided into 0.2 and 0.5 mL aliquots. The 0.5 mL 
aliquot was stored immediately at -80°C (193K) to determine the baseline values for Aβ42 
and tau. The other thirty aliquots of 0.2 mL from each patient were stored at 4°C (277K), 
room temperature (18°C (291K)) and 37°C (310K), 10 (polypropylene) tubes at each 
temperature. After 1, 2, and 3 days up to 22 days one tube stored at each of the three different 
temperatures was removed and frozen at –80°C until analysis. All 30 samples from each 
patient were thawed and analyzed, in duplicate, simultaneously in one run.  
 
Freeze/thaw cycles 
To compare unfrozen CSF with CSF frozen and thawed once, we stored two polypropylene 
aliquots of 0.2 mL CSF from five individuals for two days either at 4°C or at -80°C until 
analysis. The concentrations of Aβ42 and tau in the aliquots that had not been frozen and 
thawed (stored at 4°C) were compared with the concentrations in the aliquots that had been 
thawed once (stored at -80°C).  All aliquots were tested in duplicate. 
As most samples are stored at -80°C until analysis, the best way to simulate daily practice is 
to compare samples subjected to one freeze/thaw cycle with samples that have undergone 
several freeze/thaw cycles. Therefore, CSF of 10 individuals was centrifuged and aliquoted 
into six portions of 0.11 mL. One (polypropylene) tube from each patient was kept at -80°C 
until analysis and the concentration of Aβ42 and tau in this aliquot was used as baseline value 
(100%). The other five (polypropylene) tubes from each patient were stored at -80°C and 
thawed 2, 3, 4, 5, or 6 times at room temperature for 2 hours and stored again at -80°C until 
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analysis. The relative Aβ42 and tau concentrations of the 10 patients (%) were compared with 
the baseline value (100%) and plotted against the number of freeze/thaw cycles.  
 
Influence of centrifugation  
CSF from five individuals was aliquoted in five 0.5 mL polypropylene tubes. Tube 1 was 
centrifuged at 2100g for 10 minutes at 4°C within 2h after CSF collection and stored 
immediately at -80°C. The concentrations of Aβ42 and tau determined in tube 1 were used as 
baseline value. Tubes 2, 3, and 4 were stored at 4°C and centrifuged after 4, 48, and 72 hours. 
After centrifugation the supernatant was pipetted into polypropylene tubes and stored frozen 
for maximal 1 month until analysis. Tubes 5 were not centrifuged at all and kept for 4 days at 
4°C before storage at freezing temperature. Relative Aβ42 and tau concentrations (%) in 
samples not centrifuged were compared to samples centrifuged after 1, 4, 48 and 72 hours. In 
addition, we compared a haemolytic CSF sample obtained after a traumatic lumbar puncture 
(28,800 erythrocytes/µL, equivalent to approximately 0.5% whole-blood contamination), that 
was not centrifuged but had been stored at -80°C, with a sample from the same patient 
centrifuged within 2 hours and stored at 4°C until analysis. 
 
Analysis of Aβ42 and tau 
Aβ42 concentrations for all experiments were determined with the sandwich ELISA 
INNOTEST β-amyloid (1-42) (Innogenetics, Ghent, Belgium). Monoclonal antibody (Mab) 
21F12, which is highly specific for the C-terminus of the Aβ42 peptide, was used as capturing 
antibody, and the biotinylated Mab 3D6, specific for the N-terminus, was used as detector 
antibody. 6 For quantification of tau we used the sandwich ELISA INNOTESTTM  hTau 
Antigen (Innogenetics) constructed to measure both total tau and phosphorylated tau with 
Mab AT120 as capturing antibody and HT7 and BT2 as detection antibodies. 10 For the 
stability experiment, performed at Innogenetics, the mean intra-assay coefficients of variation 
(CVs) were calculated from the difference between duplicate measurements. The mean CVs 
for Aβ42 were 6.2% at an Aβ42 level of ≤ 500 pg/ml (N=61) and 7.2% at an Aβ42 level of > 
500 pg/ml (N=59). For tau the mean intra-assay CV’s were 8.7% (tau ≤ 300 pg/ml, N=61) and 
13.3% (tau > 300 pg/ml, N=26). The mean CV’s at the VUMC laboratory were calculated by 
the precision from the difference between duplicate measurements (SDx100/mean) of 60 
routine samples.  For Aβ42 mean CV was 4.0% at concentrations in the low range (125-300 
pg/ml), 2.9% at concentrations in the middle range (600-800 pg/ml), and 3.4% at 
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concentrations in the high range (1000-2000 pg/ml). For tau the CVs were 6.5% at low 
concentrations (75-200 pg/ml), 4.7% at concentrations in the middle range (500-700 pg/ml) 
and 4.6% at a high concentration (900-1200 pg/ml). The mean inter-assay CVs of 3 different 
pools, evaluated in advance and tested in the stability, centrifugation and freeze/thaw 
experiments, were 12.1% for Aβ42 (N=7) and 8.1% for tau (N=7). Mean recoveries from four 
samples to which 1:1 dilutions of the highest calibrators for Aβ42 or tau were added were 
77% (range 73%-81%) for Aβ42 and 109% (range 108%-112%) for tau.  
 
Results 
Stability at -80°C according to the Arrhenius equation 
The relative concentrations (%) of Aβ42 and tau in CSF from the four and three patients on 
the consecutive days were calculated at 4°C, 18°C and 37°C, with the baseline value (-80°C) 
set at 100%. Plotting the relative concentrations (%) versus the days of heat stress, the rate 
constants at each investigated temperature (k(T)) were calculated (Table 1). The calculated 
k(T) values, determined at the three temperatures, were not different from zero, indicating that 
Aβ42 and tau are stable in CSF when stored at -80°C.  
 
Table 1 Rate constants (k(T)) for Aβ42 and tau 
Temperature (K) 
 
k(T) of Aβ42 k(T) of tau 
277 
 
-0.0043 (±0.04) 0.0018 (0.03) 
291 
 
-0.0032 (0.03) -0.0016 (0.03) 
310 0.050 (0.03) -0.039 (0.03) 
 
Percentages of remaining measurable protein were plotted versus days of heat stress at each temperature. Mean 
(SD) k values were determined for the three temperatures at the slope of the best-fit line. 
 
Stability during mailing conditions 
When we plotted the mean CSF Aβ42 values for samples from four patients stored at the 
three different temperatures against time, the protein concentrations were highest at baseline 
(–80°C) and during the first two days, the concentrations decreased by 20% in samples stored 
at 4°C, 18°C and 37°C (Figure 1A). Thereafter, the concentration of CSF Aβ42 remained 
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Figure 1 Relative concentrations of Aβ42 in CSF samples stored at 4°C, 18°C and 37°C 
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Mean percentages of Aβ42 plotted vs time, in samples collected from four subjects, and stored at 4°C, 18°C and 
37°C compared with the baseline sample, stored at -80°C and stated as 100%.  
 
 
Figure 1B 
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Percentages of Aβ42 plotted vs time in CSF samples from subject 1 (mixed type dementia) and subject 2 
(control) and stored at 4°C, 18°C and 37°C 
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relatively stable up to 22 days, although we observed considerable variability between 
aliquots from the same individual (Figure 1B). Tau plots showed that the protein was stable in 
CSF at 4°C and 18°C, whereas the concentration decreased at 37°C after approximately 12 
days (Figure 2).  
 
Figure 2 Relative concentrations of tau in CSF samples stored at 4°C, 18°C and 37°C 
0 5 10 15 20 25
Days
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
R
el
at
iv
e 
co
on
ce
nt
ra
tio
n 
(%
)
4 ºC
18 ºC
37 ºC
 
Mean percentages of tau, plotted vs time, in CSF samples collected from three patients and stored at 4°C, 18°C 
and 37°C compared with baseline sample, stored at -80°C and stated as 100%.  
 
Freeze/thaw cycles 
No difference could be demonstrated between concentrations of Aβ42 and tau in CSF that had 
not been thawed and CSF that had undergone one freeze/thaw cycle (visualized for Aβ42 in 
Figure 3A). In Figure 3B the mean (SD) relative concentrations (%) for Aβ42 vs the number 
of freeze/thaw cycles are shown. A decrease of 20% after 3 freeze/thaw cycles was observed. 
Thereafter, no decline could be demonstrated and the values remained constant at 80% of the 
baseline concentration during 6 freeze/thaw cycles. The change in concentration varied 
among individuals, ranging from no change in the samples from one patient to a large 
decrease in samples from another. We could not demonstrate a difference between samples 
with high concentrations of Aβ42 (≥ 550 pg/ml, n=5) and low concentrations of Aβ42 (<550 
pg/ml, n=5). In Figure 3C the mean (SD) relative concentrations (%) of tau vs the number of 
freeze/thaw cycles are shown. No change during 6 freeze/thaw cycles could be demonstrated.  
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Figure 3 Effect of freezing/thawing on Aβ42 and tau concentrations 
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Plot of CSF Aβ42 concentration in five samples that had not been subjected to a freeze/thaw cycle compared 
with samples that had been subjected to one freeze/thaw cycle.  
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Mean (SD, error bars) relative CSF Aβ42 concentrations (%) in samples of ten patients versus numbers of 
freeze/thaw cycles. The values of Aβ42 after 1 freeze/thaw cycle of each subject were used as baseline value and 
stated as 100%. 
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Figure 3C  
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Mean (SD, error bars) relative CSF tau concentrations (%) in samples of nine patients versus numbers of 
freeze/thaw cycles. The values of tau of each subject after 1 freeze/thaw cycle were used as baseline value and 
stated as 100%. 
 
Influence of centrifugation 
No difference was found between CSF concentrations of Aβ42 and tau in samples that were 
stored at 4°C and centrifuged after 1, 4, 48, or 72 hours. Furthermore, there was no difference 
in concentrations of the markers in samples stored frozen after centrifugation, and samples 
that were not centrifuged and stored for 4 days at 4°C. In addition, no difference in Aβ42 and 
tau concentrations could be shown in the haemolytic sample not centrifuged and stored at -
80°C (Aβ42 662 ng/L; tau 232 ng/L) and the sample centrifuged and stored at 4°C (Aβ42 = 
596 ng/L; tau = 230 ng/L). 
 
Discussion 
Using the Arrhenius approach, we showed that the Aβ42 and tau concentrations are stable in 
CSF samples when frozen immediately and stored for a longer period at -80°C. Furthermore, 
the concentration of Aβ42 in CSF decreased by approximately 20% during the first two days 
when stored at 4°C, 18°C and 37°C compared to the baseline value, and then remained 
constant for up to 22 days, although with considerable variability between aliquots from the 
same individual. CSF tau concentration was stable at 4°C and 18°C, but showed a decrease 
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after 12 days when stored at 37°C. After 4 freeze/thaw cycles the concentration of Aβ42 in 
CSF decreased by 20%, while tau remained stable during 6 freeze/thaw cycles. Centrifugation 
did not influence the outcome of either biomarker. 
 
To the best of our knowledge, the stability of Aβ42 and tau in CSF samples stored at -80°C 
for many years has never been systematically investigated. Two previous studies found that 
CSF Aβ42 2,5 and tau5 concentrations remained stable when stored for > 6 months at –70°C or 
-80°C. The first study showed that the correlation between CSF Aβ42 measured at different 
times during 1 year and reanalysis at one time was high (correlation coefficient = 0.96). 2 
Unfortunately, the regression coefficient (or slope of the line) is not mentioned in that study, 
while this could give more accurate information about degradation of the protein. The second 
study did not find a relation between CSF Aβ42 or tau and shelf life. 5 In our study we 
investigated the long-term stability at -80°C with an accelerated stability testing protocol 
according to the Arrhenius method. No significant decline in Aβ42 and tau concentration at 
4°C, 18°C, and 37°C was found, except for tau at 37°C, and only after 12 days. Therefore, the 
degradation constant was not different from zero, and no Arrhenius-plot or projected stability 
time could be calculated. From this we conclude that both proteins are very stable in CSF and 
that the samples can be stored for a very long period at -80°C. However, a real-time stability 
experiment performed in the future is needed to confirm our data. 
The stability of various forms of Aβ in CSF samples stored at different temperatures has been 
described in two studies11,12 using in-house ELISAs. In the first study11, the immunoreactivity 
of CSF Aβ40 and Aβ42 decreased by 8% and 10% when kept for 24 hours at 20°C, but 
remained stable the first 24 hours at 4°C. In the second study12, CSF total Aβ levels were 
measured and found to be unstable if samples were stored at –20°C, 4°C, and room 
temperature, with the largest decrease during the first day and plateauing after the third day. 
Although different assay formats were used, measuring different types of Aβ, 
abovementioned findings support our results of a decrease in concentration of CSF Aβ42 
during the first two days for samples stored at 4°C, 18°C and 37°C. Although incubation at 
higher temperatures could have an effect on the binding capacity of Aβ42 6, 13,14, storage of 
CSF at different temperatures does not seem to affect the Aβ42 concentration6, which is 
supported by our findings showing comparable Aβ42 concentrations in CSF samples stored at 
4°C or 37°C. There was a difference in Aβ42 concentration only between samples stored at -
80°C immediately after collection or stored at higher temperatures after collection. An 
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interesting finding in one study11 was that the antibody-binding capacity of synthetic Aβ42 
was lower in CSF than in water. In addition, Aβ42 levels were lower in artificial CSF with 
physiological concentrations of albumin than without albumin. An explanation for this finding 
could be that binding of Aβ42 to albumin masks the epitope recognized by Aβ42-specific 
antibodies. 15,16 This binding of Aβ42 to other proteins might also cause the low recovery rate 
of the Aβ42 ELISA, although Vanderstichele et al.6 and others17 could not find interference 
with Aβ by other proteins, including human albumin. However, interference experiments are 
largely dependent on the protocol being used, and whether pre-incubation is needed. 
Furthermore, results are also dependent on which medium is used, either artificial CSF, 
human CSF or another medium such as sample diluent. 6 The difference in concentrations of 
Aβ42 between samples stored at –80°C and at higher temperatures could also be the result of 
binding of Aβ42 to other proteins, but conformational changes, aggregation18 or degradation 
may be involved as well. The variability in Aβ42 concentrations among centers5 might very 
well be attributable to the procedure for sample treatment the first hours after collection, with 
one center immediately freezing samples on dry ice and another center storing samples at 
room temperature until further processing (our center). This is an important factor to be 
considered and investigated in future multicenter studies. 
Our finding of decreased concentrations of Aβ42 in CSF after repeated freeze/thaw cycles 
corresponds with the outcome of several other studies6,11,12, and stresses again the importance 
of avoiding freeze/thaw cycles in order to minimize the risk of falsely low Aβ42 values. The 
decrease of CSF Aβ42 after repeated freeze/thaw cycles might also be explained by the same 
physicochemical mechanisms –i.e. conformational change of the fibrillary β-sheeted Aβ42 
protein or masking of the epitope by binding to other proteins- that led to a decrease of Aβ42 
concentration during the first two days when stored at 4°C. This is sustained by our finding of 
comparable CSF Aβ42 concentrations between samples that had not been been subjected to a 
freeze/thaw cycle (stored for two days at 4°C) versus samples that had been subjected to 1 
freeze/thaw cycle.  
 
Tau protein is considered to be very stable, and also repeated freeze/thaw cycles do not seem 
to influence the concentration of this protein. Therefore, it is remarkable that tau decreases 
after 12 days storage at 37°C. At this temperature, the protein may be degraded by proteases, 
form aggregates or undergo conformational changes, producing a form that is not detectable 
by one or both anti-tau antibodies used in the ELISA.10 Little is known about the relationship 
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between CSF tau and temperature. The pathological core protein of paired helical filaments 
(PHF), consisting of a portion of tau, is found to be protease and heat resistant.19 However, 
the aggregation of tau into PHF has been demonstrated to increase at temperatures above 
30°C.20 The tau protein is generally highly soluble, but the aggregated pathological form 
found in the neurofibrillary tangles in the brain might not be released in CSF. The nature of 
tau in CSF is not well documented, but previous studies have revealed different molecular 
masses of tau in lumbar CSF ranging from 25-80 kDa. 21 The low molecular weight of 25 kDa 
is not found in the brain, suggesting that CSF tau is truncated when released into CSF, 
probably as a result of degradation processes occurring in the brain. The truncated forms of 
tau in CSF should be well recognized by the anti-tau antibodies as they cover only a small 
part of the large full-length tau. We speculate that the 12 days storage of CSF at 37°C might 
lead to a change of the truncated form of tau into a more aggregated form, which is 
undetectable by the antibodies incorporated in the ELISA. 10 
 
In conclusion, both Aβ42 and tau are stable in CSF at -80°C for a long period. However, CSF 
Aβ42, when stored at 4°C, 18°C and 37°C, decreased by 20% during the first two days 
compared with the baseline value (-80°C).  Furthermore, the concentration of Aβ42 in CSF is 
influenced by the number of freeze/thaw cycles. To avoid these difficulties it is best to 
process CSF as soon as possible after collection and store it at –80°C for long storage. 
Preferably, CSF samples should be sent on dry ice when stored frozen. 
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APPENDIX Estimation of stability by the Arrhenius method 
The best way to determine the stability of analytes in body fluids is to perform a real time stability experiment. This can be done by storing 
paired aliquots of a sample and determining the concentrations of the proteins after certain time points, varying from some months to many 
years, taking into account that the sample is thawed once. However, this approach requires long experimental periods. Moreover, in real 
stability time studies, the determination of the protein must be performed at the beginning, during and at the end of the study. These 
measurements can often not be performed using the same batch of reagents. An increased inter-assay coefficient of variation may be the 
result. 
Therefore, estimation of protein stability should rather be performed using an accelerated stability testing protocol. The kinetics of protein 
denaturation are comparable with that of a first order reaction, which means that the degradation rate is proportional to the concentration of 
the respective analyte. The equation for the accelerated stability testing protocol is:  
-d[C]/dt = k[C] or ln C(t)/C(0) = -k.t 
where C(0) is the initial protein concentration, C(t) is the concentration after time t, and k is the rate constant. The rate constant, which is 
dependent of the temperature, is determined at the three fixed temperatures 4ºC, 18ºC and 37ºC, assuming that at -80ºC the concentrations 
remain constant during the time of this storage experiment. Afterwards the Arrhenius equation is applied, using this formula: 
Ln k(T) = A + E/RT 
in which A = the pre-exponential factor and E/R = the slope of the equation. Using the equation of the best-fit line, it is possible to calculate 
the degradation rate constant at each desired temperature:  
Ln k(T) = A + B/T  
or  
y =A + Bx 
A and B have fixed values. By substituting the temperature of interest, e.g. -80º C = 193ºK ? k(193) is calculated. We can calculate the time 
after which 90% or 95% of Aβ42 or tau can be recovered, by substituting Ct)/C(0) = 0.90 or 0.95 in the equation:  
Ln(0.90) = -k(193).t 
 -0.105 = -k(193).t 
t = 0.105/k(193) 
or  
Ln(0.95) = -k(193).t 
-0.0513 =   -k(193).t 
t = 0.0513/k(193) 
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Abstract 
Background: Differences in absolute concentrations and clinical performance of cerebrospinal 
fluid (CSF) amyloid β 42 (Aβ42) between laboratories is partly attributable to the antibodies 
selected for the assay. We compared Aβ42 levels and diagnostic accuracy of two Aβ42 assays 
in the same CSF samples. 
Methods: Aβ42 levels were measured in CSF of 39 Alzheimer’s disease (AD) patients, 24 
patients with frontotemporal lobar degeneration (FTLD) and 30 controls. One ELISA used the 
monoclonal antibodies 3D6 and 21F12 directed against amino acids 1-6 of the N-terminal part 
and amino acids 36-42 of the C-terminal part of Aβ42 (Aβ 1-42). The other ELISA used the 
monoclonal antibody 6E10 specific to an epitope present on 1-17 amino acid residues of the 
N-terminal part and the polyclonal antibody R165 directed against amino acids 33-42 of the 
C-terminal part of Aβ42 (Aβ N-42). 
Results: Absolute concentrations of CSF Aβ 1-42 and Aβ N-42 were comparable in all CSF 
samples. In AD versus controls sensitivity and specificity values for CSF Aβ 1-42 and Aβ N-
42 were equal; Aβ 1-42: sensitivity 90% and specificity 93%; Aβ N-42: sensitivity 90% and 
specificity 87%. A slightly better differentiation of AD from FTLD was obtained with CSF 
Aβ N-42 than CSF Aβ 1-42 (area under the ROC curve Aβ 1-42= 0.77, 95%CI 0.64-0.90 and  
Aβ N-42= 0.87,  95%CI 0.76-0.97, P=0.045). 
Conclusions: Both Aβ42 assays provided equal diagnostic accuracy comparing AD with 
controls. Further studies are needed to investigate the involvement of the different forms of 
Aβ42 in AD and FTLD patients. 
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Amyloid β 42 (Aβ42) concentrations in cerebrospinal fluid (CSF) are used to identify 
Alzheimer disease (AD)1, but reported concentrations differ among studies as does diagnostic 
accuracy. 2 These differences may relate to the patient and control groups (3) studied, 
processing and storage methods4, intra- and inter-assay variation of the assays, or to the 
reagent antibodies used. A recent meta-analysis2 stressed the importance of standardizing 
assays for Aβ42 in CSF. In most studies CSF Aβ42 was reported to be decreased, but in two 
studies, CSF Aβ42 was not significantly changed in AD2, and in one study even increased in 
the early stages of AD.5 These dissimilarities might reflect the specificities of the antibodies 
incorporated in the assays. 
 
The first aim of our study was to compare levels of Aβ42, as measured by two different 
assays in the same CSF samples. The first assay, widely used in Europe6, uses two 
monoclonal antibodies (Mabs) and detects full length Aβ42 peptide, Aβ 1-42. 7  The second 
assay [Aβ (N-42)], used mainly in the United States8, detects both full length Aβ42 and Aβ 
peptides truncated at the N-terminus. 9  
The second aim of the study was to compare diagnostic accuracies of the assays for patients 
with AD compared with non-demented controls and patients with frontotemporal lobar 
degeneration (FTLD). 
Finally, we investigated the relationship between CSF Aβ 1-42 and Aβ N-42 concentrations 
and albumin ratio, age, disease duration, and disease severity. 
 
Between October 2000 and December 2002 39 AD patients, 24 FTLD patients and 30 non-
demented controls were recruited at the Alzheimer Center of the VU University Medical 
Center (VUMC). All patients underwent a standardized investigative protocol. 3 A diagnosis 
of ‘probable’ AD was made according to the NINCDS-ADRDA criteria10; the clinical picture 
of FTLD (including frontotemporal dementia, semantic dementia, and progressive aphasia) 
was based on international clinical diagnostic criteria. 11 Disease duration in AD and FTLD 
patients was defined as the time in years between the first symptoms by history and the 
lumbar puncture.  
The control group (n = 30) consisted of 20 persons with subjective memory complaints, who 
had undergone the same protocol of examinations as the patients; five healthy spouses of 
patients without memory complaints; three individuals with a positive family history for AD, 
all without memory complaints; one patient with a suspicion of benigne intracranial 
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hypertension and one patient with a possible neuritis vestibularis. No controls developed 
dementia or mild cognitive impairment within 1 year. The Mini Mental State Examination 
(MMSE) score12 was used as a measure of global cognitive impairment.The study was 
approved by the ethics review board of the VUMC. All patients and controls gave written 
informed consent. 
CSF was collected and stored as described previously. 4 The albumin ratio (serum 
albumin/CSF albumin) was used as a measurement of the intactness of the blood-brain 
barrier. Except for one FTLD patient and 2 controls, the blood-brain barriers of the patients 
were intact (Table 2).   
The INNOTESTTM β-AMYLOID(1-42) (Innogenetics) uses Mab 21F12, which binds the C-
terminus of the Aβ42 peptide (amino acids 36-42), as capture antibody, and biotinylated Mab 
3D6, which binds the N-terminus (amino acids 1-6), as detector antibody (6). Aβ (1-42) 
peptides from Bachem were used for calibration. To minimize aggregates in the peptide 
stocks used to prepare calibrators, we obtained three different batches of Aβ1-42 (Bachem) 
and processed them together. Peptides were pre-treated to eliminate the occurrence of small 
oligomers/aggregates. This test was performed at the Department of Clinical Chemistry of the 
VUMC. 
The sandwich ELISA for Aβ N-42 uses the commercially available Mab 6E10, specific to an 
epitope covering N-terminal amino acid residues 1-17 of Aβ42 (Signet Labs) as capture 
antibody, and the polyclonal antibody R165 as detector antibody. R165 was made by 
immunizing rabbits with conjugated Aβ33-42 peptides (Ana Spec). Aβ1-42 from Bachem 
was used for calibration, although production procedures for the calibrators were slightly 
different between the two laboratories. This test was performed at the New York site 
according to an in-house protocol. 
For statistical analysis, SPSS version 11.0 was used. Non-parametric statistics were used, as 
the distribution of the variables was not normal. Passing and Bablok regression 13 was 
calculated with Medcalc, V 4.30 (Medcalc Software), and we also prepared a Bland and 
Altman plot. 14 For group differences we applied the Kruskall-Wallis test, followed by the 
Mann Whitney U test applying the Bonferroni correction. The Chi-square test with continuity 
correction was used to test group differences within genders. 
The sensitivities and specificities for CSF Aβ 1-42 and Aβ N-42 were also calculated by 
Medcalc. Cut points corresponded to a sensitivity ≥ 85% (15), but if a higher sensitivity was 
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obtained for a reasonable specificity, it was used. Receiver operating characteristic (ROC) 
curves were constructed and compared. 16 Spearman correlations were calculated. A test was 
considered significant at P < 0.05. All reported tests are two-tailed unless stated otherwise. 
 
The CSF Aβ 1-42 and Aβ N-42 concentrations were not statistically significantly different 
(Table 1, Figures 1 and 2, see also Appendix and the online version of this Technical Brief at 
http://www.clinchem.org/content/vol51/issue 6/).  
 
Table 1 Passing and Bablok regression equation 
 N Equation Slope 95% CI Intercept 95% CI 
AD 39 Y=0.71X+35 0.51-1.01 -39 - +106 
FTLD 24 Y=1.17X-39 0.89-1.59 -230 - +99 
Controls 30 Y=1.36X-245 0.81-2.44 -947 - +89 
All subjects 93 Y=1.12X-67 0.95-1.3 -140 - -3 
 
AD = Alzheimer’s disease; FTLD = frontotemporal lobar degeneration. CI = confidence interval. Variable X = 
Aβ 1-42, variable Y = Aβ N-42. 
 
Concentrations of both CSF Aβ 1-42 and Aβ N-42 levels were significantly lower in AD 
patients than in FTLD patients and controls (Table 2). 
CSF Aβ 1-42 concentrations differed significantly between FTLD patients and controls, 
whereas CSF Aβ N-42 concentrations did not differ significantly between the two groups 
(Table 2). The ratio of Aβ 1-42 to Aβ N-42 differed significantly only between the AD and 
FTLD patient groups. 
ROC curves for CSF Aβ 1-42 and Aβ N-42 are shown in Figure 3. In AD versus controls 
sensitivity and specificity for CSF Aβ 1-42 were 90% and 93% at 473 ng/L, and for CSF Aβ 
N-42 90% and 87%, respectively, at 383 ng/L. No difference was present in diagnostic 
accuracy of CSF Aβ 1-42 compared to CSF Aβ N-42 (Figure 3A); AUC Aβ 1-42 = 0.94, 
95%CI 0.86 - 0.99 versus AUC Aβ Ν−42 = 0.92, 95% CI 0.83 - 0.97, P = 0.47.  
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 Table 2 Demographic data and CSF analyses for each diagnostic category 
    AD
(N=39) 
FTLD  
(N=24) 
Co + OND  
(N=30) 
AD vs FTLD 
(P-value) 
AD vs controls 
(P-value) 
FTLD vs controls 
(P-value) 
 
 
Age (yrs) 
 
Sex (M/F) 
 
Duration (yrs) 
 
MMSE 
 
Albumin ratio 
 
Aβ 1-42 (pg/mL) 
 
Aβ N-42 (pg/mL) 
 
Aβ 1-42/Aβ N-42 
 
  
 
62 (52-79) 
 
20/19 
 
4 (1-11) 
 
20 (3-28) 
 
4.8 (2.0-10.6) 
 
315 (140-626) 
 
288 (116-674) 
 
1.1 (0.5-1.7) 
 
 
 
 
63 (49-85) 
 
16/8 
 
3 (1-11) 
 
24 (3-29) 
 
5.3 (1.5-17.3) 
 
495 (202-1087) 
 
588 (150-1324) 
 
0.9 (0.4-1.3) 
 
 
 
 
64 (32-79) 
 
14/16 
 
-- 
 
30 (25-30) 
 
5.2 (2.8-18.5) 
 
651 (337-1224) 
 
629 (218-1075) 
 
1.0 (0.6-2.6) 
 
 
 
 
0.58 
 
0.26 
 
0.054 
 
0.02 
 
0.6 
 
<0.001    
 
<0.001  
 
0.001 
 
 
 
 
0.14 
 
0.90 
 
-- 
 
<0.001 
 
0.47 
 
<0.001 
 
<0.001 
 
0.24 
 
 
 
 
0.66 
 
0.41 
 
-- 
 
<0.001 
 
0.99 
 
0.02 
 
0.66  
 
0.07 
 
 
 
AD = Alzheimer’s disease; FTLD = frontotemporal lobar degeneration; Co = controls; yrs = years; M/F = Male/Female; MMSE = Mini Mental State Examination; ≥ 1 ε4 
alleles = one or two ε4 alleles. Values are expressed as medians (minimum-maximum). P-values refer to statistical difference between AD vs FTLD, AD vs controls or FTLD 
vs controls. 
 
 
   
  
When comparing AD with FTLD, a specificity of 67% was obtained for CSF Aβ 1-42 at a 
sensitivity of 85% (448 ng/L). For CSF Aβ N-42 specificity was 75% at a sensitivity of 87% (373 
pg/mL). The AUCs for CSF Aβ N-42 and CSF Aβ 1-42 tended to be different (Figure 3B); AUC 
Aβ 1-42= 0.77 (0.64-0.90) and AUC Aβ N-42= 0.87 (0.76-0.97), P =0.045. The AUCs for CSF 
Aβ 1-42 and CSF Aβ N-42 (Figure 3C) in distinguishing FTLD patients from controls were 
significantly different [AUC Aβ 1-42= 0.69 (0.55-0.81) and AUC Aβ N-42= 0.54 (0.39-0.67), 
P=0.007], but the discriminatory value was small for Aβ 1-42 and negligible for Aβ N-42, with 
the confidence interval for the AUC including 0.5. 
We found no significant correlation of either CSF Aβ 1-42 or Aβ N-42 with albumin ratio, 
MMSE, age or disease duration (AD and FTLD) in either group. 
 
The absolute concentrations of CSF Aβ 1-42 and Aβ N-42 were comparable. However, in earlier 
studies concentrations of CSF Aβ N-42 ranged from 36 pg/mL to 623 pg/mL in AD and 111 
pg/mL to 629 pg/mL in controls. 8,17,18 The reason for the low CSF Aβ N-42 concentrations 
measured in these studies could be a difference in the affinity of the Aβ N-42 polyclonal 
antiserum samples or the purity and solubility of the peptides used as calibrator. 8 The sensitivity 
of an ELISA depends largely on the binding characteristics of the antigen, which may vary with 
temperature and buffer solutions, or among different reagent lots. 6 In addition, the affinity of the 
antibodies used in the assays might vary for the various Aβ42 peptides involved in the AD 
pathogenesis, including oligomers of the Aβ42 peptide. A future study exchanging calibrators 
and antibodies among various ELISAs is necessary for harmonization. ROC curve analysis 
revealed no difference in the ability of the two assays to differentiate between AD patients from 
controls. Next to the C-terminal heterogeneity, various N-terminal truncated peptides are found in 
the Aβ pools of AD brains. 19,20 These peptides are considered to play a role in the increased 
Aβ42 production in developing AD. We speculate that Aβ 1-42 and Aβ N-42 concentrations go 
hand in hand at a certain stage of disease, in mild to moderate AD as well as in controls. Because 
the N-terminally truncated Aβ42 peptides can be demonstrated early in the disease process9, they 
might be promising markers for the preclinical diagnosis of AD, when used simultaneously with 
Aβ 1-42. 21  
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Figure 3 ROC curve Aβ 1-42 versus Aβ N-42 
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ROC curve comparing Aβ 1-42 (straight line) with Aβ N-42 (dotted line) in AD versus controls 
3B. AD vs FTLD 
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ROC curve comparing Aβ 1-42 (straight line) with Aβ N-42 (dotted line) in AD versus FTLD 
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ROC curve comparing Aβ 1-42 (straight line) with Aβ N-42 (dotted line) in FTLD versus controls 
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The difference in diagnostic accuracy of CSF Aβ 1-42 and Aβ N-42 comparing AD with FTLD 
is remarkable. Several authors found a decrease of Aβ 1-42 in CSF in a subset of FTLD patients. 
3,22 Hardly any information is available about the CSF Aβ N-42 concentration in FTLD. 17 The 
reason for a decrease of CSF Aβ 1-42 in FTLD is unknown, although there might be a relation 
with the presence of an Apo E ε4 allele or with age. 23 Interestingly, a few studies have shown the 
involvement of three mutations in the presenilin 1 gene (PSEN1) mutations in familiar forms of 
FTLD. 24-26 These possible ‘loss of function’ PSEN1 mutations might act as inhibitors of the γ-
secretase cleavage of APP27, leading to a decrease of Aβ 1-42 in the brain. Although most FTLD 
patients included in our study have the sporadic form of FTLD, we cannot exclude the possibility 
of a mutation in the PSEN1 gene in some of them.  
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Abstract 
Various C-terminally truncated amyloid β peptides (Aβ) are linked to Alzheimer’s disease (AD) 
pathogenesis. Cerebrospinal fluid (CSF) concentrations of Aβ38, Aβ40, and Aβ42 were 
measured by enzyme-linked immunosorbent assay in 30 AD patients and 26 controls. CSF Aβ42 
levels were decreased in AD, while CSF Aβ38 and Aβ40 levels were similar in AD and controls. 
All three Aβ peptides were inter-related, particularly CSF Aβ38 and Aβ40. Diagnostic accuracy 
of CSF Aβ42 was not improved by applying the ratios of CSF Aβ42 to Aβ38 or Aβ40.  
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Introduction 
The amyloid β (Aβ) peptides comprise a heterogeneous set of N-and C-terminally truncated 
peptides as has been demonstrated in cell culture supernatants, brain tissue and cerebrospinal 
fluid (CSF). 1-3 The three best known C-terminally truncated Aβ peptides are Aβ38, Aβ40 and 
Aβ42. Aβ38 has been found to be the second prominent soluble Aβ peptide species in CSF after 
Aβ40.3 Aβ42 is decreased in CSF of Alzheimer’s disease (AD) patients compared with control 
subjects.4,5 There is evidence that soluble Aβ peptides are more related to disease severity in AD 
than the insoluble Aβ42 peptide.3,6 Furthermore, the ratio of Aβ42 to Aβ40 is stated to classify 
more AD patients correctly compared with CSF Aβ42 alone.7  
 
With the emerging strategies for disease modification in AD8,9, quantification of other Aβ 
species, in addition to Aβ42, linked to AD pathology may gain importance. To evaluate this, we 
measured CSF concentrations of Aβ38, Aβ40, and Aβ42 by enzyme-linked immunosorbent 
assays in AD and control subjects. The relations between the Aβ species and their correlations to 
clinical variables were also investigated. Finally, the diagnostic accuracy of CSF Aβ42 in AD 
versus controls subjects was compared with that of the ratios of CSF Aβ42 to Aβ40 and CSF 
Aβ42 to Aβ38.  
 
Subjects and methods 
Subjects 
Thirty AD patients and 26 controls were recruited at the Alzheimer Center of the VUMC. All AD 
patients underwent a standardized investigative protocol as described in detail previously .5 
Diagnosis of probable AD was made according to the NINCDS-ADRDA criteria.10  The control 
group consisted of 20 subjects with subjective memory complaints, two subjects with a positive 
family history and four healthy spouses without memory complaints. None of the controls 
experienced development of dementia within a follow-up period of one year. The Mini Mental 
State Examination (MMSE) score11 was used as a measure of global cognitive impairment. 
Disease duration in AD patients was defined as the time in years between the first symptoms and 
the lumbar puncture. The study was approved by the Ethical Review Board of the VU University 
Medical Center. Patients and controls gave written informed consent to participate in the study.   
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CSF analyses 
Antisera to Aβ40 and Aβ42 were produced in rabbits by immunizing Aβ32-40 and Aβ35-42 
peptides.12  Antisera to Aβ38 peptide were produced in rabbits by immunization of peptide 
“hCys-aminohexoanoyl-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-GlyOH” as described previously.12  
The antisera were made specific for Aβ38 by passing through the affinity column, and eluting the 
specific antibody at low pH.  The antibody lacked reactivity against Aβ40 or Aβ42 peptides as 
examined by sandwich enzyme-linked immunosorbent assay and Western blot analysis (data not 
shown). Levels of Aβ38, Aβ40, and Aβ42 were quantified in CSF using a combination of mouse 
monoclonal antibody (6E10), and antibodies specific for Aβ38, Aβ40 and Aβ42 in a double 
antibody sandwich sandwich enzyme-linked immunosorbent assay as described13.  The detection 
limit for the assay was 10 pg/ml for all Aβ peptides.  The mean of the coefficient of variation 
within assay was 5.0% for Aβ38, 4.6% for Aβ40, and 9.3% for Aβ42.  
 
Statistical analysis 
For statistical analysis, SPSS version 11.0 was used. Mann Whitney U or Chi-square tests were 
used to test group and frequency differences. Spearman correlation coefficient was used for 
calculation of correlations. Statistical significance was set at p < 0.05. To determine the relation 
between Aβ38 and Aβ40 the Passing and Bablok regression method14 was used, calculated by 
Medcalc V 4.30 Software (Medcalc Software, Mariakerke, Belgium). Applying a sensitivity of ≥ 
85% or greater5, the corresponding specificities for Aβ42, and Aβ42/Aβ40 and Aβ42/Aβ38 ratios 
were calculated. Receiver operating curves (ROC) curves were drawn by plotting the true-
positive rate (sensitivity) against the false-positive rate (100-specificity). The area under the 
curve (AUC) and the confidence interval of 95% (95%CI) were calculated. To assess the 
statistical difference of the diagnostic performance between Aβ42 and the Aβ42/Aβ40 and 
Aβ42/Aβ38 ratios the Hanley and McNeil method15 was applied. 
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Results 
Subject characteristics and CSF levels of Aβ38, Aβ40, and Aβ42 
AD patients and controls were comparable regarding age and gender (Table). Median disease 
duration in AD was 4 years, ranging from 1 to 11 years. Median MMSE was 21 (range 3-28) in 
AD and 29 (range 25-30) in control subjects. CSF Aβ42 and the ratios of Aβ42 to Aβ40 
(Aβ42/Aβ40) and Aβ42 to Aβ38 (Aβ42/Aβ38) were significantly lower in AD compared with 
control subjects. CSF levels of Aβ38 and Aβ40 in patients with AD and control subjects were 
comparable.  
Table Subject characteristics and CSF levels of Aβ38, Aβ40, and Aβ42 
 AD Controls P-value 
Age 60 (52-79) 65 (45-79) 0.79 
Sex (M/F) 15/15 12/14 0.32 
Aβ38 (ng/mL) 2.7 (1.3-6.4) 3.2 (1.4-5.1) 0.22 
Aβ40 (ng/mL) 16.9 (7.4-42.7) 19.2 (7.6-33.3) 0.90 
Aβ42 (ng/mL) 0.29 (0.12-0.67) 0.63 (0.22-1.07) <0.001 
Aβ42/Aβ40 0.017 (0.006-0.048)   0.034 (0.016-0.069) <0.001 
Aβ42/Aβ38 0.11 (0.04-0.26) 0.24 (0.07-0.37) <0.001 
 
AD = Alzheimer’s disease. Aβ42/Aβ40 = ratio of Aβ42 to Aβ40; Aβ42/Aβ38 = ratio of Aβ42 to Aβ38. Values are 
expressed as medians (minimum-maximum). 
 
Relations of CSF levels of Aβ38, Aβ40, and Aβ42 
In the whole group, a significant correlation could be shown between CSF Aβ38 and Aβ40 
(R=0.89, P<0.001). The relation between Aβ38 and Aβ40 is shown in the Figure. Correlation 
coefficients per diagnostic group of Aβ42 versus Aβ38 are 0.46 for AD (P=0.01) and 0.58 for 
control subjects (P=0.02). For Aβ42 versus Aβ40 we found for AD R=0.43 (P=0.02) and R=0.65 
(P<0.001) for control subjects. In the whole group, positive correlations were found between CSF 
Aβ38 and Aβ40 and age (R=0.30, P=0.023 and R=0.28, P=0.037, respectively). There was no  
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Figure Plot of CSF Aβ38 and Aβ40 in AD and Controls 
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The line represents the regression line Y = 0.66 + 0.115X correlation among CSF levels of Aβ38, Aβ40, Aβ42, and 
age, disease duration or MMSE in either group.    
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correlation among CSF levels of Aβ38, Aβ40, Aβ42, and age, disease duration or MMSE in 
either group. 
 
Diagnostic performance of Aβ42 and the Aβ42/Aβ40 and Aβ42/Aβ38 ratios 
Comparing AD patients with control subjects specificity for CSF Aβ42 was 88% at a sensitivity 
of 87% using a cut off value of 0.37 ng/mL. For the Aβ42/Aβ40 and Aβ42/Aβ38 ratios 
specificities were 81% and 77% at a sensitivity of 87%. Calculation of ratios did not improve the 
diagnostic accuracy of CSF Aβ42 (AUC Aβ42 = 0.91, 95% CI 0.80 - 0.97, AUC Aβ42/Aβ40 
ratio = 0.92, 95% CI 0.81 - 0.97, and AUC Aβ42/Aβ38 ratio = 0.90, 95% CI 0.79-0.96; Aβ42 
versus Aβ42/Aβ40 ratio, P= 0.88, Aβ42 versus Aβ42/Aβ38 ratio, P= 0.80). 
 
Discussion 
Our data showed that CSF concentration of Aβ42 was decreased in AD, whereas CSF Aβ38 and 
Aβ40 levels were similar in patients with AD compared with control subjects. All three Aβ 
peptides were related to each other, with the strongest correlation between CSF Aβ38 and Aβ40. 
Diagnostic accuracy of CSF Aβ42 alone was not different from the Aβ42/Aβ40 and Aβ42/Aβ38 
ratios. 
To our knowledge, no other study has been published, in which Aβ38, Aβ40 and Aβ42 have been 
estimated by a quantitative method in the same CSF samples. By employing SDS-page gel 
electrophoresis3 it was reported that the absolute amount of CSF Aβ42 was decreased in AD, 
while CSF Aβ38 and Aβ40 concentrations were similar between AD and control subjects. When 
the amount of the single Aβ peptide species was calculated relative to total Aβ, an increase of 
CSF Aβ38 and Aβ40 was found. However, it is unclear how the total amount of Aβ was 
measured in this study. Using the surface-enhanced laser desorption/ionization time-of-flight 
(SELDI-TOF) technique 16 they found an increased peak of Aβ38 in pooled CSF from AD 
patients, whereas CSF Aβ40 remained unchanged. The unchanged CSF concentration of Aβ40 is 
consistent with previous studies.4,7,17 The discrepancy of the Aβ38 findings could be attributed to 
the use of different methods. Furthermore, as both Aβ38 and Aβ40 are soluble peptides, they are 
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supposed to be released easily into the CSF, which might result in comparable concentrations in 
AD and controls.  
The correlation between CSF Aβ42 and CSF Aβ38 or Aβ40 was most prominent in control 
subjects. Our findings are in line with the other study3, in which a close correlation was found 
among the quintet Aβ37, Aβ38, Aβ39, Aβ40 and Aβ42 in control subjects. The various C-
terminally truncated Aβ peptides are formed by (alternative) γ-secretase cleavage of APP. Aβ42 
is deposited in the plaques as a result of fibrillation. In all stages of plaque formation Aβ42 is 
abundant, while Aβ40 and to a lesser extent Aβ38 are found in later stages of plaques 
maturation.18,19 In some control subjects, Aβ38, Aβ40 and Aβ42 can be found in the brain, but to 
a much lower extent.19 Analysis of CSF rests upon the assumption that CSF reflects the 
biochemical processes taking place in the brain. The decrease of Aβ42 in CSF thus can be 
explained by deposition of this peptide in the brain of patients with AD. Our findings further 
support this hypothesis, since we found only Aβ42 to be decreased in CSF, which correlated 
poorly to Aβ38 and Aβ40 in AD.   
 
We found no difference in diagnostic accuracy of CSF Aβ42 compared to the Aβ42/Aβ40 and 
Aβ42/Aβ38 ratios for the differentiation of AD from control subjects. The Aβ42/Aβ40 and 
Aβ42/Aβ38 ratios are considered to give information about the disease progression, typically in 
the early stage of disease, as the cerebral deposition of Aβ42 probably starts already before the 
disease becomes clinically overt.20 This is in line with an earlier report showing an increased ratio 
of Aβ40/Aβ42 before the clinical onset of AD.17 CSF Aβ42 alone is considered to be a stage 
marker, reflecting the presence of the disease at a certain stage.20 It would be of interest to 
investigate the ratio of Aβ42 to Aβ40 and Aβ38 in a group of patients with mild cognitive 
impairment, observed longitudinally, to be informed when Aβ42 starts to decrease in CSF as 
compared to Aβ38 and Aβ40, in relation with clinical progression. 
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CHAPTER 5 
 
 
 
CSF Aβ42, TAU AND PHOSPHORYLATED TAU IN ALZHEIMER’S DISEASE 
VERSUS FRONTOTEMPORAL DEMENTIA  
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CHAPTER 5.1  
 
 
 
Amyloid β 42 (1-42) and phosphorylated tau in CSF as markers for early 
onset Alzheimer’s disease 
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Abstract 
Objective:  To determine the diagnostic value of CSF amyloid β 1-42 (Aβ42), CSF total tau and 
CSF tau phosphorylated at threonine 181 (Ptau-181) in early onset AD (EAD) vs frontotemporal 
lobar degeneration (FTLD). 
Methods: Levels of Aβ42, total tau and Ptau-181 in CSF were measured using commercially 
available ELISAs in 47 EAD patients, 28 FTLD patients and 21 non-demented controls. 
Results: CSF Aβ42 was significantly lower, and CSF total tau and CSF Ptau-181 significantly 
higher in EAD patients compared to FTLD patients and controls.  There was an increase in 
diagnostic accuracy for CSF Ptau-181 vs CSF total tau (P=0.067). Combining low CSF Aβ42 and 
high CSF Ptau-181 allowed EAD patients to be separated from FTLD patients with a sensitivity 
of 72% and a specificity of 93%. Logistic regression analysis with CSF Aβ42 and CSF Ptau-181 
as independent continuous variables resulted in correct classification of 46/47 (98%) EAD 
patients and 23/28 (82%) FTLD patients. The diagnostic accuracy for EAD was independent of 
gender, disease duration or disease severity.  
Conclusion: The combination of CSF Αβ42 and CSF Ptau-181 may help differentiating EAD 
from FTLD.  
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Introduction 
In early onset AD (EAD), disorders of language, praxis or executive functions are more common 
than memory problems.1,2 Compared to the other major types of early onset dementia2 EAD is 
most difficult to distinguish from frontotemporal lobar degeneration (FTLD) on clinical and 
radiological grounds, especially in the early phase of disease. The clinical and radiological 
overlap calls for more specific diagnostic tools.  
The combination of decreased CSF levels of amyloid β 1-42 (Aβ42) and increased levels of total 
tau has been found to be a highly sensitive discriminator of AD from normal aging.3,4 In FTLD, 
levels of CSF Aβ42 have been found to be normal or moderately low5, while CSF total tau was 
either normal6 or increased.7-9 The few studies that investigated CSF phosphorylated tau10-12 all 
showed better separation between AD and FTLD compared to total tau. However, in two studies 
patients were not matched for age10,11, corrected for by analysis of variance with age as co-
variate10. A third study included an older AD and FTLD population of comparable age12, but the 
prevalence of AD in late onset dementia is considerably higher than FTLD. When a priori 
chances of dementia syndromes differ according to age, the usefulness of biomarkers to 
distinguish them becomes less relevant. A recent study13 demonstrated that the prevalence of AD 
and FTLD may be comparable in an early onset dementia population. To date, only one study has 
described the value of two biomarkers -neurofilament protein and total tau- for the differential 
diagnosis of EAD and FTLD.14 We investigate the diagnostic value of the currently most specific 
commercially available biomarkers CSF Aβ42, CSF total tau and CSF Ptau-181 in a large group 
of EAD patients, FTLD patients and non-demented age-matched controls.  
 
 
Materials and methods 
Subjects  
Between October 2000 and June 2003 47 EAD patients and 22 FTLD patients (12 with FTD, 
seven SD and three PA) were consecutively investigated at the Alzheimer Center of the VU 
University Medical Center (VUMC), Amsterdam. An additional six FTLD patients were recruited 
from the Erasmus Medical Center, Rotterdam (four FTLD and two SD). In all EAD and FTLD 
patients symptoms started before the age of 65. All patients underwent a standardized 
investigative battery, including medical history, physical and neurological examination, screening 
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laboratory tests, psychometric evaluation, EEG, and brain MRI or CT. In two EAD and five 
FTLD patients with normal or inconclusive findings on structural imaging, Single Photon 
Emission Computed Tomography (SPECT) with 99mTc-hexamethyl propyleneamine oxime was 
performed. Dementia severity was assessed by the clinical dementia rating scale (CDR, all EAD 
and FTLD patients) 15 and Mini Mental State Examination (MMSE) score (all EAD patients and 
controls, 21 out of 28 FTLD patients).16 Disease duration was defined as the time in years 
between the first symptoms (by history) and the first clinical diagnosis. At that time all patients 
underwent a lumbar puncture. The initial diagnoses were made in conference by a team of 
neurologists, neuropsychologists, a neurophysiologist, a psychiatrist and a radiologist. Diagnosis 
of probable AD was made by exclusion according to the NINCDS-ADRDA criteria17; for FTLD 
we used the clinical diagnostic criteria of Neary et al.18  
The team involved in the diagnostic work-up was blinded to the results of the CSF analyses. For 
most of the EAD and FTLD patients, clinical diagnoses were revisited and confirmed after a 
minimum follow up period of six months and used in the analysis as the golden standard. The 
diagnoses of the six FTLD cases from the Erasmus Medical Center were confirmed after a follow 
up period of at least one year. In the 22 FTLD cases from the VUMC diagnoses were revisited 
and confirmed by an independent neurologist. The three EAD patients, from whom CSF was 
collected in June 2003 had been referred for a second opinion, and had been extensively 
evaluated elsewhere. They underwent the same diagnostic procedure as all the other patients. In 
19 EAD patients disease started with memory problems, while in the rest of the patients, aphasia, 
apraxia or executive problems were initial features. Two EAD patients had first-degree family 
members with confirmed AD starting before the age of 65, while the other EAD patients with a 
positive family history for dementia had family members with late-onset type of AD. No further 
genetic analysis took place in these patients. There were two FTLD patients with a positive 
family history for early onset dementia; in one FTLD patient the P301L tau mutation was present. 
The control group consisted of 21 non-demented subjects with a maximum age of 70. The group 
included 13 subjects with subjective memory complaints, who were seen at the Alzheimer Center 
of the VU University Medical Center and had undergone the same examinations as the patients; 
five healthy spouses of patients with no memory complaints; two subjects with a positive family 
history for AD and one patient with intracranial hypertension. None of the control subjects had 
developed dementia after a follow up period of at least 6 months. The study was approved by the 
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ethical review boards of both the VU and Erasmus Medical Centers. All patients and controls 
gave written informed consent to participate in the study.   
 
CSF analysis 
CSF was obtained by lumbar puncture between the L3/L4 or L4/L5 intervertebral space, and 12 
ml was collected in polypropylene tubes. At the same time a serum sample was taken. Within an 
hour, CSF and serum samples were centrifuged at 3000 rpm for 10 minutes at 4°C. A small 
amount of CSF was used for routine analysis, including total cells, total protein, and erythrocytes. 
CSF was aliquoted in polypropylene tubes of 0.5 or 1 ml, and stored at -80°C until analysis. CSF 
Aβ42, CSF total tau and CSF Ptau-181 were measured by commercially available sandwich 
ELISAs (Innotest β-amyloid (1-42) 19, Innotest hTAU-Ag20 and Innotest Phosphotau (181P); 
Innogenetics, Ghent, Belgium).21 All CSF analyses were performed at the department of Clinical 
Chemistry of the VUMC.   
 
Statistical analysis 
For statistical analysis, SPSS version 11.0 was used. In the study population none of the 
variables, except age, were normally distributed. Non-parametric analyses (Kruskall Wallis 
followed by the Mann Whitney U test) were used to compare medians of age, disease duration, 
disease severity (CDR and MMSE), CSF Aβ42, CSF total tau and CSF Ptau-181. Statistical 
significance was set at p<0.05. To calculate correlations between sex, age, disease duration, 
disease severity and CSF Aβ42, CSF total tau and CSF Ptau-181 Spearman correlation 
coefficient was used. Receiver Operating Characteristic (ROC) curves were drawn by plotting the 
true-positive rate (sensitivity) against the false-positive rate (100-specificity). Based on the 
assumption that the clinical criteria for AD provide a sensitivity of approximately 85%22, we 
applied a sensitivity of ≥ 85% for each individual biomarker in accordance with the Reagan 
Consensus report.23 We calculated the corresponding specificities and cut-off values, using EAD 
as positive cases and FTLD or controls as negative cases. The areas under the ROC curves 
(AUC) and standard errors (SE) were calculated by Medcalc V 4.30 Software (Medcalc Software, 
Mariakerke, Belgium). To assess the statistical difference of the discriminating power of CSF 
total tau and CSF Ptau-181 as well as CSF Αβ42 and CSF Ptau-181 from ROC curves the Hanley 
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and McNeil method was applied using the same statistical program.24 To differentiate EAD and 
FTLD a logistic regression analysis with backward stepwise selection method was used as a 
statistical modeling technique to estimate the simultaneous impact of the variables sex, disease 
duration, disease severity (CDR), CSF Aβ42, and CSF Ptau-181. 
 
Results 
EAD patients were well matched for age with FTLD patients (Table 1). Furthermore, age at onset 
of disease was comparable between the two patient groups. In EAD and control subjects women 
were overrepresented, while in FTLD there was a surplus of men. There was a tendency towards 
a longer disease duration in EAD patients compared to FTLD patients. EAD patients were more 
functionally impaired than FTLD patients as measured by the CDR and MMSE.   
CSF Aβ42 was significantly lower, and CSF total tau and Ptau-181 were significantly higher in 
EAD patients than FTLD patients and control subjects. Total tau was increased in FTLD patients 
compared with control subjects (P=0.03), while no difference in CSF Aβ42 and CSF Ptau-181 
could be demonstrated (P=0.2 and P=0.7). There was a trend of increased CSF Ptau-181 in 
patients with the temporal variant of FTLD (P=0.06). 
No significant associations were found between the three biomarkers and gender, disease 
duration or disease severity in EAD, FTLD and controls. In FTLD, a negative correlation 
between CSF Aβ42 and age could be demonstrated (r=-0.39, P=0.04). Furthermore, there was a 
trend towards a positive correlation between age and CSF Ptau-181 in control subjects (r=0.39, 
P=0.08). Positive correlations were found between CSF total tau and CSF Ptau-181 in each group 
(EAD: r=0.95, P<0.001; FTLD: r=0.8, P<0.001; controls: r=0.85, P<0.001) 
Sensitivity and specificity for each biomarker were calculated using ROC analyses. Using a cut 
off value of 413 pg/mL for CSF Aβ42, EAD patients could be separated from FTLD patients 
with a sensitivity of 85% and a specificity of 75%. Sensitivity and specificity values for CSF total 
tau were 85% and 74% at a cut off value of 377 pg/mL. For CSF Ptau-181 sensitivity was 85% 
and specificity 82% at a cut off value of 54 pg /mL. There was a tendency towards a significant 
increase in diagnostic accuracy for CSF Ptau-181 compared with CSF total tau (CSF total tau: 
AUC = 0.813, 95% CI 0.706-0.894; CSF Ptau-181: AUC = 0.866, 95% CI 0.767-0.933 P=0.067). 
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Table 1: Demographic data and CSF analyses per diagnostic category 
 
 
EAD (n=47) 
 
 
FTLD (n=28) 
 
Controls (n=21) 
 
P-value* 
 
P-value** 
 
Age (yrs) 
 
 
59 (52-68) 
 
60 (43-68) 
 
62 (39-70) 
 
0.7 
 
0.9 
 
Sex (F:M) 
 
 
29:18 
 
10 :18 
 
14 :7 
 
0.03 
 
0.7 
 
Disease duration  
 
 
4 (1-11) 
 
3 (1-11) 
 
-- 
 
0.08 
 
-- 
 
CDR 
 
 
1 (1-3) 
 
1 (0.5-2) 
 
-- 
 
0.002 
 
-- 
 
MMSE 
 
 
20 (3-28) 
 
25 (3-29) 
 
29 (27-30) 
 
0.01 
 
< 0.001 
 
Aβ42 (pg/ml) 
 
 
307 (124-525) 
 
603 (245-1072) 
 
604 (337-1224) 
 
< 0.001 
 
< 0.001 
 
Total tau (pg/ml) 
 
 
642 (75-2692) 
 
330 (65-1527) 
 
191 (95-587) 
 
<0.001 
 
<0.001 
 
Ptau-181 (pg/ml) 
 
 
79 (18-279) 
 
41 (18-141) 
 
35 (18-87) 
 
< 0.001 
 
< 0.001 
 
 
EAD = early onset Alzheimer’s disease; FTLD = Frontotemporal Lobar Degeneration; CDR = Clinical Dementia Rating; MMSE = Mini Mental State Examination; M = male, F = female; yrs = years; 
Ptau-181 = tau protein phosphorylated at threonine 181; Aβ42 = amyloid β 1−42. Disease duration is defined as the time in years between the first symptoms (by history) and the first clinical diagnosis. 
Values are expressed as medians (minimum-maximum). P-values refer to statistical difference between EAD vs FTLD (*) and EAD vs controls (**). 
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Figure 1 Plot CSF amyloid β 1-42 and CSF tau phosphorylated at threonine 181 in EAD vs 
FTLD 
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EAD=early onset Alzheimer’s disease, FTLD= frontotemporal lobar degeneration. Ptau-181 = tau phosphorylated at 
threonine 181. Dotted lines represent the cut-off values for EAD vs FTLD  
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Table 2 Cross tabulation of CSF amyloid β 1-42 and CSF tau phosphorylated at threonine 181 in 
EAD, FTLD and controls 
 EAD 
(N=47) 
FTLD 
(N=28) 
Controls  
(N=21) 
Two markers positive  
Aβ42 ≤ 413 pg/mL and Ptau-181 > 54 pg/mL 
34 2 0 
One marker positive: Aβ42 
Aβ42 ≤ 413 pg/mL and Ptau-181 ≤ 54 pg/mL 
6 5 1 
One marker positive: Ptau-181                                 
Ptau-181 > 54 pg/mL and Aβ42 > 413 pg/mL 
6 3 5 
Two markers negative 
Aβ42 > 413 pg/mL and Ptau-181 ≤ 54 pg/mL 
1 18 15 
EAD = early onset Alzheimer’s disease; FTLD = Frontotemporal Lobar Degeneration.  
Ptau-181 = tau protein phosphorylated at threonine 181; Aβ42 = amyloid β 1−42  
 
No difference was present in diagnostic accuracy for CSF Aβ42 and CSF Ptau-181 as 
demonstrated by the AUC values (CSF Aβ42: AUC = 0.860, 95% CI 0.760-0.929; CSF Ptau-
181: AUC = 0.866, 95% CI 0.767-0.933; P=0.92).   
In EAD versus control subjects sensitivity for CSF Aβ42 was 96% at a specificity of 95% using a 
cut off value of 471 pg/mL. Specificity for CSF total tau was 90% at a sensitivity of 85% with a 
cut off value of 369 pg/mL. For CSF Ptau-181 sensitivity was 85% and specificity 76% at a cut 
off value of 54 pg/mL. Diagnostic accuracy of CSF Aβ42 was better than CSF Ptau-181 (CSF 
Aβ42: AUC = 0.981, 95% CI 0.918-0.998; CSF Ptau-181: AUC = 0.879, 95% CI 0.783-0.943; 
P=0.01). No difference was present in diagnostic accuracy of CSF total tau versus CSF Ptau-181 
(P=0.27). 
In Table 2 the number of EAD patients, FTLD patients and control subjects are depicted with at 
least one marker being positive or negative, or with the combination of CSF Aβ42 and CSF Ptau-
181 being positive or negative, using abovementioned cut off values for EAD vs FTLD. These 
findings are visualised in Figure 1. For EAD vs FTLD, sensitivity and specificity for the 
combination of Aβ42 and Ptau in the AD range is 72% and 93%. For EAD vs controls, the 
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combination of Aβ42 and total tau gives a sensitivity of 81% and a specificity of 100% using the 
cut off values for EAD vs controls.  
Positive and negative likelihood ratios (+LR and -LR) for the differentiation between EAD vs 
FTLD are calculated using the data depicted in table 2. The combination of two markers being 
positive compared with at least one marker negative gives a +LR of 10 and a -LR of 0.30. A 
negative value of both biomarkers compared with at least one positive gives a +LR of 2.72 and a 
-LR of 0.03. 
When using parametric statistics (univariate analysis of variance) after log-transformation of the 
variables no influence of the covariates MMSE and disease duration on the primary variables 
Aβ42, total tau and Ptau-181 could be demonstrated. Logistic regression analysis with diagnosis 
(EAD or FTLD) as dependent variable and CDR, CSF Aβ42 and Ptau-181 as independent 
variables resulted in correct classification of 44/47 (94%) EAD patients and 24/28 (86%) FTLD 
patients. Removing CDR from the model correctly classified 46/47 (98%) EAD patients and 
23/28 (82%) FTLD patients. Disease duration or gender did not affect the outcome of the model.  
 
Discussion 
In this study, we found a high diagnostic accuracy for the combination of low CSF Aβ42 and 
high CSF Ptau-181 in differentiating EAD from FTLD.  The diagnostic accuracy for EAD 
achieved by this combination of markers was independent of gender, disease duration and disease 
severity. Furthermore, we confirmed the results of other studies describing an increase in 
diagnostic accuracy for CSF Ptau-181 compared with CSF total tau in differentiating AD from 
FTLD.  
 
Our observation of decreased CSF levels of Aβ42 in EAD patients is consistent with two 
previous studies in which early onset AD and sporadic (or late onset) AD (LAD) were compared. 
6,25 Although levels of CSF Aβ42 in EAD and LAD were comparable in one of these studies 6, 
the significantly lower CSF Αβ42 values in EAD compared with LAD in the second study25 are 
suggestive of pathophysiological heterogeneity. It could be argued that EAD is a more ‘pure’ 
form of AD, in which the formation of neuritic plaques by overproduction of Aβ42 is a relatively 
early and prominent phenomenon, whereas in LAD multiple (vascular) pathogenic factors are 
thought to play a role.26  The heterogeneity of AD could also explain the discordance of CSF 
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markers between different studies27, and support the notion of separating EAD from LAD 
patients in research on diagnostic markers. 
 
Our findings of an increase of CSF Ptau-181 in five of the 28 FTLD patients do not correspond 
with those from two previous studies10,21, in which Ptau-181 was found to be significantly lower 
in FTLD patients compared to AD patients and controls. A possible explanation for this 
discrepancy could be that the authors compared younger FTLD patients (mean age of 65 years) to 
older AD patients (mean age of 74 years) and controls (mean age of 72 years). In our study we 
found a trend towards a positive correlation between age and Ptau-181 in controls, which might 
have been stronger if subjects with a broader age range had been included. An age-related 
increase of CSF total tau in healthy individuals has previously been demonstrated28,29, and may 
reflect age related neuronal or axonal degeneration. Recently, a positive correlation between CSF 
Ptau-231 and age was found in a population of depressed subjects.30  These consistent 
correlations between age and total tau and Ptau stress the importance of comparing only groups 
that are strictly matched for age. 
Another explanation for the discrepant results between our study and the aforementioned 
studies10,21 could be the heterogeneity in underlying pathology of FTLD.31 Although the extent of 
abnormal phosphorylation of tau is supposed to be higher in tau deposits in the brain of AD 
patients compared with FTLD patients, phosphorylation of tau at threonine 181 itself is a normal 
phenomenon32, which could either be decreased10 or increased, as in some of our FTLD patients. 
Two of the FTLD patients had an increase of CSF total tau without an increase of CSF Ptau-181 
resulting in a better diagnostic accuracy of CSF Ptau-181. Overall, the increase of CSF total tau 
in a subset of FTLD patients could be a reflection of tau deposits, which are found in a minority 
of FTLD patients.31 However, the hypothesis of a direct association between tau pathology and 
an increase of CSF total tau remains unproven as demonstrated recently by normal CSF total tau 
levels in FTLD patients with tau mutations that cause intracerebral tau-deposition.33  
It could be argued that our results lack biological validity in the absence of post-mortem 
verification. This applies to many of the studies published in the field of diagnostic markers and 
in our opinion does not invalidate the results. We tried to achieve the highest diagnostic certainty 
by means of the same rigorous diagnostic work up in every patient, use of all available imaging 
information, including a high resolution MRI protocol in all patients, and ensuring clinical follow 
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up of at least 6 months. From class I studies (prospective studies with neuropathological 
confirmation) it is known that the NINCDS-ADRDA for probable AD have a high sensitivity but 
a moderately high specificity.22,34 Although none of the other diagnostic measurements 
(neuropsychological tests, MRI scan) have neuropathological validation, serial tests should 
increase the overall specificity of the diagnosis.34 
 
The difference in diagnostic value of the single biomarkers for EAD and FTLD on the one hand 
and EAD and controls on the other hand is noteworthy. For the differentiation of EAD from 
FTLD, CSF Ptau-181 seems to be a slightly more specific marker than CSF Αβ42; seven out of 
28 FTLD patients had a CSF level of Aβ42 below the cut off value. Although plaques are not a 
common feature in the sporadic form of FTLD, several authors found decreased CSF levels of 
Αβ42 in a subset of FTLD patients5, which may be related to the presence of an Apo E ε4 allel or 
older age35 as in our patients. For the differentiation of EAD from age-matched elderly controls 
CSF Αβ42 alone is found to be the most sensitive and specific marker, followed by CSF total tau, 
whereas CSF Ptau-181 was increased in five out of 21 controls. This increase of CSF Ptau-181 
could be related to aging, but there remains the possibility that these five subjects may develop 
AD in the future, particularly as four of the five had subjective memory complaints. This 
hypothesis is supported by a recent study showing that high CSF levels of Ptau-231 at baseline, 
but not total tau levels, correlated with cognitive decline and conversion from mild cognitive 
impairment (MCI) to AD.36 
 
According to the Reagan Consensus Report23 an ideal biomarker needs to have a specificity of 
75-85% and a sensitivity of ≥ 85% to be clinically useful. To date, no single marker has been 
found to be specific enough to differentiate AD from other dementias, and the use of a 
combination of markers has been advocated to increase specificity.37 Indeed, in our study only 
two FTLD patients (both with PA) had a value of both markers in the AD range (specificity 
93%), an increased specificity of more than 10% compared with the use of CSF Aβ42 or CSF 
Ptau-181 alone. It would be informative to collect further autopsy data from these two PA 
patients. Although the majority of PA cases presented in the literature have non-AD pathology, 
several case reports of patients with non-fluent aphasic syndromes have been described, who 
revealed typical AD pathological features at autopsy.2    
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For the use of the markers to assist with the differential diagnosis of EAD and FTLD in clinical 
practice, a low negative likelihood ratio may be even more important.23 A test to exclude EAD 
will be of great benefit to the patient and would provide the clinician the opportunity to direct the 
diagnostic effort elsewhere. Furthermore, it has been demonstrated by retrospective 
neuropathological studies that the specificity of the NINCDS-ADRDA criteria for the differential 
diagnosis of AD vs FTLD is only 23%.38 A negative laboratory test may be more informative to 
the clinician regarding the neuropathological nature of the underlying type of dementia, when 
clinical and radiological criteria fail to do so. Our findings of a very low -LR (0.03) when both 
markers are negative make this combination of markers quite robust.  
 
 88
 
   
  
References 
1. Greicius MD, Geschwind MD, Miller BL. Presenile dementia syndromes: an update on 
taxonomy and diagnosis. J Neurol Neurosurg Psychiatry 2002;72:691-700. 
2. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of 
Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study 
of 13 cases. Brain 2000;123:484-98. 
3. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using 
beta amyloid 1-42 and tau levels in CSF. Neurology 1999;52:1555-62.  
4. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta 
42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E 
genotype. Arch Neurol 1998;55:937-45. 
5.  Riemenschneider M, Wagenpfeil S, Diehl J, et al. Tau and Abeta42 protein in CSF of 
patients with frontotemporal degeneration. Neurology 2002;58:1622-8. 
6. Sjögren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta amyloid 1-42 
      and GAP-43 in frontotemporal dementia, other types of dementia and normal 
     aging. J Neural Transm 2000;107:563-79. 
7. Green AJE, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal 
fluid of patients with frontotemporal dementia and Alzheimer’s disease. Neurosci Lett 
1999;259:133-5. 
8. Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid tau levels in 
neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res 
Commun 1997;236:262-4.        
9. Fabre SF, Forsell C, Viitanen M, et al. Clinic-based cases with frontotemporal dementia 
show increased cerebrospinal fluid tau and high apolipoprotein E epsilon 4 frequency, but 
no tau gene mutations. Exp Neurol 2001;168:413-8.      
10. Sjögren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are 
increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:624-30. 
11. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau 
protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s 
disease. Ann Neurol 2001;50:150-6. 
 89
 
   
  
12. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer disease 
with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch 
Neurol 2002;59:1267-72. 
13. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal 
dementia. Neurology 2002;58:1615-21. 
14. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton 
proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000;54:1960-
4. 
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. 
Neurology 1993;43:2412-4. 
16. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98. 
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical 
diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the 
auspices of Department of Health and Human Services Task Force on Alzheimer’s 
Disease. Neurology 1984;34:939-44. 
18. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus 
on clinical diagnostic criteria. Neurology 1998;51:1546-54. 
19. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of 
beta amyloid 1-42 in cerebrospinal fluid and plasma. Amyloid 2000;7:245-58. 
20. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal 
and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked 
immunosorbent assay. J Neurochem 1993;61:1828-34. 
21. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau 
phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a 
synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52. 
22. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in 
Alzheimer's disease and related dementias. Arch Neurol1994;51:888-95. 
23. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association. 
Consensus report of the working group on: “Molecular and biochemical markers of 
Alzheimer’s Disease”. Neurobiol Aging 1998;19:109-16. 
 90
 
   
  
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating 
characteristic curves derived from the same cases. Radiology 1983;148:839-43. 
25. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta amyloid (1-42) in 
Alzheimer disease. Differences between early- and late-onset Alzheimer disease and 
stability during the course of disease. Arch Neurol 1999;56:673-80. 
26. Scheltens P, Vermersch P, Leys D. Heterogeneity of Alzheimer's disease. Rev Neurol 
(Paris) 1993;149:14-25. 
27. Sunderland T, Linker G, Mirza N, et al. Decreased β-Amyloid 1-42 and increased tau 
levels in cerebrospinal fluid of patients with Alzheimer’s disease. JAMA 2003;289:2094-
2103. 
28. Sjögren M, Vanderstichele H, Ågren H, et al. Tau and Aβ42 in cerebrospinal fluid from 
healthy adults 21-93 years of age: establishment of reference values. Clin Chem 
2001;47:1776-81. 
29. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Cerebrospinal fluid tau 
levels increase with age in healthy individuals. Dement Geriatr Cogn Disord 
2001;12:127-32. 
30. Buerger K, Zinkowski R, Teipel S, et al. Differentiation of geriatric major depression 
from Alzheimer’s disease with CSF tau protein phosphorylated at threonine 231. Am J 
Psychiatry 2003;160:376-9. 
31. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, 
phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000;33:95-130. 
32. Morishima-Kawashima M, Hasegawa M, Takio K, et al. Hyperphosphorylation of tau in 
PHF. Neurobiol Aging 1995;16:365–71. 
33. Rosso SM, Van Herpen E, Pijnenburg YAL, et al. Total tau and phosphorylated tau 181 
levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L 
and G272V tau mutations. Arch Neurol 2003;60:1209-13. 
34. Qizilbash N, ed. Evidence-based Dementia Practice. Oxford: Blackwell Science Ltd, 
2002. 
35. Mann DM, McDonagh AM, Pickering-Brown SM, Kawaa H, Iwatsubo T. Amyloid beta 
protein deposition in patients with frontotemporal lobar degeneration: relationship to age 
and apolipoprotein E genotype. Neurosci Lett 2001;304:161-4. 
 91
 
   
  
36. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 
231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-9. 
37. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau 
protein as biomarkers for Alzheimer’s disease. Mol Neurobiol 2001;24:87-97.  
38. Varma AR, Snowden JS, Lloyd JJ, et al. Evaluation of the NINCDS-ADRDA criteria in 
the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol 
Neurosurg Psychiatry 1999;66:184-8. 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
We thank Peggy Verelst, Innogenetics NV, Ghent, Belgium, for supplying ELISAs. Silla 
Notten is thanked for technical assistance at the Department of Clinical Chemistry, VUMC. 
Bernard MJ Uitdehaag (MD, PhD) is gratefully acknowledged for his unbiased critique and 
helpful discussion.  
Niki SM Schoonenboom was partly funded through a grant from Alzheimer Nederland, 
Bunnik (V2001-023). Additional funding was received from the Stichting Alzheimer and 
Neuropsychiatry Foundation, Amsterdam.  
 92
 
   
  
 
 93
 
   
  
CHAPTER 5.2  
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Frontotemporal lobar degeneration (FTLD),1 a neurodegenerative disorder presenting with a 
spectrum of behavior changes, executive disturbances, or aphasia, is often unrecognized. Patients 
with FTLD are many times considered to have a psychiatric disorder or Alzheimer disease (AD). 
Imaging studies and psychometric testing can be normal at an early stage.2 CSF biomarkers have 
been considered in the diagnosis of FTLD. One study found that the combination of CSF tau and 
amyloid β (1–42) (Aβ42) provided assistance in the diagnosis of FTLD.4 We investigated CSF 
tau and Aβ42 in FTLD compared with age-matched AD patients and cognitively healthy control 
subjects.  
Methods Thirty-five patients with FTLD (18 frontotemporal dementia, 11 semantic dementia, and 
6 progressive nonfluent aphasia) were compared with 51 patients with probable AD3 and 27 
nondemented control subjects. All patients underwent a standard medical history, physical and 
neurologic examination, screening laboratory tests, psychometric tests, EEG, MRI, or CT.  
99mTc-Hexamethylpropyleneamine oxide SPECT was performed in seven cases with normal or 
inconclusive findings on structural neuroimaging. Only patients whose clinical diagnoses were 
evaluated by a multidisciplinary team and supported by either structural or functional 
neuroimaging were included. All but two of the FTLD cases were sporadic. Genetic screening 
took place in one of the familial cases, yielding a P301L mutation. The clinical diagnosis was 
confirmed pathologically in one case, showing neuronal degeneration without tau pathology. The 
Clinical Dementia Rating Scale (CDR)5 was used to assess dementia severity. 
The control group consisted of 16 subjects with subjective memory complaints, who underwent 
the same examinations as the patients, 5 cognitively healthy subjects with a positive family 
history, as well as 6 healthy spouses of patients with no memory complaints. 
CSF was obtained by lumbar puncture between the L3 to L4 or L4 to L5 intervertebral space after 
informed consent. Within an hour, CSF samples were centrifuged at 3,000 rpm for 10 minutes at 
4 °C followed by storage in polypropylene tubes at _80 °C until analysis. CSF tau and Aβ42 were 
determined by sandwich ELISA (Innotest β-amyloid(1—42) and Innotest hTAU-Ag; 
Innogenetics, Ghent, Belgium). 
Results Clinical, demographic, as well as CSF tau and Aβ42 data are displayed in the table. No 
significant differences in CSF tau between the FTLD subgroups were found. In progressive 
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nonfluent aphasia, Aβ42 was lower than in frontotemporal dementia (p = 0.033) and semantic 
dementia (p = 0.015). 
A cut-off value of 908 pg/mL for CSF tau distinguished FTLD from AD at a sensitivity of 86% 
and a specificity of 26%. To distinguish FTLD from controls, a CSF tau cut-off of 193 pg/mL 
yielded a sensitivity of 86% at a specificity of 41%. For CSF Aβ42, a cut-off value of 315 pg/mL 
distinguished FTLD from AD at a sensitivity of 86% and a specificity of 59%. The number of 
FTLD patients that was correctly classified by a CSF tau range between 193 and 908 pg/mL and 
a CSF Aβ42 value higher than 315 pg/mL was 21 (60%). 
Discussion Even though significant differences were found, there was extensive overlap of CSF 
tau and Aβ42 values between FTLD, AD, and control subjects. In a relatively young population 
where the a priori chance of FTLD is at best 50%,6 the positive predictive value of a CSF tau 
value between 193 and 908 pg/mL combined with a CSF Aβ42 value higher than 315 pg/mL 
would be 51% with a negative predictive value of 52%, which is not above chance level. 
Therefore, we conclude that measurement of tau and Aβ42 in CSF is not useful for the diagnosis 
of FTLD. 
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Table Clinical and demographic data and values of CSF biomarkers 
Data FTLD, N = 35 AD, N = 51 Controls, N = 27 Statistical significance 
Age, y 61 (51–85) 63 (53–78) 66 (39–76) P = 0.50 
Sex, M:F 
 
23:12 22:29 11:16 P < 0.001 
CDR 
 
1 (0.5–2) 1 (1–3) — P = 0.009 
 
Disease duration, y 3 (1–11) 4 (1–11) — P = 0.014 
 
CSF tau, pg/mL 
 
 
353 (49–1,740) 
 
632 (195–1,822) 
 
298 (95–993) 
 
FTLD vs AD, P = 0.002 
FTLD vs controls, P = 0.03 
CSF Aβ42, pg/mL 
 
 
565 (178–1,225) 298 (124–592) 634 (232–1,243) FTLD vs AD, P <  0.001 
FTLD vs controls, P = 0.13 
 
Values are medians (range). For statistical analysis, nonparametric tests were used (Kruskal–Wallis, Mann–
Whitney); differences in male/female distribution were analyzed using the χ2 test. FTLD = frontotemporal lobar 
degeneration; AD = Alzheimer disease; CDR = Clinical Dementia Rating Scale; Aβ42  = amyloid β (1–42), y = 
years 
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Abstract 
The aim of the study was to compare clinical variables between MCI patients at different risk for 
Alzheimer’s disease (AD) according to their biomarker profile. Fifty-four % out of 39 MCI 
patients had a low Aβ42 and high tau in cerebrospinal fluid (CSF) (high-risk), 26% either a low 
CSF Aβ42 or high CSF tau (intermediate-risk) and 20% a normal CSF Aβ42 and tau (low-risk). 
Both high- and intermediate-risk subjects differed from the low-risk group in episodic memory, 
executive functions and the preclinical AD scale (PAS), which combines a set of clinical 
parameters. Subjects at high-risk did not differ from subjects with an intermediate-risk. Aβ42 
levels correlated with the MTA and PAS scores, tau levels with episodic memory. These 
correlations suggest that the biomarkers are not independent when compared to the other AD 
markers. Longitudinal studies are necessary to interpret the correlations between biomarkers, 
imaging, and neuropsychological markers. 
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Introduction 
Mild cognitive impairment (MCI) is considered to be a transitional state between normal aging 
and dementia16 and 10-15% of the patients with MCI progress to Alzheimer type dementia (AD) 
each year. 17 Several studies have shown that a subgroup of MCI patients has low cerebrospinal 
fluid (CSF) amyloid β 1-42 (Aβ42) and high total tau (tau) levels that are considered indicative 
for AD. However, most of these studies have been performed in specific research settings.1,2,20 
Little is known about how frequently such a typical AD biomarker profile is seen in MCI patients 
selected from a setting that reflects daily clinical practice.32  
No cross-sectional studies investigated to what extent MCI patients with an AD biomarker profile 
differ from MCI patients with a normal biomarker profile with respect to other clinical markers or 
risk factors of AD. This is important to know for two reasons. First, investigating the relation 
between biomarkers and other markers of AD will show whether these markers are independent 
predictors for AD at baseline. Second, it will yield information regarding the pathophysiology of 
AD in the early stage. 
The aim of the present study is threefold. First, we investigate how many subjects with amnestic 
MCI from our Memory Clinic display high-risk (low CSF Aβ42 and high CSF tau), intermediate 
risk (low CSF Aβ42 and normal CSF tau or normal CSF Aβ42 and high CSF tau), and low-risk 
(normal CSF Aβ42 and normal CSF tau) biomarker profiles. Secondly, we compare age, disease 
duration, MMSE, Apo E genotype, neuropsychological test performance, and medial temporal 
lobe atrophy (MTA) score among these groups. In addition, we compare the score on the 
preclinical Alzheimer’s disease Scale (PAS)29 between the groups with different biomarker risk 
profiles. The PAS is a scale that applies a set of clinical parameters to estimate the risk for AD in 
MCI patients. Finally, we investigate the correlation between the two biomarkers and the other 
risk factors for AD. 
 
Patients and methods 
Patients 
Thirty-nine patients younger than 85 years with amnestic MCI were consecutively recruited at the 
Alzheimer Center of the VU University Medical Centre (VUMC), Amsterdam, between January 
2001 and November 2003. Patients were referred to our memory clinic by general practitioners 
(N=30) or by other neurologists/specialists as second opinions (N=9). Diagnosis of amnestic MCI 
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was made according to the criteria of Petersen et al.17, indicating that a patient had subjective and 
objective memory impairment with no interference with daily activities, and no dysfunction in 
other cognitive domains. The patients underwent a standardized clinical assessment, including 
medical history, physical and neurological examination, laboratory tests, psychometric 
evaluation, EEG, and brain MRI or CT. The initial diagnoses were made in conference by a team 
of neurologists, neuropsychologists, a neurophysiologist, a psychiatrist, and a radiologist. The 
team involved in the diagnostic work-up was blinded to the results of the CSF analyses. The Mini 
Mental State Examination (MMSE) score7 was used as a measure of global cognitive impairment. 
Disease duration was defined as the time in years between the first symptoms (by history) and the 
lumbar puncture (LP) for CSF sampling. Median time between first assessment and LP was 2 
months (range 0-23). All patients met criteria for amnestic MCI at the time of the LP. The ethical 
review board of the VUMC approved the study and all subjects gave written informed consent. 
 
CSF analysis 
CSF was obtained by lumbar puncture (LP) between the L3/L4 or L4/L5 intervertebral space and 
collected in polypropylene tubes. Within an hour, CSF samples were centrifuged at 3000 rpm for 
10 minutes at 4°C. A small amount of CSF was used for routine analysis, including total cells, 
total protein, and erythrocytes. CSF was aliquoted in polypropylene tubes of 0.5 or 1 ml, and 
stored at -80°C until analysis. CSF Aβ42 and tau were measured by commercially available 
sandwich ELISAs (Innotest β-amyloid (1-42)27 and Innotest hTAU-Ag26, Innogenetics, Ghent, 
Belgium). All CSF analyses were performed at the department of Clinical Chemistry of the 
VUMC.  
 
Calculation of the cut off values 
The optimal cut-off values for CSF Aβ42 and tau were set at data obtained from 92 probable AD 
patients15 and 38 controls also recruited at the Alzheimer Centre, VUMC. After drawing Receiver 
Operating Characteristics (ROC) curves, we applied a sensitivity of ≥ 85% for each individual 
biomarker in accordance with the Ronald and Nancy Reagan Consensus report.25 The 
corresponding specificities and cut-off values were calculated. Sensitivity and specificity values 
for CSF Aβ42 were 86% and 89% using a cut off level of ≤ 494 pg/mL. For CSF tau sensitivity 
and specificity were 89% and 74% at a cut off level of  > 356 pg/mL. 
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Apo E genotype  
DNA was isolated from 10 ml EDTA blood and was available from 36 out of 39 patients. ApoE 
genotype was determined with the Light Cycler ApoE mutation detection method (Roche 
diagnostics GmbH, Mannheim, Germany). Patients were dichotomized on the basis of no or ≥ 1 
ε4 allele. 
 
MRI analysis 
MRI scans were made on a 1.0 (N=30) or 1.5 (N=4) Tesla scanner (Siemens), in coronal (mp-
rage, slice thickness 1.5 mm) and axial direction (FLAIR, slice thickness 5 mm). In 3 MCI 
patients no MRI was made because of claustrophobia (N=1) or the presence of a pacemaker 
(N=2). Two other patients were also excluded from MRI analysis, one patient because the time 
between LP and MRI scan was > 12 months and in another patient because no coronal scan was 
available. Median time between LP and MRI scan was 2 months (range 0-10). The MTA score 
was rated visually according to the method of Scheltens et al.30 The MTA score is based on a 
visual estimation of the volume of the medial temporal lobe, including the hippocampus proper, 
dentate gyrus, subiculum, and parahippocampal gyrus, and the volume of the surrounding CSF 
spaces, in particular the temporal horn of the lateral ventricle and the choroid fissure, on both 
sides. The MTA score ranges from 0 (no atrophy) to 4 (severe atrophy). MTA scores of the right 
and left hippocampi were added up in each patient. Furthermore, the scores were dichotomised 
into a normal value, with a grade 0 or 1 in each hippocampus, or an abnormal value with at least 
grade 2 in one hippocampus. The MTA score was estimated as part of routine patient care by two 
trained raters, who were blinded to the clinical information.  
 
Neuropsychological measurements 
From the neuropsychological evaluation we used the data of the visual association test (VAT)13 as 
a measure of episodic memory. The VAT was administered in 33 out of 39 patients. The material 
of the VAT consists of six association cards showing two interacting objects and six cue cards 
showing only one of the objects. Recall is tested without delay. The maximum score of the VAT 
is 6 points. An impaired score on the VAT was defined as a score < 5. The VAT was 
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dichotomised into a normal score (VAT ≥ 5) and an abnormal score (VAT < 5). The verbal 
fluency (the ability to name as many animals as possible within 1 minute) was measured in 37 
patients and used as a measure of language function. Furthermore, Trailmaking test A (TMT A, 
32 patients) and Trailmaking test B (TMT B, 29 patients) were used as measures of executive 
function. Fluency, TMT A, and TMT B were corrected for age, sex, and education and expressed 
as z-scores on the basis of a reference population of cognitively normal subjects (Visser et al., 
2000). Impairment on the fluency, TMT A, and TMT B was defined as a z-score below -1.28 
(corresponding with a score below the 10th percentile). The sign of the z-scores of the TMT A 
and B was inverted such that a negative z-score indicated below average performance. Median 
time between LP and neuropsychological evaluation was 1.5 months (range 0-10).  
 
PAS scoring  
The PAS consists of six markers of AD: age, MMSE score, functional impairment, cognitive test 
performance, MTA score and Apo E genotype. Increasing PAS scores indicate a higher risk for 
AD. The PAS item ‘functional impairment’ was scored with the Global Deterioration Scale 
(GDS) (Reisberg et al., 1982). The PAS item ‘cognitive test performance’ was obtained with the 
VAT, fluency, and TMT B measures using the cut-off scores described above. Medial temporal 
lobe (MTL) atrophy was rated using the MTA scale as described above. Complete PAS scores 
were available for 26 subjects. The PAS and scoring instructions can also be found at www-
np.unimaas.nl/scales/pas/.29 
 
Statistical analysis 
For statistical analysis, SPSS version 11.0 was used. On the basis of abovementioned cut off 
values for CSF Aβ42 and tau, MCI patients were divided into three groups at different risk for 
AD: a high-risk biomarker profile (low CSF Aβ42 and high CSF tau), an intermediate risk 
biomarker profile (low CSF Aβ42 and normal CSF tau or normal CSF Aβ42 and high CSF tau), 
and a low-risk biomarker profile (normal CSF Aβ42 and CSF tau). Mann Whitney U test 
(continuous variables) or Chi-square test with continuity correction (dichotomous variables) was 
used to test group differences. Correlations between the biomarkers CSF Aβ42 and tau versus 
gender, age, disease duration, MMSE, VAT, TMT A, TMT B, Fluency, MTA and PAS were 
calculated using the Spearman correlation coefficient. Statistical significance was set at p < 0.05. 
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Results 
Twenty-one (54%) of the 39 MCI subjects had a high-risk biomarker profile, 10 subjects (26%) 
had an intermediate risk biomarker profile (low Aβ42 (n=4) or high tau (n=6)), and 8 (20%) had 
a low-risk biomarker profile (Table 1, Figure 1). Median values of Aβ42 and tau in the high-risk 
biomarker group were comparable with the values from AD patients (data not shown). Compared 
to subjects with a low-risk biomarker profile, patients with a high-risk biomarker profile had 
more impaired TMT A and higher PAS scores (Table 1). Furthermore, they tended to have more 
impaired VAT and higher MTA scores. The intermediate biomarker profile group had higher 
PAS scores and lower MMSE and more impaired VAT scores, and a tendency towards higher tau 
levels and more impaired TMT A scores compared to the low-risk biomarker profile group 
(Table 1). No differences in neuropsychological and imaging markers existed between the high-
risk and the intermediate risk biomarker profile group (Table 1). Furthermore, there were no 
differences in age, sex, disease duration, MMSE, and Apo E genotype between the three groups. 
In the whole MCI sample, Aβ42 levels correlated with tau levels, with MTA score, and with the 
PAS score. Tau levels correlated with the score on the VAT (Table 2). There were no correlations 
between the levels of Aβ42 and tau with disease duration or MMSE. Furthermore, there was no 
correlation between VAT and MTA score (R = -0.19, P=0.33). 
 
Discussion 
About half of the MCI patients included in this cross-sectional study had a high risk of 
developing AD according to their biomarker profile at baseline. Twenty-six percent had either a  
low CSF Aβ42 and normal CSF tau level or a normal CSF Aβ42 and a high CSF tau level, while 
20% had both normal CSF Aβ42 and tau levels. Subjects with a high-risk biomarker profile did 
not differ from subjects with an intermediate risk biomarker profile with respect to other markers 
of AD, while both high-risk and intermediate risk subjects differed significantly from the low-
risk group in neuropsychological markers and PAS scores.                                                                                  
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Table 1 Patient characteristics and clinical variables 
 
  High risk  
(N=21) 
(Group 1) 
 
Intermediate risk  
(N=10) 
(Group 2) 
Low Risk  
(N=8) 
 (Group 3) 
P-value 
Group 1 vs 
Group 2 
 P-value 
Group 1 vs 
Group 3 
P-value 
Group 2 vs 
Group 3 
 
Age 
 
  
70 (53-81) 
 
69 (58-80) 
 
75 (56-78) 
 
0.61 
  
0.49 
 
0.42 
Sex (F/M)  11/10 6/4 2/6 0.99  0.31 0.31 
 
Duration of 
cognitive 
complaints 
(yrs) 
  
 3 (0-11) 
 
3 (1-10) 
 
 2 (1-6) 
 
0.64 
  
0.37 
 
0.22 
 
MMSE 
 
  
26 (23-30) 
 
26 (24-28) 
 
28 (23-29) 
 
0.17 
  
0.32 
 
0.04 
Aβ42 
(pg/mL) 
 395 (142-479) 527 (241-1223) 767 (504-916) 0.03  <0.001 0.37 
 
Tau   
(pg/mL) 
  
707 (379-1108) 
 
410 (260-1545) 
 
262 (145-355) 
 
0.006 
  
<0.001 
 
0.07 
 
≥ 1 ε4 allele 
(%) 
  
78 
 
40 
 
43 
 
 
 
0.11 
  
0.23 
 
0.99 
 
 
MTA R+L 
MTA score 
abnormal (%) 
 3.5 (2-5) 
61 
3 (0-6) 
56 
2 (0-4) 
29 
0.48 
0.99 
 0.09 
0.31 
0.42 
0.57 
         
VAT  
< 5 (%) 
 2.5 (0-6) 
82 
1 (0-4) 
100* 
5 (1-6) 
38 
 
0.17  0.06 
0.08 
0.01 
0.04 
Fluency 
z < -1.28 (%) 
 
 
TMT A 
z < -1.28 (%) 
 
 
TMT B 
z < -1.28 (%) 
 
 
PAS 
 15 (11-33) 
42 
 
 
52 (34-97) 
39 
 
 
156 (70-486) 
88 
 
 
8.1 (3-11) 
18 (11-23) 
22 
 
 
64 (34-82) 
50 
 
 
150 (75-300) 
67 
 
 
8.2 (7-11) 
 
17 (10-24) 
25 
 
 
37 (27-55) 
14 
 
 
108 (65-249) 
57 
 
 
5.8 (4-7) 
0.68 
0.55 
 
 
0.86 
0.99 
 
 
0.66 
0.57 
 
 
0.74 
 0.87 
0.61 
 
 
0.04 
0.43 
 
 
0.14 
0.28 
 
 
0.02 
0.69 
0.99 
 
 
0.08 
0.43 
 
 
0.32 
0.99 
 
 
0.02 
 
MTA R+L = medial temporal lobe atrophy right and left, VAT = visual association test, TMT A = trail making test A, TMT B = trail making test 
B, PAS = Preclinical Alzheimer’s disease Scale. Groups 1, 2 and 3 are defined on the basis of the optimal cut off values for Aβ42 and tau 
comparing AD vs controls. Group 1: Aβ42 ≤ 494 and tau > 356; Group 2: Aβ42 ≤ 494 or tau > 356; Group 3: Aβ42>494 and tau ≤ 356. Disease 
duration is defined as the time in years between the first symptoms (by history) and the lumbar puncture. Values are expressed as medians 
(minimum-maximum) or percentages when dichotomised. MTA score was abnormal when at least one hippocampus had a score of ≥ 2. *: VAT 
was available in only 7 out of 10 patients, all with a value of < 5. Impairment on the fluency, TMT A, and TMT B was defined as a z-score below 
-1.28. 
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Furthermore, low CSF Aβ42 levels were associated with high MTA and high PAS scores, while 
high CSF tau levels were associated with low memory scores. 
 
The high percentage of subjects with a high-risk biomarker profile is consistent with the high 
conversion percentage to AD in subjects with amnestic MCI.12,17 The increased risk for AD in 
this group is further corroborated by the high frequency of other markers of AD such as the 
ApoE-ε4 allele, memory impairment, and MTL atrophy. The findings in the group of patients 
with an intermediate risk biomarker profile are intriguing. Since there were no differences in 
clinical characteristics between the high-risk versus the intermediate risk group it seems likely 
that these subjects also have an increased risk for AD, even though one of the biomarkers was 
still in the normal range. Which biomarker is changed first in the disease process is not clear yet, 
as contradictory findings were reported by various studies describing either an increased CSF 
tau6,14,32 or decreased CSF Aβ4223 at baseline.  
Another possible explanation for the intermediate risk could be that some of the patients will 
develop another type of dementia, for example frontotemporal lobar degeneration, in which a 
high CSF tau or a low CSF Aβ42 can be found. 21 Adding phosphorylated tau to the panel of 
biomarkers might help in differentiating MCI patients at risk for AD or other types of dementia. 5 
 
About 20% of the patients had a low-risk biomarker profile. These subjects also had less often 
other AD markers compared to patients with a high or intermediate-risk biomarker profile. This 
underlines the fact that these subjects indeed might have a low risk for the development of future 
AD. Furthermore, the percentage of 20% fits well with the results of a long-term study showing 
that about 20% of the MCI subjects do not progress to AD21, but clearly, longitudinal studies are 
necessary to determine whether these subjects will remain non-demented. The PAS score was the 
variable that was found to differentiate best between high/intermediate and low-risk biomarker 
profile groups. Since MCI is a heterogeneous disorder it is not surprising that the PAS, which 
combines a number of tests, differentiates better between MCI subjects at different risk for AD 
according to their biomarker profile than a single test.  
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Figure 1 Plot Aβ42 and tau 
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The dotted lines represent optimal cut off values obtained by comparing AD patients (N=92) with controls (N=38) 
(cut off value for Aβ42 ≤ 494 pg/mL; cut off value for tau > 356 pg/mL). Squares indicate MCI patients.  
 
 
Table 2 Correlations between biomarkers, VAT, MTA and PAS score  
 
 
 Aβ42 
 
Tau 
VAT 
 
PAS 
 
MTA 
 
0.26 
 
-0.43* 
 
-0.39* 
-0.44**
 
0.28 
 
-0.03 
Tau -0.34* -- 
 
 
MTA = atrophy score of medial temporal lobe; VAT = visual association test; PAS = Preclinical Alzheimer’s disease 
Scale. *P < 0.05, **P < 0.01. 
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The increase of CSF tau is supposed to be the result of release from dying neurons containing a 
large number of neurofibrillary tangles (NFT), an important hallmark of AD. Our finding of a 
correlation between CSF tau and episodic memory impairment, as measured by the VAT, is 
consistent with clinicopathological studies 8,10 , in which a strong correlation between memory 
impairment with NFT densities and neuron numbers in the entorhinal cortex and hippocampus 
was found. As CSF tau is associated with neuronal loss one would also expect an association 
with the MTA score, but we did not find such a correlation. This finding is consistent with 
another study showing no association between CSF tau levels and global brain atrophy at 
baseline.31 It is possible that the increase of CSF tau in our MCI population could be the result of 
neuronal loss in the entorhinal cortex or hippocampus at the very early stage of the disease, which 
may precede MTL atrophy as rated visually on MRI. A future study comparing CSF tau with the 
size of the hippocampus or entorhinal cortex as measured by volumetry could provide additional 
information about the cross-sectional relation between CSF tau and imaging markers of AD. It is 
also possible that tau is more a ‘state marker’, reflecting the intensity of the neuronal damage and 
degeneration .4 Evidence for this explanation comes from a recent study showing an association 
between higher CSF tau levels at baseline and more rapid progression of atrophy after 1-year 
follow-up. 31 
Aβ42 is thought to be decreased in CSF as a result of deposition in senile plaques. In various 
studies, only a weak or no correlation between amyloid burden in the brain and cognitive status 
was found. 3,8 The absence of an association between decreased CSF Aβ42 and 
neuropsychological measurements in the present study is in line with this. The observation that 
lower CSF Aβ42 levels were associated with more atrophy in the medial temporal lobe is 
consistent with two other studies22,31, showing a correlation between decreased CSF Aβ42 and 
atrophy of the whole brain, ventricles or temporal lobe in patients with MCI and AD. CSF Aβ42 
may thus be considered as a ‘stage marker 4,31, indicating the presence and severity of the disease 
at a certain stage and reflecting the total brain damage that has occurred since the onset of the 
disease. The correlation between CSF Aβ42 and the PAS score at baseline in MCI could be a 
reflection of both markers being independent predictors of AD, which was confirmed for Aβ42 in 
a recent study. 11 
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A limitation of our study was the small cohort we included with the risk of selection bias and 
insufficient power to draw firm conclusions. Between January 2001 and November 2003 we 
collected CSF from approximately one third of all amnestic MCI patients seen at the Alzheimer 
Center, VUMC. The patients who underwent a LP were significantly younger compared to the 
patients without a LP, which can be explained by the inclusion criteria since we included only 
patients younger than 85 years. Cognition as measured by the MMSE was similar between the 
two groups. In addition, the degree of memory impairment and hippocampal atrophy, as well as 
the presence of ≥ 1 ε4 allele comparing the high-risk to the low-risk biomarker profile group 
correspond very well with those found in a recent population study when comparing MCI 
patients with controls and AD patients. 9  This makes us confident that no selection bias has 
occurred and that our cohort is representative of a ‘normal’ MCI group.  
The relative high percentage of one or more ε4 alleles in the three groups –even in the low-risk 
group- may be explained by the fact that all MCI patients could have an increased risk of AD, as 
was supported by the study of Smith et al.24, who also found a prevalence of 40% of the ε4 allele 
in their MCI cohort. Both Apo E genotype and memory impairment are indicator markers for AD 
in MCI. 
 
Our study underscores the recognition that MCI is a heterogeneous group of patients containing 
various biomarker profiles. MCI patients with a high- and intermediate-risk biomarker profile for 
AD also differed in other indicator markers from patients with a low-risk biomarker profile, 
adding to the biological validity of these markers. In addition, the relation between the 
biomarkers and other AD markers suggests that the markers are not independent at baseline. 
Longitudinal studies are necessary to interpret the correlations between biomarkers, imaging, and 
neuropsychological markers as well as their contribution to the diagnosis or as predictor of the 
severity of developing AD in the pre-dementia stage.   
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Abstract 
Background: Decreased amyloid β (1-42) (Aβ42) and increased (phosphorylated) tau in 
cerebrospinal fluid (CSF) are considered to be a reflection of plaques, tangles, and neuronal 
degeneration in Alzheimer’s disease (AD). Atrophy of the medial temporal lobe (MTA) on 
magnetic resonance imaging (MRI) reflects neuronal loss in this area. 
Objective: To compare diagnostic accuracy of CSF biomarkers and MTA in AD versus controls. 
Methods: Aβ42, tau and tau phosphorylated at threonine 181 (Ptau-181) were measured in CSF 
from 61 AD patients and 32 controls by sandwich enzyme-linked immunosorbent assay. A CSF 
biomarker profile for AD was constructed. MTA was rated visually on MRI.  
Results: When AD patients and controls were evaluated separately, no correlations were present 
between the CSF markers and MTA score. Both MTA and CSF biomarker profile were 
independently associated with the diagnosis AD (MTA: OR (95% CI) = 28 (3 – 239); CSF 
biomarker profile: OR (95% CI) = 57 (13 – 262)). Among individuals younger than 65 years old 
and without MTA 60% suffered AD, and the finding of an abnormal CSF biomarker profile was 
limited to AD patients only.  
Conclusions: MTA and CSF biomarkers seem to be of incremental value for the diagnosis AD. 
CSF analysis is most sensitive in the absence of MTA, and especially among early-onset AD 
patients.  
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Introduction 
Decreased cerebrospinal fluid (CSF) amyloid β (1-42) (Aβ42) in Alzheimer’s disease (AD) is 
associated with intracerebral deposition of neuritic plaques, mainly composed of Aβ42 [2,31]. 
Increased CSF tau protein (tau) is considered to be a reflection of neuronal degeneration, caused 
by intraneuronal accumulation of neurofibrillary tangles containing (phosphorylated) tau. 2,6,7 
Especially CSF phosphorylated tau (Ptau) is increased in AD compared to other types of 
dementia. 2,27 Although the combination of CSF Aβ42, tau and Ptau provides reasonable accuracy 
in the differentiation of AD from controls CSF concentrations of these biomarkers do overlap 
between groups. 16,27 
Atrophy of the medial temporal lobe (MTA) on magnetic resonance imaging (MRI) has been 
found to be an early and sensitive marker for AD37 and is assumed to reflect underlying neuronal 
loss of the hippocampus and the temporal lobe. However, MTA may also be present in other 
types of dementia and absence of MTA does not exclude the diagnosis AD, especially in the early 
stages. 37 The latter particularly applies to early-onset AD (EAD), where MTA is often not 
prominently present. 13,20 
 
Relatively little is known about the association between MTA and CSF markers, while both are 
presumed to reflect Alzheimer pathology. From post mortem work it is known that hippocampal 
volume is a good indicator of the amount of plaques and tangles deposition 8,14,30, which led us to 
suspect an association with CSF Aβ42 and (P)tau. An association between MTA and (P)tau 
would provide further evidence for the notion that both are measures of neuronal degradation or 
neuronal loss. 3,9,18 In addition, while MTA has become a widely used marker in AD diagnosis, 
CSF markers still have to be established as such. The aim of this study was twofold: first, to 
study the association between CSF markers and MTA, to provide insight whether both types of 
markers reflect the same neuropathological substrate. The second aim was to investigate whether 
both disease markers are independent predictors for the diagnosis AD.  Therefore, we studied the 
relations between CSF Aβ42, tau, and Ptau with MTA in AD and controls. Furthermore, 
diagnostic accuracy of MTA and the combination of CSF Aβ42, tau and Ptau was compared in 
AD versus controls.  
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Methods 
Participants 
Sixty-one AD patients and 32 controls younger than 85 years old were recruited consecutively at 
the memory clinic of the Alzheimer Center VU University Medical Center, Amsterdam. All 
patients underwent a standardized diagnostic work-up, including medical history, informant 
interview, physical and neurological examination, screening laboratory tests, EEG, and Magnetic 
Resonance Imaging (MRI). The majority of patients underwent neuropsychological testing. 
Diagnoses were made in conference by a team of neurologists, neuropsychologists, a 
neurophysiologist, a psychiatrist and a radiologist. Diagnosis of probable AD was made 
according to the NINCDS-ADRDA criteria. 23 Although brain MRI contributed to the diagnostic 
process, it should be noted that MTA scores were not used. All clinicians participating in the 
diagnostic conference meeting were blinded to CSF results. Clinical diagnoses were revisited and 
confirmed after a minimum follow up period of 1 year and used in the analysis as gold standard. 
Disease duration was defined as the time in years since the first symptoms by history. The Mini-
Mental State Examination (MMSE) was used as a measure of global cognitive function. 11 In 
addition, memory function was assessed using the visual association test. 22 
The control group of 32 subjects included 25 subjects with subjective memory complaints and 
three subjects with a positive family history for AD. These subjects presented at our memory 
clinic and underwent exactly the same diagnostic work-up as the AD patients. Patients were 
considered to have subjective memory complaints if all clinical investigations were normal. 
Additionally, four healthy spouses of patients without memory complaints were included. None 
of the controls had developed dementia after a follow up period of 1 year. The study was 
approved by the ethical review board of the VUMC. All subjects gave written informed consent 
to participate in the study.  
 
Apo E genotype 
DNA was isolated from 10 ml EDTA blood and was available from 57 AD patients, and 31 
controls. Apolipoprotein E (Apo E) genotype was determined with the light cycler Apo E 
mutation detection method (Roche diagnostics GmbH, Mannheim, Germany). Patients were 
divided into two groups according to the absence or presence of ≥ 1 ApoE ε4 alleles. 
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CSF analysis 
CSF was obtained by lumbar puncture (LP) between the L3/L4 or L4/L5 inter-vertebral space, 
and collected in 12 mL polypropylene tubes. After centrifugation at 3000 rpm for 10 minutes at 
4°C, CSF was aliquoted in polypropylene tubes of 0.5 or 1 mL, and stored at -80°C until analysis. 
CSF Aβ42, tau and tau phosphorylated at threonine-181 (Ptau-181) were measured by 
commercially available sandwich ELISAs (INNOTESTTM β-amyloid [1-42], INNOTESTTM, 
hTAU-Ag and INNOTESTTM Phosphotau (181P)). 33-35 The optimal cut off values for CSF Aβ42 
were set at data obtained in earlier studies, in which we applied a sensitivity of ≥ 85% for each 
individual biomarker in accordance with the Ronald and Nancy Reagan Consensus report after 
drawing Receiver Operating Characteristics curves. 7,27,28 The following cut off values were used: 
CSF Aβ42 < 495 pg/mL, CSF tau > 356 pg/mL and Ptau-181 > 54 pg/mL. 27,28 Based on the three 
markers, a CSF biomarker profile was constructed. The CSF profile was defined as abnormal 
when in addition to abnormal CSF Aβ42, also tau and/or Ptau were abnormal. The CSF 
biomarker profile was normal when CSF Aβ42, CSF tau and Ptau-181 were all in the normal 
range.  
 
MRI analysis 
MRI scans were made on a 1.0 (N = 44 AD and 26 controls) or 1.5 (N = 17 AD and 6 controls) 
Tesla scanner (Siemens), and included a coronal T1-weighted 3D inversion-prepared gradient 
echo-sequence (168 slices, FOV 250mm, matrix 256x256; slice thickness 1.5 mm, in-plane 
resolution 1 mm). Mean (SD) time between LP and MRI scan was 2 (2.8) months in both AD and 
controls. The MTA score was rated visually according to the method described earlier. 37 The 
MTA score is based on a visual estimation of the volume of the medial temporal lobe, including 
the hippocampus proper, dentate gyrus, subiculum, and parahippocampal gyrus, and the volume 
of the surrounding CSF spaces, in particular the temporal horn of the lateral ventricle and the 
choroid fissure, on both sides. The MTA score ranges from 0 (no atrophy) to 4 (severe atrophy). 
MTA scores of the left and right hippocampus were averaged. 21 MTA scores were dichotomized, 
and an average MTA ≥ 1.5 was considered abnormal (requiring a score of 2 at least on one side). 
One rater (FB), who was blinded to the clinical information, performed the MTA ratings, with 
good intra-rater agreement for the MTA score. 36 
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Statistical analysis 
SPSS version 11.0 was used. Mann Whitney U test was used to compare medians of clinical, 
CSF and MRI variables between AD and controls. Chi-square test was used to compare 
frequencies between groups. To determine associations between CSF biomarkers and MTA 
Spearman correlation coefficient was used. To estimate the impact of the different variables on 
diagnosis, logistic regression analysis was used, with diagnosis as dependent factor, CSF 
biomarker profile and MTA as independent factors, and age and gender as covariates. Apo E 
genotype was additionally corrected for in a separate model. Odds ratios (OR) with 
accompanying 95% confidence intervals (CI) are presented. Statistical significance was set at p < 
0.05.  
 
Results 
AD patients and controls were well matched for age and gender (Table 1). There were no 
differences between groups in the prevalence of history of hypertension, diabetes mellitus, or 
myocardial infarction (p > 0.10). Median disease duration in AD was 4 years (range 0.5-11 
years), median MMSE was 20 (9-28) in AD and 29 (25-30) in controls (p<0.001). CSF Aβ42 
levels were decreased and CSF tau and Ptau-181 levels were increased in AD patients compared 
to controls. MTA score was significantly higher in AD patients compared to controls. The 
prevalence of Apo E ε4 was higher among patients with AD than among controls. In 37 AD 
patients, disease started before the age of 65 years (= early onset AD, EAD).  
 
Table 2 shows characteristics of patients with early onset compared to patients with late onset 
AD. Patients with EAD had comparable disease severity as measured using the MMSE. In 
addition Apo E ε4 prevalence and level of CSF biomarkers were comparable among groups. 
Patients with late onset AD had more MTA than patients with EAD. 
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Table 1 Subject characteristics and CSF and MRI analyses  
 AD (N=61) Controls (N=32) P-value 
Age (years) 66 (53-82) 64 (45-83) 0.43 
Gender (M/F) 28/33 16/16 0.71 
≥ 1 Apo E ε4 (%) 44 (77%) 15 (48%) 0.006 
CSF Aβ42 pg/mL 324 (124-590) 648 (232-1450) <0.001 
CSF tau (pg/mL) 632 (75-2615) 256 (100-993) <0.001 
CSF Ptau-181 (pg/mL) 78 (18-279) 48 (18-123) <0.001 
≥ 1 Apo E ε4 (%) 44 (77%) 15 (48%) 0.006 
MTA score 1 (0-3.5) 0 (0-3) <0.001 
Values are expressed as medians (range). 
M = male, F = female; CSF = cerebrospinal fluid; Aβ42 = amyloid β (1-42); Ptau-181 = tau phosphorylated at 
threonine 181; MTA = medial temporal lobe atrophy.  
 
In the whole group, there was a significant correlation between CSF Aβ42 and tau with MTA 
(CSF Aβ42 and MTA: r = - 0.34, p = 0.001; CSF tau and MTA, r = 0.25, p = 0.02). CSF Ptau-
181 did not correlate with MTA (r = 0.13, p = 0.21). When AD patients and controls were 
evaluated separately, no correlations were present between the CSF markers and MTA score 
(Figure 1). In AD, CSF Aβ42 was low in most patients, while there was variability in MTA 
score. CSF tau and Ptau-181 levels showed a large variation in AD patients. To assess whether 
MTA and CSF markers contributed independently to the diagnosis of AD, logistic regression 
analysis was performed. MTA as well as the CSF biomarker profile contributed to diagnosis  
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Table 2 Characteristics of AD patients according to age-at-onset 
 Early onset (N=37) Late onset (N=24) P-value 
Age (years) 59 (53-68) 74 (69-82)  
Gender (M/F) 17/20 11/13 0.99 
MMSE 20 (9-28) 19.5 (10-28) 0.37 
Visual association testa 3 (0 – 12) 3 (0 – 10) 0.77 
≥ 1 Apo E ε4  (%) 74% 83% 0.42 
CSF Aβ42 pg/mL 307 (124-525) 342 (197-590) 0.36 
CSF tau (pg/mL) 697 (75-2615) 533 (304-2605) 0.64 
CSF Ptau-181 (pg/mL) 79 (18-279) 78 (46-254) 0.57 
MTA  1 (0-2.5) 1.5 (0-3.5) 0.01 
Values are expressed as medians (range). 
M = male, F = female; MMSE = mini-mental state examination, CSF = cerebrospinal fluid; Aβ42 = amyloid β (1-
42); Ptau-181 = tau phosphorylated at threonine 181; MTA = medial temporal lobe atrophy. a available for 20 
patients with early onset and  17 with late onset AD. 
 
when entered separately in models with age and gender as covariates (MTA: OR (95% CI) = 14 
(3 – 69); CSF biomarker profile: OR (95% CI) = 40 (11 – 143)). When both MTA and CSF 
biomarker profile were added in a model with age and gender, each disease marker contributed 
independently to AD diagnosis, with even higher odds ratios (MTA: OR (95% CI) = 28 (3 – 
239); CSF biomarker profile: OR (95% CI) = 57 (13 – 262)). Additional correction for Apo E ε4 
status only marginally affected the results (MTA: OR (95% CI) = 23 (3 – 193); CSF biomarker 
profile: OR (95% CI) = 46 (10 – 217)). 
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Table 3 MTA and CSF biomarker profile in AD and controls according to age 
  <65  ≥65  
  AD controls AD  controls 
MTA absent Normal CSF profile 
 
2     (5%) 16 (100%) 1     (4%) 11 (69%) 
 Abnormal CSF profile 
 
22 (60%) 0 8   (33%) 3   (19%) 
MTA present Normal CSF profile 
 
2     (5%) 0 4   (17%) 1    (6%) 
 Abnormal CSF profile 
 
11 (30%) 0 11 (46%)  1    (6%) 
Total  37 (100%) 16 (100%) 24 (100%) 16 (100%) 
 
MTA = medial temporal lobe atrophy, CSF = cerebrospinal fluid. MTA absent = MTA score 0 or 1; MTA present = 
MTA score ≥ 2; normal CSF profile = Aβ42 > 494 pg/mL and tau < 357 pg/mL and Ptau-181 < 55 pg/mL; abnormal 
CSF profile = Aβ42 < 495 pg/mL and either tau > 356 pg/mL or Ptau-181 > 54 pg/mL. 
 
When the analysis was restricted to controls and patients with mild AD only (MMSE ≥20, n=65), 
the contribution of MTA became less strong (OR (95% CI) = 10 (0.9 – 124)), while the CSF 
biomarker profile remained a significant predictor (OR (95% CI) = 37 (8 – 178)). 
 
Visual inspection of younger and older patients separately (table 3), revealed that the majority of 
AD patients with early onset had no appreciable atrophy of the medial temporal lobe (65%; 
24/37). Among individuals younger than 65 and without MTA, 60% (24/40) suffered AD (a 
priori). The finding of an abnormal CSF biomarker profile was limited to AD patients only, and 
therefore raised the a posteriori chance to 100%. Alternatively, among those younger than 65, all 
individuals with MTA were patients with AD, and therefore there was no added value of CSF 
analysis in the presence of MTA.  
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Figure 1  
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Scatterplots of medial temporal atrophy (MTA) by (a) amyloid β (1-42) (Abeta42), (b) tau and (c) tau phosphorylated tau at threonine 181 (ptau 
181), respectively. Patients with AD are depicted by empty squares, and controls by filled diamonds. Within diagnostic groups, Spearman’s 
correlations are not significant. 
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For individuals over 65 years of age, and without atrophy of the medial temporal lobe, the a priori 
chance to be an AD patient in our study was 39% (9/23). The additional finding of abnormal CSF 
biomarker profile raised this to an a posteriori chance of 73% (8/11). If MTA was present, an 
individual was likely to suffer AD (88%; 15/17). Additional finding of abnormal CSF raised this 
to an a posteriori chance of 92% (11/12).  
 
Discussion 
In the present study, we could not demonstrate cross-sectional relations between CSF Aβ42, tau 
and Ptau-181 with MTA in AD or controls. Both MTA and the combination of CSF Aβ42, tau 
and Ptau-181 contributed independently to the diagnosis AD. Our data suggest that CSF analysis 
is most sensitive in the absence of MTA, and especially among younger patients.  
 
Only a few studies investigated the cross-sectional relation between CSF biomarkers and atrophy 
on MRI in small groups of patients 4,9,10,15,26,29,38, with conflicting results: some observed no 
relation between CSF tau and cerebral atrophy 26,38, while others found a significant inverse 
relationship between CSF Ptau and hippocampal volume in subjects with mild cognitive 
impairment 9,10, or, on the other hand, CSF tau levels corresponding to higher baseline 
hippocampal volume in AD. 15 Two studies showed lower CSF Aβ42 levels corresponding to 
lower brain volume 38 or volume of the temporal lobes. 29 The discrepancies between the different 
studies could be attributed to the selection of different patient groups as well as to the use of 
diverse methods to measure brain and hippocampal atrophy. The strength of our study is that we 
included a larger group of subjects than in former studies, in which we were able to compare all 
three biomarkers with MTA in subjects with AD and controls.   
 
Our observation of higher CSF tau and Ptau concentrations in AD patients with relatively little 
MTA is in line with higher CSF tau and Ptau levels in patients with larger baseline hippocampal 
volumes mentioned in an earlier study. 15  Neuropathological studies have shown that 
neurofibrillary tangles precede entorhinal cortex (EC) and hippocampal neuronal loss. 24 The 
increase of CSF Ptau and tau might reflect the intensity of neuronal loss induced by the 
neuropathological changes 38, which precedes volume loss as visualized on MRI.  
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Our finding of a relation between CSF Aβ42 and MTA in the whole group corresponds to the 
results presented elsewhere 28,38, where the relation of CSF Aβ42 with cerebral atrophy in 
patients with a wide variation of cognitive impairment is attributed to CSF Aβ42 as stage marker 
of disease. 28,38  
 
Both MTA and CSF biomarkers independently contributed to the diagnosis of AD. With the 
abovementioned absence of direct cross-sectional correlations between the two disease markers 
one could consider that imaging- and CSF biomarkers reflect different stages of disease and/or 
another neuropathological substrate at one point in time. This might in part be due to the stable 
character of CSF biomarkers; CSF Aβ42, tau and Ptau levels demonstrate little change over time. 
1,9,19,32 By contrast, MTA progresses with disease advancement, and the rate of atrophy is 
considered a valuable marker for disease progression. 25 Our data suggest that especially in the 
early stage of the disease, when cognitive scores are still high and when MTA is not yet 
prominently present, the value of CSF analysis is evident. CSF analysis may prove especially 
valuable in patients with EAD, which relatively often do not show MTA on MRI. 12,13,20  
 
One of the limitations of the present study is the cross-sectional design, in which the value of two 
different diagnostic methods was compared in subjects with the clinical diagnosis as gold 
standard. Furthermore, we cannot exclude an overestimation of the value of CSF biomarkers over 
the MTA score; the majority of the AD patients had an abnormal biomarker profile, while only 
half of the patients had considerable MTA. This might be due to the relatively higher proportion 
of subjects aged below 65 years old in this study, in which a LP is almost standard routine in our 
memory clinic. Alternatively, it is conceivable that MTA is not the most powerful measure in this 
group of patients. Other MRI-measures, such as whole brain volume or ventricle size should be 
evaluated in further studies.  
Among the strenghts of the study is the fact that only subjects with a follow-up period of at least 
one year were included, while a standardized diagnostic work up was used for every subject. In 
addition, MTA scores were assessed blinded for diagnosis. Although on visual inspection, our 
data suggest a difference in MTA score but not in CSF markers between AD patients with early 
and late onset disease -the latter is not congruent with a recent study 17- further study with larger 
sample sizes is needed to properly assess these differences. 
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 In conclusion, both CSF biomarkers and MTA seem to be of incremental value for the diagnosis 
AD. By applying both disease markers together, diagnostic accuracy could be increased. CSF 
biomarkers seem to be most promising in patients without appreciable MTA, which is common in 
early onset AD patients.  
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CHAPTER 8 
 
 
GENERAL DISCUSSION 
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The area of research on biochemical markers in AD is very broad and refers to the fundamental 
principles of the pathophysiology of AD as well as to the clinical utility. With this thesis we tried 
to provide some tools for how to use the three CSF markers Aβ42, tau and Ptau within the 
clinical context of a memory clinic of a secondary referral center. Before I come to the 
conclusion and future perspectives of this thesis, I will comment on the studies described in 
chapters 3-7.  
 
8.1 Comments on chapters 3-7 
 
Chapter 3.2 Effects of processing and storage conditions on CSF amyloid β (1-42) and tau 
concentrations in cerebrospinal fluid: implications for use in clinical practice 
According to the study described in chapter 3.2 CSF Aβ42 and tau are stable in samples stored 
for several years at -80°C. The stability has been determined, however, by a protocol based on 
the Arrhenius equation. The validity of this method for the peptides CSF Aβ42 and tau should be 
confirmed in a real-time stability experiment. Furthermore, Ptau needs to be added to this panel 
of biomarkers. A very recent study confirmed our data29, and showed that CSF Ptau was the most 
stable marker of all three CSF markers. Since the end of 2000 we have collected CSF samples, 
but for follow up studies longer time intervals are needed with large collections of CSF pools. 
Another important issue is that the variability of CSF Aβ42 among centers might well be 
attributable to the procedure of sample treatment in the first hours after collection. This issue has 
not been investigated in our study and needs to be considered and studied in multi-center studies. 
An international validity study has been started recently.30 
The last point we would like to discuss here is the influence of internal factors -recovery rate and 
linearity- on the quantitative test results of the INNOTESTTM β-amyloid (1-42) ELISA (see also 
the Appendix for results from our laboratory). These findings, which might not be solely 
attributed to this particular ELISA, give concern about the robustness of the Aβ42 assay. 
Possibly, the same mechanisms might be involved as during repeated freeze/thaw cycles or when 
samples are stored at temperatures > -80°C, i.e. conformational changes in the fibrillary β-
sheeted Aβ peptide or masking of the epitope by binding to another protein.23 Therefore, we also 
wonder what is exactly measured in the INNOTESTTM β-amyloid (1-42) ELISA; full length 
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peptide Aβ42 only or the full length peptide in combination with an Aβ peptide, bound to a 
combination of other proteins, like -Apo J, Apo E, α1-antichymotrypsin and/or albumin?31,32 In 
the studies by Wiltfang et al.23,32 freezing prior to analysis influences the concentration of CSF 
Aβ42 as measured by SDS-PAGE/immunoblot, while a higher CSF Aß42 concentration is 
measured by this technique compared to ELISA. This might be attributed to carrier mediated 
epitope masking, as SDS-heat denaturation may strip the Aβ42 peptide from the binding epitope 
as detected in the Aß42 ELISA. Knowledge about whether we detect free or bound Aβ peptide is 
very important applying CSF Aβ42 as marker of progression in longitudinal studies, especially 
when measuring the effect of anti-amyloid drugs. Furthermore, it needs to be taken into account 
in the differentiation of AD from other types of dementia, i.e. FTD and CJD, in which also 
decreased CSF Aβ42 concentrations are found.36  
Nonetheless, the Aβ42 peptide concentration has been shown to be decreased in CSF from the 
majority of AD patients when measured by different laboratory techniques21, which makes the 
use of CSF Aβ42 as diagnostic marker for AD very promising. 
 
Chapters 4.1 and 4.2 Differences and similarities between two frequently used assays for 
Amyloid β 42 in cerebrospinal fluid and Amyloid β 38, 40, and 42 species in cerebrospinal fluid: 
more of the same? 
The main findings of the two studies are that absolute concentrations of CSF Aβ42 as measured 
by two distinct ELISAs are comparable and that CSF Aβ42 is selectively decreased in CSF as 
compared to the other two most prominent CSF Aβ peptides, Aβ38 and 40. These results are 
encouraging for the implementation of CSF Aβ42 as diagnostic marker for AD in clinical 
practice, and seem to be irrespective of the ELISA used. Taking a closer look at the data, several 
issues need attention. The first issue is the binding characteristic of the antigen which may vary 
with temperature, buffer solutions and even among lots. Second issue is the variability of the 
affinity of the antibodies for the various CSF Aβ peptides involved in the pathogenesis of AD. 
With this study we did not exchange calibrators and antibodies used in the two assays, i.e. 6E10 
and 3D6 (see also chapters 3.1 and 4.1) as well as the different C-terminally directed antibodies. 
Innogenetics did study this issue to some extent33, and roughly the same results were found by a 
multiparameter xMapTM technology-based assay: CSF Aβ42 is decreased in AD as measured by 
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different N-terminally directed antibodies (6E10, 3D6 and 4G8), although diagnostic accuracy 
varied to some extent. The SELDI-TOF data reported by Innogenetics33 and SDS-
PAGE/Immunoblot data by Wiltfang23 give a more refined impression of the different types of 
Aβ42 present in CSF, which may not only be promising for use in the early (MCI) stage of 
disease, but also for differentiation between different types of dementia, especially between AD 
and FTD. The tendency towards a difference in concentration between CSF Aβ 1-42 and Aβ N-
42 in FTD (chapter 4.1) is remarkable, and needs further investigation. By several research 
groups a putative role for beta amyloid metabolism disturbances in the pathogenesis of some 
types of FTD is found34,35.  
 
The decrease of Aβ42 in CSF compared to the other C-terminally truncated Aβ peptides, Aβ38 
and 40, might be due to deposition of insoluble Aβ42 in the plaques has been stated in chapter 
4.2. However, this is by far not clear yet. Another explanation might be that CSF Aβ42 is to a 
higher extent bound to another protein than CSF Aβ38 and 40 as has been shown before32. 
Evidence for this hypothesis is the decrease of CSF Aβ42 in Creutzfeldt-Jakob patients36 in 
which no classic β-amyloid (neuritic) plaques are found in the brain 37 Here, a comparable (the 
same?) pathological chaperone might be involved as well.  
 
Chapter 5.1 Amyloid β 42 (1-42) and phosphorylated tau in CSF as markers for early onset 
Alzheimer’s disease 
The combination of low CSF Aβ42 and high Ptau-181 yields the highest diagnostic accuracy in a 
cohort of EAD patients compared to FTD patients. This especially accounts for the specificity 
and for the negative likelihood ratio with two markers negative compared to one positive. These 
findings are most essential for clinical practice; a diagnostic marker is useful when it has a low 
false positive rate and when it can with great certainty rule out the presence of a disease. The 
sensitivity of the combination of CSF Aβ42 and tau did not achieve ≥ 85% in AD, which is 
needed for an ideal biomarker in accordance to the Reagan Consensus Report (see also 
Appendix).38 In some EAD patients either CSF Aβ42 was low or Ptau-181 was high. This is 
probably due to the low cut off value applied for CSF Aβ42 comparing EAD with FTD. 
Moreover CSF Aβ42 is also decreased in a substantial proportion of the FTD patients (see also 
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chapter 5.2). Therefore, according to our results, the best single marker to differentiate EAD 
from FTD is CSF Ptau. On the contrary, CSF Ptau alone is found to be less specific than CSF tau 
and Aβ42 in controls with subjective memory complaints. Comparing AD with controls, CSF 
Aβ42 is the marker with the highest sensitivity for AD (Chapter 5.1). 21,39 
 
Until now three assays are available measuring CSF tau phosphorylated at different epitopes; 
phosphorylation at threonine 231 (Ptau-231), threonine 181 (Ptau-181), and serine 199 (Ptau-
199). These markers demonstrate comparable diagnostic accuracy comparing AD with controls.40 
For the differentiation of AD from other types of dementia CSF Ptau-231 and Ptau-181 
performed equally well (see also Appendix for our unpublished results comparing AD with 
FTD). Combinations of the three markers did not add to the discriminative power when compared 
to a single marker.40? Neuropathological data have shown that phosphorylation of tau at the three 
epitopes occurs at different stages of disease. Unfortunately, no difference in the prediction of the 
rate of cognitive decline between the different phosphorylated Ptau epitopes could be shown in 
MCI patients with 1 year clinical follow up.41 A possible explanation for this finding might be the 
relatively short time of follow up, but also test characteristics might be involved: not the absolute 
quantification of the phosphorylation of tau at the specific epitope is measured in CSF, but the 
presence of Ptau phosphorylated at this particular epitope in CSF. In addition, little is known 
about CSF flow, kinetics and clearance dynamics and their influence on the concentration of 
(P)tau proteins.42 
 
Chapter 6 Biomarker profiles and their relation to clinical variables in mild cognitive 
impairment 
The findings of this study point to a relation of CSF Aβ42 and tau to clinical markers of AD in 
the MCI stage of disease. These results are very important, not only because they add to the 
biological validity of the markers, but they also support the added value of the biomarkers in 
selecting MCI patients for clinical studies. We divided the MCI patients into three groups 
according to their biomarker profile. The biomarker profile was assumed positive for AD when 
the CSF Aβ42 concentration was decreased and CSF tau was increased. Preliminary results show 
that 56% of our MCI cohort developed AD in a follow up period of 19 months.43 Both CSF Aβ42 
and tau were significantly associated with AD at follow-up comparing progressive with stable 
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MCI patients. These associations were also found when the markers were analyzed separately. 
These results justify our choice to divide the patients into three groups; high-, intermediate- and 
low-risk group. Overall, patients within the high- and intermediate- risk group were comparable 
for all clinical variables. Including CSF Ptau to the panel of biomarkers did not influence the 
results and conclusions (unpublished results). All patients with a high CSF tau also had a high 
CSF Ptau, except for one patient, who would therefore have an intermediate risk for AD instead 
of a low risk.  
 
The different relations of CSF Aβ42 and tau with MTA, PAS and memory impairment is 
remarkable. However, our results are in line with those of another independent cohort study.44  
The cross-sectional associations between CSF tau and neuropsychological markers may very well 
be restricted to the MCI stage of disease. The VAT is an instrument that is changed very early in 
the disease process45, even before the clinical diagnosis of AD is obtained. Until now, it was not 
possible to find consistent relations between CSF biomarkers and neuropsychological markers in 
AD46, except for a relation between CSF Ptau-231 at baseline and annual rate of change in 
MMSE score in MCI.47 
 
Chapter 7 Cerebrospinal fluid and magnetic resonance imaging markers independently 
contribute to the diagnosis Alzheimer’s disease 
Major finding of this study was that both CSF and MRI markers contribute to the clinical 
diagnosis AD. Both diagnostic markers are supposed to reflect neuropathology of AD.48-50 All 
studies investigating hippocampal volumes with postmortem neuropathology have found 
reasonable associations with neuron loss as well as plaques and tangles densities.42,48,49 
Associational studies between biochemical markers and postmortem neuropathological data are 
very sparse and not conclusive.50,51 Unfortunately, postmortem CSF tau-, Ptau- and Aβ42-
concentrations seem not to be valuable to use for associational studies with neuropathological 
findings, as the CSF concentrations are totally different from antemortem CSF concentrations, 
with no distinction between AD and controls (unpublished results).52 Several explanations for the 
absence of a relation between CSF biomarkers and MTA are described in the paper. Here, I 
would like to comment on the presumed differences in early onset AD versus late onset AD 
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(EAD vs LAD), as well as the inability to detect longitudinal changes in CSF Aβ42, tau and Ptau 
concentrations.  
Although clinical presentation differs between EAD and LAD53, neuropathological findings are 
comparable. However, the distribution of neuronal loss is in proportion to the clinical picture 
from patients, especially in the early stage of disease; patients who present with focal signs like 
aphasia, apraxia, executive dysfunction or visual disturbances have predominantly focal 
degeneration of the brain, and in lesser extent hippocampal atrophy.54 In our study we did not 
divide the AD patients into a memory versus a non-memory type according to their 
neuropsychological profile. This would have revealed whether differences between the EAD and 
LAD group with respect to discordance between CSF markers and MTA was due to fewer 
patients in the EAD group presenting with memory disturbances and thus with less MTA. 
Interesting in this light is the finding of a relationship between the clinical phenotype of EAD –
either the amnestic phenotype or the non-memory phenotype- and the presence of ≥ 1 Apo E ε4 
allele.55 Furthermore, hippocampal atrophy is also considered to increase with age.56 Patients with 
AD still tended to have higher MTA scores compared to age-matched controls (unpublished 
results, see also Appendix).57 However, we cannot exclude the possibility that younger AD 
patients have less MTA than older AD patients due to the age factor. 
 
Until now no longitudinal changes of CSF Aβ42, tau and Ptau could be demonstrated, except for 
CSF Aβ42 in one study with prolonged follow up.58 If the CSF markers are supposed to reflect 
neuropathological changes in AD, one would expect a decrease of CSF Aβ42 and an increase of 
CSF tau and/or Ptau with time, as a result of increased plaque deposition and neuron loss, 
comparable to the increase of MTA with progression of disease. Probably more complex 
mechanisms are involved; one hypothesis might be that there is an increased total production of 
Aβ42 during progression of disease, not per se leading to a decreased but even to a steady or a 
paradoxically increased CSF Aβ42 concentration, which can only be detected after prolonged 
follow up. In addition, with disease progression less neurons are left to release (P)tau in CSF, 
which might result in steady or decreased CSF (P)concentrations. But, also CSF flow and 
clearance dynamics might be involved42,59, as well as ELISA characteristics like epitope masking 
of Aβ42, or the presence of various Aβ peptides in CSF, which might have a different role in 
progression of disease. Taking all these considerations into account, it is not surprising that the 
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CSF biomarkers Aβ42, tau and Ptau, which are already changed before the clinical picture of AD 
becomes overt, do not have a relation with MTA, which increases as disease progresses.  
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8.2 CONCLUSIONS 
 
The studies described in this thesis intended to assess whether the CSF biomarkers Aβ42, tau and 
Ptau can be used for early and differential diagnosis of AD. Findings from former studies were 
confirmed in a clinical setting, with the addition of some new insights: the combination of CSF 
Aβ42 and Ptau achieved the highest diagnostic accuracy for the differentiation of EAD from 
FTD; CSF biomarkers are not independent from other clinical parameters in the MCI stage of 
disease; and both CSF Aβ42, tau and Ptau and MTA are of incremental value for the diagnosis 
AD. Furthermore, the variability of CSF Aβ42 concentrations is explained by pre-analytical and 
internal (ELISA) factors. However, the commercial ELISAs are quite reliable as diagnostic 
method compared to the other methods available.  
None of the biochemical markers is sufficiently accurate to be used as the sole diagnostic tool. 
Will there ever be one, as the gold standard for AD is still the clinical diagnosis? Without a 
doubt, more clinicopathological studies are needed, although it is not very likely that all clinically 
diagnosed AD patients will have a pure form of AD neuropathologically, which might be again 
confusing to interpret the CSF data. Be that as it may , the results of the present thesis led us to 
the conclusion that the three CSF biomarkers Aβ42, tau and Ptau can be used as diagnostic tool 
for AD in a secondary referral setting within the clinical context and only in addition to other 
diagnostic methods. Most promising are the CSF markers in the diagnostic evaluation of EAD. 
Furthermore, CSF Aβ42, tau and Ptau are potential markers for prediction of AD in MCI 
patients. Until now, CSF Aβ42, tau and Ptau do not appear to be good markers to track 
progression of disease. The absence of neuropathological confirmation of the diagnosis in most 
cases requires prolonged follow up time of the patients especially in the early stage of disease. 
Answers to the questions in chapter 2 are summarized below. Recommendations or guidelines 
for the use of the CSF biomarkers in clinical practice are listed at the end of this paragraph (see 
also chapter 1.2): 
 
Are CSF samples stable as far as Aβ42 and tau are concerned? 
- CSF Aβ42 and tau are stable when stored for years at -80°C. CSF Aβ42 concentrations 
are influenced by storage temperatures > -80°C and after repeated freeze/thaw cycles. 
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CSF tau is stable under these conditions, except when stored for more than 10 days at 
37°C. 
 
Are CSF concentrations of Aβ42 comparable when measured by two different ELISAs? 
- In AD and controls CSF Aβ42 concentrations are comparable when measured by two 
different ELISAs for Aβ42. In FTD, CSF Aβ42 concentrations as measured by the two 
ELISAs slightly differ, which suggest a role of β amyloid metabolism disturbances in 
FTD. Both ELISAs have a comparable diagnostic accuracy in AD versus controls.  
 
Is there a relation between various C-terminally truncated Aβ peptides in CSF? 
- All three C-terminally truncated Aβ peptides in CSF are interrelated in both AD and 
controls. CSF Aβ42 is selectively decreased in AD. 
 
What is the diagnostic value of CSF Aβ42, tau and Ptau in early onset AD versus frontotemporal 
dementia?  
- Diagnostic accuracy of the combination of CSF Aβ42 and Ptau-181 in a cohort of EAD 
and FTD patients is good, especially the specificity and negative likelihood ratio. CSF 
Ptau is a better marker for the differentiation of EAD from FTD than CSF tau. 
 
Are CSF Aβ42 and tau independent predictors of AD? 
- At baseline in MCI, CSF Aβ42 and tau have relations with other indicator markers of AD, 
i.e. MTA and memory loss.  Furthermore, patients with a higher risk of AD according to 
their biomarker profile also perform less well on neuropsychological tests as well as the 
preclinical AD scale. These findings suggest that the CSF markers are not independent in 
the MCI stage of disease. 
 
What is the relation between CSF markers and medial temporal lobe atrophy? 
- No relation could be found between CSF markers and MTA in AD or controls.  Both 
disease markers seem to reflect another neuropathological substrate at one point in time. 
Both disease markers contribute independently to the diagnose AD. 
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Guidelines for the use of CSF Aβ42, tau and Ptau in clinical practice 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Determine Aβ42, tau and Ptau in CSF when there is doubt about the diagnosis AD, 
and when MRI markers and neuropsychological findings are not conclusive 
Determine Aβ42, tau and Ptau in CSF in presenile dementias, as the differential 
diagnosis here is wider and more complicated, and the existing diagnostic tools less 
sensitive  
Determine Aβ42, tau and Ptau in CSF in the early stage of disease, in patients for 
whom treatment is being considered.  
All three biomarkers CSF Aβ42, tau and Ptau should be measured in order to 
differentiate AD from subjects ith subjective memory complaints as well as patients 
with other types of dementia  
The biomarker profile is positive for AD when in addition to CSF Aβ42, also tau or 
Ptau are abnormal; i.e. at least two markers should be positive 
Try to achieve postmortem verification of the diagnosis or otherwise prolonged follow 
up time 
In case of a negative biomarker profile at baseline, repeat the CSF measurements 
when the patient clinically progresses to AD or MCI, preferably at least one year after 
the first LP   
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Laboratory guidelines for the use of CSF Aβ42, tau and Ptau  
1. Preferably, samples should be stored at -80°C immediately after collection 
2. Baseline- and follow up- CSF samples should be analyzed after comparable storage 
conditions and within the same ELISA to avoid confounders by repeated freeze/thaw 
cycles or test characteristics 
3. For longitudinal studies we recommend storing large collections of CSF pools, which 
can be used as control samples to measure degradation of biomarkers over time 
4. As the median concentrations of CSF Aβ42, tau and Ptau differ between laboratories, 
we recommend to define internal cut off values until international validity studies are 
completed (see Appendix for reference values of the VUMC) 
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8.3 FUTURE PERSPECTIVES 
 
In chapter 2 ‘topics for future research’ are listed. In the present chapter I will mainly focus on 
how and which biomarkers could be used for tracking the progression of the disease, especially in 
the early stage of disease and in relation to promising therapies. Next, a brief commentary on the 
few studies about plasma markers for the (early) diagnosis of AD will be given. 
 
Obviously, more longitudinal prospective studies are needed. CSF Aβ42 is a good marker to 
predict AD, even in asymptomatic elderly patients.60 Very interesting in this light are the results 
of Fagan et al.61, in which a relation was found between in vivo brain amyloid, as detected by 
PET imaging of the amyloid-binding agent PIB, and decreased CSF Aβ42 levels in 7 patients, 
including 3 non-demented subjects. These findings however are not yet replicated by others. 
Results depend also on which type of Aβ42 peptide is measured: the N-terminally truncated 
forms of Aβ42, which might be indicator markers of the early stage of disease18,33 or full length 
Aβ 1-42, which is decreased throughout the whole spectrum of disease. Then, oligomers of Aβ 
peptides seem to be very promising for early detection of disease and possibly therapeutic 
monitoring, also because they are directly associated with memory loss due to their toxic effects 
on synapses. 82 
 
No change of CSF Aβ42 is found with progression of disease, but also not in relation to therapy, 
as has been shown in studies with acetylcholinesterase inhibitors62,63, and even after Aβ 
immunization CSF Aβ42 remained the same.64 Although concentrations of CSF Aβ40 are found 
to be comparable between AD and controls, there might be a role for this peptide in follow-up 
studies, as the peptide has been shown to be increased in CSF of MCI patients at follow up.28 
CSF Aβ38 might be interesting to study in relation to therapy, as this peptide has been shown to 
increase after treatment with non-specific anti-inflammation drugs (NSAIDs) in cells and mice 
studies, while amyloidogenic CSF Aβ42 is decreased, probably due to an allosteric effect on γ-
secretase.65,66 No studies are published yet investigating the effect of NSAIDs on CSF Aβ42 or 
38 in humans, and only a trend was found to decreased plasma Aβ42 levels in NSAID users.67 
Recently a promising study is published, in which the effect of γ-secretase inhibitors on 
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reductions of CSF Aβ40 levels in mice is described.68 While CSF Aβ42 is thus not a good marker 
to measure effect of therapeutics, Aβ (auto) antibodies might be69; subgroup analysis suggests 
that patients who developed antibodies reactive to amyloid plaques after Aβ immunization 
perform better on neuropsychological tests compared to patients who did not develop these 
antibodies.70 However, all these studies are very preliminary and must be interpreted cautiously. 
The same implies for the decrease of CSF tau in 11 patients, who received Aβ immunization, 
which might be due to reduced rate of cellular degeneration in patients who developed high titers 
of anti-AN1792 antibodies64, but also a dilutional effect of CSF tau might be involved, as 
ventricular enlargement and reduced brain volume is found in the antibody responders.71 CSF 
Ptau-231 has been shown to decrease in AD with disease progression in one study.72 Further 
studies are needed to investigate the value of CSF tau and Ptau to track progression of AD/MCI. 
 
The plasma Aβ42 and Aβ40 markers are not useful for diagnosis, as has been shown by 8 
studies.69 Aβ42 is increased in plasma of affected and even unaffected family members with 
mutations in PSEN 1 and 2 and APP, as well as in patients with Down syndrome with and 
without dementia.73 Probably this increase of plasma Aβ42 is a result of an overall increase in 
Aβ42 production, in the brain but also in peripheral sources such as blood.74  There are findings 
pointing to an increase of Aβ42 in plasma of some patients long before and during the early 
stages of AD, with a decline thereafter.74 The plasma Aβ42 marker might therefore be used to 
track patients at risk for AD (which might be patients with ≥ 1 Apo E ε4 allele and a strong 
positive family history), but only when followed for longer periods as the differences in 
frequency of AD by plasma Aβ42 emerge only after 2-3 years and the specificity of AD 
diagnosis is higher in more advanced stages.74 Moreover, ethical issues are involved; until there 
is no absolute cure for AD the knowledge for the patient of having a biomarker profile indicative 
for AD is not warranted, making the use of Aβ42 as predictive (plasma or CSF) marker in most 
cases only a topic for research.  
 
Isoprostanes are markers of oxidative stress and involved in a number of neurodegenerative 
disorders, including AD. It can be measured in CSF, plasma and urine, and is increased in AD 
and MCI in CSF.75,76 Conflicting results are found in plasma concentrations of isoprostanes in 
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AD versus controls.75,77 One study showed an increase of isoprostanes in CSF at follow up in 
MCI.42 As diagnostic marker isoprostanes seem not be very useful as they lack specificity, but 
there might be possible role as marker of progression to dementia. 
Conflicting results are also found in inflammatory markers measured in serum: some authors 
found an increase of interleukine 6 (Il-6) in serum of AD patients, while others could not 
replicate this finding. 69 The same accounts for α1-antichymotrypsine (α1-ACT) in serum.78 
These differences might be contributed to differences in assay methodology and sensitivity, and 
small sample sizes with heterogeneous patient and control populations. We could not find 
differences in Il-6 and α1-ACT in serum between AD and controls in our laboratory (unpublished 
results). In a collaboration study with investigators in Milan we could not demonstrate 
differences between the chemokines Interferon-γ-inducible Protein-10 (IP-10), Interleukin-8 (IL-
8), and Monocyte Chemotactic Protein-1 (MCP-1) in serum from AD, MCI and controls.79,80 CSF 
appears to be a better fluid to investigate interleukins and chemokines, however, as differences 
were found in a cross-sectional study for CSF IP-10, IL-8 and MCP-1 in mild-moderate AD and 
MCI versus controls80, although the last two markers seem not to be specific for AD.81 Follow-up 
studies in MCI might reveal whether these markers might be used for prediction or even 
progression of disease. Furthermore, additional studies are needed to confirm our unpublished 
data of increased CSF α1-ACT concentrations in AD versus controls as compared to the serum 
concentration. As α1-ACT is found at a very early stage of AD in the neuritic plaques, studies are 
underway to investigate the relation of α1-ACT and Aβ42 in CSF and whether it is possible to 
detect complexes of these two peptides in CSF.  
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Chapter 1.1 
 
NINCDS-ADRDA criteria1: 
Probable AD 
- Dementia 
- Clear conscience 
- Dysfunction in two or more cognitive domains 
- Progressive deterioration of cognitive dysfunction 
- Age between 40 and 90 years old 
- No signs of systemic disorder or other brain disease 
 
Possible AD 
- Dementia of the Alzheimer type 
- Presence of a systemic disorder or brain disease 
 
Amnestic MCI (Petersen et al. 16) : 
- Memory complaint 
- Memory disturbances at neuropsychological screening tests 
- No other cognitive dysfunction 
- Intact function in daily activities 
- No dementia 
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Chapter 1.1 
 
Proteolysis of amyloid precursor protein (APP)87 
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Chapter 3.3 
Figure 1 
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Chapter 3.3 
Figure 2 
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Chapter 8.1 
 
Spike recovery of CSF Aβ42 concentration 
 
 Table 1 
 Sample1 
(pg/mL) 
 
Sample 2  
(pg/mL) 
Sample 3  
(pg/mL) 
Sample 4  
(pg/mL) 
Undiluted 
(pg/mL) 
 
438 520 266 319 
Measured Aβ42 
concentration 
(calculated 
concentration)  
 
981(1119) 917(1260) 896(1133) 875(1160) 
Recovery (%) 
 
76.2 72.7 79.0 75.4 
 
The spike recovery of CSF Aβ42 was evaluated in two different runs by spiking four CSF 
samples 1:1 with the highest standard of the INNOTESTTM β-amyloid (1-42) ELISA, i.e. 2000 
pg/mL. Recoveries ranged from 75.4 to 79% with an overall mean recovery of 76%. 
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Recovery of expected value of CSF Aβ42 concentration  
 
 
Table 2 
Sample + 
sample 
diluent 
 
Sample  1 
(pg/mL)  
Recovery 
of exp 
value (%) 
Sample 2 
(pg/mL) 
Recovery of 
exp value 
(%) 
Sample 3 
(pg/mL) 
Recovery 
of exp 
value (%) 
100 + 0  
 
1055 100 806 100 1124 100 
80  + 20  
 
966 114 605 94 930 103 
60  + 40 
  
802 125 593 122 ----- ---- 
50  + 50  
 
778 147 446 111 851 151 
40  + 60  
 
696 165 375 116 ----- ------ 
20  + 80  
 
403 191 255 158 451 201 
 
In three different runs three CSF samples were assayed at five serial dilutions with sample 
diluent. In Table 2 the percent recovery of expected value (or linearity) is listed. Recoveries 
ranged from 158 to 201% in the experiment with the highest dilution (1:5). See also Figure 1.  
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Figure 1 Recovery of the expected value of CSF Aβ42 concentration 
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Chapter 8.1 
 
Criteria for an ideal biomarker for AD38: 
 
- Reflection of neuropathological changes in AD 
- Gold standard: at autopsy neuropathological changes typical for AD  
- Sensitivity ≥ 85% 
- Specificity ≥ 75% 
- Able to detect AD early on the course of disease 
- Useful in monitoring disease progression and treatment effect 
- Reliable and precise 
- Non-invasive and simple procedure 
- Not expensive 
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Chapter 8.1 
 
ROC curve CSF Ptau-231 and Ptau-181 in AD (N = 30) versus FTD (N =21) 
 
ROC Curve
Diagonal segments are produced by ties.
1 - Specificity
1,0,8,5,30,0
S
en
si
tiv
ity
1,0
,8
,5
,3
0,0
Source of the Curve
Reference Line
PTAU231
PTAU181
 
 
Ptau-181, cut off 55 pg/ml, sensitivity = 87%, specificity = 62% 
Ptau-231, cut off 40 pg/ml, sensitivity = 87%, specificity = 62% 
 
Areas under the curve (95% CI): 
Ptau-181 = 0.79 (0.66-0.92) 
Ptau-231 =  0.78 (0.64-0.92) 
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Chapter 8.1 
 
MTA in EAD and LAD versus age-matched controls  
 
 
Table 3 
 < 65 years old   ≥ 65 years old   
 AD Controls P AD Controls P 
Average MTA (min-max) 1 (0-2.5) 0 (0-0.5) <0.001 1.5 (0-3.5) 0 (0-3) 0.001 
 
MTA = medial temporal lobe atrophy; Average MTA: MTA R+L/2; P = P-value comparing AD 
with controls (Mann Whitney U test). 
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Chapter 8.2  
 
 
Reference values of the VUMC 
 
AD:       Controls: 
 
Aβ42 < 500 pg/mL    Aβ42 ≥ 500 pg/mL 
Tau > 350 pg/mL    Tau ≤ 350 pg/mL 
Ptau-181 > 60 pg/mL    Ptau-181 ≤ 60 pg/mL  
 
 Aβ42 Tau Ptau 
Alzheimer’s disease 
 
 
Decreased  
 
Increased Increased 
Lewy Body Dementia 
 
Decreased Normal Normal 
Vascular Dementia 
 
Normal - decreased Normal - increased Normal 
Frontotemporal Dementia 
 
Normal - decreased Normal – increased  Normal 
Creutzfeldt Jakob Disease 
 
Normal - decreased Strongly increased Relatively normal 
Non-demented elderly 
 
Normal Normal Normal 
 
 
 
 
 
 
 
 
 
 
 172
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 173
 
   
  
SUMMARY 
 
 
The diagnose Alzheimer’s disease (AD) is based on clinical criteria, supported by 
neuropsychological tests, neuroimaging and extended follow up. A definite diagnose can only 
be obtained at autopsy.  With the advent of disease modifying therapeutics, it is important to 
diagnose AD as early as possible, before extensive brain damage has occurred. In this early 
stage biochemical markers are needed for diagnosis as clinical symptoms are subtle and other 
diagnostic methods fairly normal. Up to now amyloid β 42 (Aβ42), total tau (tau) and 
phosphorylated tau (Ptau), as measured in cerebrospinal fluid (CSF), are considered to be the 
most promising biochemical markers for AD. The present thesis tells us how and when to use 
these markers for the early and differential diagnosis AD in clinical practice.  
 
We conclude that the triplet of Aβ42, tau and Ptau must be measured in CSF in order to 
differentiate AD from normal aging and other types of dementias. Particularly useful are 
these biomarkers in presenile dementias –starting before 65 years old- as the differential 
diagnosis here is wider and more complicated. At least two of the markers must be abnormal 
for the diagnosis AD, while all three markers negative can practically rule out the disease. 
CSF Aβ42, tau and Ptau are potential markers to predict AD in the preclinical stage of 
disease. However, in this early stage the markers are not independent from other clinical 
parameters. Moreover, the combination of the three CSF markers and atrophy of the medial 
temporal lobe are of incremental value for the diagnosis AD. Hence, the three CSF 
biomarkers Aβ42, tau and Ptau can only be used as diagnostic tool in addition to other 
diagnostic methods. Variability of CSF Aβ42 concentrations is explained by pre-analytical 
and internal (ELISA) factors. Current (commercial) ELISAs are quite reliable as diagnostic 
method compared to the other methods available.  
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SAMENVATTING 
De diagnose ziekte van Alzheimer (AD) wordt gesteld op basis van klinische criteria, met 
ondersteuning van neuropsychologische tests, beeldvorming en langdurige follow-up. De 
definitieve diagnose kan alleen worden vastgesteld bij obductie. Van belang is om de 
diagnose in een zo vroeg mogelijk stadium te stellen zodat, voordat er in de hersenen schade 
is aangericht, kan worden gestart met therapie. Juist in dit preklinische stadium van de ziekte 
is er behoefte aan biochemische markers, aangezien de klinische symptomen subtiel zijn, en 
andere diagnostische methoden vaak normaal. Liquor cerebrospinalis (cerebrospinal fluid, 
CSF) wordt verondersteld een goede afspiegeling te geven van wat zich in de hersenen 
afspeelt. Tot nu toe is gebleken dat bepaling van Aβ42, totaal tau (tau) en Ptau in CSF erg 
sensitief is voor de diagnose AD. In dit proefschrift wordt uiteengezet hoe en wanneer deze 
drie biochemische markers het beste kunnen worden gebruikt voor de diagnose AD in een 
klinische setting. 
 
Alledrie de markers zijn nodig om AD te kunnen onderscheiden van normale veroudering en 
verschillende soorten dementie. Voor de diagnose AD moeten twee van de drie markers 
positief zijn, terwijl als alledrie de markers negatief zijn de ziekte vrijwel is uitgesloten. De 
markers zijn met name van belang bij het onderscheid tussen verschillende vormen van 
preseniele dementie (ontstaan van klachten voor het 65ste jaar), waarbij de differentiële 
diagnose uitgebreid is, en overige diagnostische methoden niet eenduidig. CSF Aβ42, tau en 
Ptau zijn veelbelovend om te gebruiken bij het voorspellen van AD in een preklinisch 
stadium. Echter, ze zijn niet onafhankelijk van andere klinische variabelen, en dragen 
supplementair bij aan de diagnose AD in combinatie met een MRI scan. Geadviseerd wordt 
om de markers alleen te bepalen naast andere diagnostische methoden. De variabiliteit van de 
Aβ42 concentratie in CSF wordt veroorzaakt door preanalytische en interne (ELISA) 
factoren. De gangbare (commerciele) ELISA’s zijn net zo goed als diagnostische methode 
vergeleken met andere analysemethoden. 
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terwijl je ondertussen ook nog neuroloog én moeder bent geworden. Petje af. 
 
Laura, Ingeborg en Maaike (en later weer Femke); met heel veel plezier denk ik aan onze 
oude kamer terug. Ik mis af en toe zeker de gezelligheid, de gesprekken, en o ja, het werk ook 
natuurlijk. In de kliniek is het toch anders en hectischer, maar gelukkig delen we die meer 
ontspannen tijd. 
 
Esther, Alie, Rutger, Jasper, Ilse, Wouter, Freek, Rolinka, en al die andere onderzoekers en 
medewerkers van het AD-centrum: het was een gezellige tijd! En Esther: wat zal jij ook blij 
zijn als je klaar bent: succes! 
 
Prof.dr. MJ De Leon, dear Mony, thank you for the opportunity to work at your lab in New 
York, the Center for Brain Health (still a brilliant name). Your experience and way of 
thinking about mechanisms behind Alzheimer’s disease are really inspiring, and I hope there 
will be in some way opportunities to stay in contact with you. The same applies for Susan De 
Santi, your co-worker and friend. 
 
Dr. PD Mehta, Pankaj, our collaboration was successful! I learned a lot about ELISA’s at 
your lab, and you have been always very hospitable. What will be the next project? 
 
Dr. H Vanderstichele, en andere medewerkers van Innogenetics: de samenwerking met jullie 
heb ik als prettig ervaren, en is uiteindelijk ook vruchtbaar gebleken. We zijn goed ontvangen 
op het lab in Gent! 
 
Daniela Galimberti and Elio Scarpini, we did a good job together! Daniela, your dedicated 
precise laboratory work and writing deserves all those publications. Hopefully we are able to 
continue the collaboration in the future (still not been in Milan….). 
 
Marijke en Ina, gouden handen hebben jullie als het gaat om assisteren bij LP’s! Volgens mij 
zouden jullie het best zelf kunnen na al die jaren. Ook alle andere medewerkers van de poli: 
 
 
   
  
bedankt voor jullie hulp met het zoeken van statussen, foto’s, kamers, en plannen van de vele 
patiënten. Ik zal niet altijd de makkelijkste zijn geweest met mijn drukdoenerij.  
 
Els van Deventer, niets was teveel, je vond altijd alle relevante literatuur en updates, dank! 
 
Dear Isabel, Kim, and Chase, you became real friends during my stay in New York. Although 
we live now in Berlin, Amsterdam, and Brooklyn, we still have contact, and I hope this 
friendship will last.  
 
Serge, je bent een echte wetenschapper, veel leerde ik van jou op dit gebied. Succes met je 
nieuwe baan bij Columbia University! 
 
Judith, Juut, jou ken ik al vanaf de intreeweek. Het eerste jaar waren we huisgenoten, en 
stond ons huis altijd open voor iedereen, met veel logeerpartijen en feestjes. Wie had toen 
gedacht dat we allebei gelijksoortig onderzoek zouden gaan doen? Met name in het begin, 
met het opzetten van de liquorbank, hebben we veel aan elkaar gehad, en zaten we tot laat in 
de avond te pipetteren. Voor mij was het niet meer dan logisch je te vragen als paranimf.  
 
Voor Annick, Lonneke, Loes, en Henneke was ik regelmatig niet bereikbaar, -je neemt nooit 
je telefoon op!- maar jullie accepteerden dat redelijk. Ik weet overigens niet of dat nu zal 
veranderen. 
 
Mijn familie is altijd een grote steun geweest, in alles wat ik doe: mijn vader door de juiste 
vragen te stellen, en bij te houden of ik op schema ben; mijn moeder door te zorgen dat ik aan 
mezelf blijf denken, en niet te hard werk; Merlijn, door te relativeren en kritisch te blijven. 
Zonder jullie was ik nooit zover gekomen. 
 
Job en Manu, er is meer dan werk; jullie zijn de ‘sjeu’ van mijn leven en Job is de stille 
kracht. Dankzij jouw onvoorwaardelijke steun en vertrouwen kan ik mijn eigen weg gaan. 
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CURRICULUM VITAE 
Niki Schoonenboom (03-03-1972) is in Wassenaar opgegroeid en voltooide daar het 
gymnasium β aan het Rijnlands Lyceum in 1990. Ze is in hetzelfde jaar geneeskunde gaan 
studeren aan de Universiteit van Amsterdam. Na de studie werd de interesse voor de oudere 
mens gewekt als AGNIO ouderenpsychiatrie bij de Robert Fleury Stichting in Leidschendam, 
en later verder als AGNIO neurologie in het Slotervaartziekenhuis in Amsterdam (1999). In 
2000 begon ze met promotieonderzoek bij prof.dr. P. Scheltens, Alzheimer Centrum, VUmc 
(2000-2004). In 2002 kreeg ze de gelegenheid om 5 maanden deelonderzoek te doen in New 
York, bij het ‘Center for Brain Health’ van NYU, en het ‘Institute for Basic Research in 
Developmental Disabilities’, Staten Island, onder leiding van respectievelijk prof.dr. MJ De 
Leon en dr. PD Mehta. Eind 2004 kon ze beginnen als AGIO neurologie in het VUmc, 
waarmee ze hopelijk in 2010 klaar zal zijn. 
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CURRICULUM VITAE 
Niki Schoonenboom (03-03-1972) grew up in Wassenaar, and graduated in 1990 from the ‘ 
Rijnlands Lyceaum’ (Gymnasium β). The same year she moved to Amsterdam (University of 
Amsterdam) to study Medicine. After obtaining her medical degree, she started her carreer as 
physician at Geriatric Psychiatry (Robert Fleury Stichting, Leidschendam) and Neurology 
(Slotervaartziekenhuis, 1999). From 2000-2004 she worked on her PhD thesis under the 
supervision of prof.dr. P Scheltens at the Alzheimer Center of the VUmc. In 2003 she got the 
opportunity to do a research project at the Center for Brain Health, NYU, New York, and the 
Institute for Basic Research in Developmental Disabilities, Staten Island, US, under the 
supervision of prof.dr. MJ De Leon and dr. PD Mehta respectively. Since 2004 she works as a 
resident in Neurology at the VUmc, which she hopefully will conclude in 2010. 
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